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Abstract  
 
 This dissertation is concerned with the latest class of the new designer 
drugs (NDDs) which overruns the world in the last few years as “legal high” drugs, 
under the name of bath salts or synthetic cathinones. Bath salts are a group of central 
nervous system stimulants that consists mainly of synthetic cathinone derivatives. In 
nature, cathinone (β-keto amphetamine) exists in the leaves of the Catha edulis plant 
which can be found easily in the region of northeast Africa and the Arabian 
Peninsula. All synthetic cathinone derivatives contain a chiral center and most 
probably sold out as a racemic mixture. Commonly, one of the enantiomers will have 
greater psychological effect in human biological system than the other one. 
Therefore it’s important to distinguish between synthetic cathinone enantiomers. 
Enantiomeric separation and determination of these NDD’s may give information 
about the source of these synthetic drugs and the raw materials that were used in the 
synthesis process and also facilitates the drug tracking.  
 The main objective of this dissertation is to develop and validate sensitive 
and selective analytical methods that use direct and indirect chiral separation and 
quantitation for synthetic cathinones in real biological samples using 
chromatography coupled with mass spectrometer detector (MSD) and Diode Array 
detector (DAD). 
 The study goals were achieved successfully by developing and validation of 
three different methods for chiral separation and quantitation for 65 compounds of 
synthetic cathinones. Enantiomer quantitation in urine and plasma were performed 
and reported for the first time in this study; also it’s the first time to report the chiral 
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separation of tertiary amine cathinones where we were able to separate 19 out 22 of 
them.      
 
Keywords: Chiral separation, quantitation, enantiomers, derivatization, Cathinones, 
bath salts, method validation, chiral column.  
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 )cibarA ni( tcartsbA dna eltiT
 
في  –الكاثينونات المصنعة  –فصل الانطباقي والتحليل الكمي لعقاقير القات المصنع ال
 عينات البوم والدم
 صالملخ
حدث فئة من العقاقير الجديدة المعروفة بالمخدرات المصنعة طروحة بأهذه الأتختص 
التي طغت على العالم في السنوات القليلة الماضية   )sgurD rengiseD weN( الحديثة
 htaB(" الاستحمامأملاح " اسماستخدامها من ناحية قانونية تحت كعقاقير مخدرة يسمح ب
ستحمام هي الاأملاح  .)senonihtaC citehtnyS( الاصطناعيةأو الكاثينونات  )stlas
مركبات الكاثينونات من  ساسا  كون أمجموعة من منشطات الجهاز العصبي المركزي و تت
في أوراق نبات القات التي يمكن  )enonihtaC( صطناعية. في الطبيعة توجد مادة الكاثينونالا
مركبات الكاثينونات و شبه الجزيرة العربية. جميع  فريقياي منطقة شمال أالعثور عليها بسهولة ف
من قبل  و أغلب الظن أنها بيعت )retnec larihC( نطباقياكز صطناعية تحتوي على مرالا
 المقابلات الضوئية إحدى غالبا ، .)erutxim cimecaR( على شكل مزيج راسيمي المروجين
لديها قدرة أكبر على التأثير النفسي في النظام البيولوجي البشري من  تكون )remoitnanE(
لمقابلات الضوئية للكاثينونات ن نميز بين اإنه من المهم أالمقابلات الضوئية الأخرى، و بالتالي ف
المقابلات الضوئية للمخدرات المصنعة الحديثة قد يعطي معلومات حول ن فصل إصطناعية. الا
 صطناعالخام التي استخدمت في عملية الا والموادصطناعية ت الالمخدرامصدر هذه ا
 صادر هذه المخدرات.يضا يسهل عملية تتبع مأو )sisehtnyS(
تسمح طرق تحليل  من علمي تحققو استحداثهو الهدف الرئيسي من هذه الرسالة 
و التحليل الكمي للكاثينونات الاصطناعية في  بالفصل الانطباقي مباشر و غير مباشر بشكل
 جهاز الكروماتوغرافيا موصولا بجهاز مطياف الكتلة باستخدامالعينات البيولوجية الحقيقية 
  .)VU – CLPH(و جهاز الصمام الثنائي الكاشف  )SM-CG(
ثلاث  من العلمي و التحقق من خلال الاستحداثنجاح الدراسة بهذه هداف أتحققت 
التحليل  قد أجريو  مركبا للكاثينونات الاصطناعية. 56الانطباقي و تحليل  طرق مختلفة للفصل
ولى من لهذا النوع من المركبات للمرة الأالكمي للمقابلات الضوئية لعينات البول و البلازما 
 x
 
لكاثينونات لولى التي يتم مناقشة الفصل الانطباقي بعمق كما أنها المرة الأ خلال هذه الدراسة
 مركب. 22صل من أ 91حيث قمنا بفصل  )enima yraitreT( مين الثالثيذات الأ
 
اشتقاق، الفصل الانطباقي، التحليل الكمي، المقابلات الضوئية، : مفاهيم البحث الرئيسية
 أسلوب، عمود فصل انطباقي. كاثينون، أملاح الاستحمام، التحقق العلمي من
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Chapter 1: Introduction 
 Cathinone 
1.1.1 Cathinone in nature (Khat) 
Khat, Catha edulis Forsk, is an ever popular flowering shrub that can be 
found growing naturally  or cultivated in the south east Africa and in  the southern 
west part of Arabian Peninsula (Krikorian 1984). Khat chewing habit has persisted 
through this part of the world for centuries. Naming of khat plants  varied with its 
origin: tchat is used in Ethiopia, qat is used inYemen (Alem, Kebede et al. 1999), 
qaad/jaad is used in Somalia (Elmi 1983), miraa is used in Kenya (Patel 2000), 
mairungi is used in Uganda (Ihunwo, Kayanja et al. 2004), Muhulo is used in 
Tanzania and Hagigat is used in Israel (Bentur, Bloom-Krasik et al. 2008). 
Abyssinian tea or Arabian tea is another name for the dried leaves of khat. However, 
khat is the most common name for this herbal stimulant (Alem, Kebede et al. 1999). 
Classification of khat can be as follows [Family: Celastraceae, genus: Catha, and 
Species C. edulis] (Nordal 1980).  
1.1.2 Khat components and stability of active material 
Regarding materials and components of Catha edulis, it was found that khat 
leaves contain different chemicals such as: amino acids, trace amount of vitamins, 
alkaloids and some metal elements such as: calcium, iron and manganese (Feyissa 
and Kelly 2008). From a forensic point of view, scientists and researchers focus on 
the alkaloids of khat which play the main role in the stimulation effect of this plant. 
Scheme 1 shows different classes of alkaloids in khat leaves.    
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Scheme 1: Summary of different classes of alkaloids in khat leaves 
Of all the alkaloids classes that are shown in the above figure, (-) Cathinone 
is known to be the major active constituent in khat leaves which can be in 
concentration range of 0.74 ± 0.40 mg per gram of khat leaf expressed as mean ± SD 
(Dimba, Gjertsen et al. 2004). 
It was noticed that khat was cultivated and consumed at the same place or 
region. The reason for this was the fragility of active compounds in khat which were 
affected strongly by sunlight and heat which caused the degradation process. 
Degradation of active materials in khat leaves such as (-) Cathinone produces new 
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compounds that have less effect in the central nervous system of the human 
biological system (Banjaw, Fendt et al. 2005).  
1.1.3 Cathinone and amphetamine 
Cathinone can be classified as psychoactive phenethylalkylamine alkaloid 
that is present in khat plants. It has similar chemical structure to a very well-known 
abused drug called “amphetamine”. The only difference in structure between 
cathinone and amphetamine is the β-keto group of cathinone which leads to different 
metabolism pathway in biological system and causes different effects (Hassan, 
Gunaid et al. 2007). 
 
Scheme 2: Chemical structures of cathinone and amphetamine 
 Legality of khat 
United Nations Convention on Psychotropic Substances (UNCP) banned 
Cathinone, a stimulant that occurs naturally in khat, as a Schedule I substance (By 
update of 1986, Cathinone was added to the list now). In addition, all international 
lists of controlled substances have listed Khat as an illegal substance, however, there 
is a variation from country to country about the legality of this herbal stimulant. 
Moreover, cathinone in khat degrades to cathine after an oxidization reaction that 
happened within 48–72 hr. The formed stimulant, i.e. cathine, after degradation had 
less potency and is thus listed as a Schedule III drug in the 1971 UN Convention. 
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Government of United Kingdom and Netherlands found that the use of khat make the 
users more violent than non-users which means that there is a relationship between 
the green plant and an organized crime (Armstrong 2008). There is some proof about 
khat use can cause health related problems such as: insomnia, gastrointestinal 
problems, and cardiovascular events and other harmful effect. As a result of that, 
khat had been treated as a controlled substance in all parts of the world, including 
China, the United Kingdom, and the Netherlands as shown in table 1. 
Table 1: List of selected countries where khat is treated as controlled substance 
Year Country 
1971 Saudi Arabia 
1981 New Zealand 
1986 Germany 
1986 Australia 
1988 Jordan 
1989 Norway 
1989 Sweden 
1990 France 
1993 Denmark 
1993 Finland 
1993 United States 
1993 Ireland 
1995 Tanzania 
1995 United Arab Emirates 
1996 Switzerland 
1997 Canada 
1999 Belgium 
2005 Poland 
2005 Italy 
2012 Rwanda 
2013 Netherlands 
2014 China 
2014 United Kingdom 
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 New designer drug (NDD) 
The psychostimulant herbal drug is chewed by addictors to extract the active 
material from green leaves. Approximately, 80 to 90% of the active material such as 
cathinone, cathine and norephedrine were extracted during green leaves chewing 
(Toennes and Kauert 2002).  On other parts of the world, especially in developed 
countries, addiction of cathinone takes place but with a new generation of modified 
cathinones. Although governments established a number of regulations and laws that 
prevent sale, distribution, and consumption of the well-known abusive drug, 
clandestine labs played a dirty game by creating new psychoactive drugs that are not 
yet included in government’s laws which give the abusers a good chance to use and 
consume these kinds of drugs under the shield of legality. 
New designer drug (NDD) or Novel Psychoactive Drug (NPD) is a common 
name that describes the new generation of abused drug that overrun the whole world 
recently, which obligate governments to look for quick solution to prevent NDD 
from destroying their countries and societies.  
1.3.1 Bath salt (synthetic cathinones) 
In this study, we focused on one class of NDD called synthetic cathinones. 
Synthetic cathinones are known in US as “bath salt” and the reason for giving 
cathinones this name is just to mask these kinds of drugs. The illicit manufacturers 
mainly used this term in order to circumvent the Federal Analog Act which will give 
them kind of legality in market. ‘‘Bath salts’’ are not sold as tablets or capsules, but 
it was mainly in the form of fragrance-free, white, yellowish or brown crystals or 
powder. In United States the street price of bath salt is approximately $25–35 per 
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half gram package (Adebamiro and Perazella 2012). ‘‘Not for human consumption’’, 
a kind of warning written by suppliers on the product and sadly it is the only good 
thing that they did for consumers. Strangely, ingredients list indicates that there is no 
presence of psychoactive compounds even safety information is not provided 
(Zawilska and Wojcieszak 2013). This attitude causes a serious threat for usage of 
synthetic cathinones that can cause calamity for users. A good question can be raised, 
how do the clandestine chemist synthesize cathinone and who is the first scientist to 
synthesis it?  
1.3.2 Methcathinone 
N-methyl analogue of cathinone, methcathinone (ephedrone), was first 
synthesized in 1928 by Germans and French (Hyde, Browning et al. 1928). In the 
1950s, Parke-Davis pharmaceutical company in US was planning to market 
methcathinone as an appetite suppressant and an antidepressant which was followed 
by a grant that funded the production process in 1957. Human testing of the new 
drug stopped due to adverse reactions of it in biological systems. Unfortunately, a 
student in University of Michigan who was working at Parke-Davis found his way to 
business through the illegal manufacturing process of methcathinone in 1989 after 
finding documents to explain the synthetic procedure of ephedrone (Bailey, 
Hernandez Martin et al. 1995). Due to the growing risk of methcathinone and its 
rapid spread in the world, methcathinone had been placed in Schedule I of the United 
Nations Controlled Substance Act in 1992 by the Drug Enforcement Administration 
(DEA) (Sikk and Taba 2015).  
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1.3.2.1 Methcathinone synthesis 
Scientist considered methcathinone as the first “synthetic cathinone” which 
was found to be at least as potent as methamphetamine, the well-known stimulant 
(Glennon, Martin et al. 1995). The most common way in methcathinone synthesis is 
to use ephedrine or pseudoephedrine as precursors since they are easy to find as 
over-the-counter drugs and can produce methcathinone by a very simple reaction. 
Oxidation reaction of ephedrine can produce methcathinone while methamphetamine 
is the product of reduction reaction of ephedrine. In fact, reductive path of ephedrine 
is much more complicated. Potassium permanganate is used in the oxidation reaction 
of ephedrine in Russia and the Eastern Europe, followed by almost no refinement, 
unlike United States where they used sodium dichromates as an oxidant agent 
followed by a number of cleanup steps (Sikk and Taba 2015). Most of the synthetic 
cathinones have been derived from methcathinone as shown in Scheme 3.  
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Scheme 3: Chemical structures of Synthetic Cathinones derived from Methcathinone  
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1.3.3 Synthetic cathinone abuse 
Synthesis of some synthetic cathinones have been known for a long time ago, 
but only recently abused. It was noticed that some of synthetic cathinones had a 
higher popularity in terms of abused such as: 4-methylmethcathinone (mephedrone), 
3,4-methylenedioxymethcathinone (methylone), and 3,4-methylenedioxyprovalerone 
(MDPV) (German, Fleckenstein et al. 2014). Although synthetic cathinones have 
been discovered long time ago, abusers ignored them until the use of cathinones by 
addictors as a legal alternative to 3,4-Methylenedioxymethamphetamine (MDMA) 
on internet drug websites in 2003 (Morris 2010) and within few years, cathinone-
derivatives became prevalent within the United Kingdom. In Europe, mephedrone is 
the most common synthetic cathinone that was abused, while MDPV and methylone 
was widely abused in US (German, Fleckenstein et al. 2014). Most frequently, 
abused techniques of these compounds varied between: snorting, which can cause 
nasal irritation that obligates many abusers to smoke bath salts, consuming them 
orally, or by injecting themselves intravenously or intramuscularly (Kavanagh, 
O'Brien et al. 2013). Bath salt can be distributed through: street-level sellers, head 
shops, smoke shops, adult book stores, gas stations and internet within US, Europe 
and worldwide. It was found that most of the synthetic cathinones are synthesized in 
China and South East Asian countries (German, Fleckenstein et al. 2014). 
Methedrone abused spread over 28 European countries at the period between 2007 
up to 2010 (EMCfDaD 2011). In 2009, UK National Poisons Information Service 
recorded no enquiry regarding cathinone toxicity and within one year the number 
jumped rapidly to over 600 reports in 2010 (James, Adams et al. 2011). As a result of 
that, mephedrone became the third most commonly abused drug in the UK by the 
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end of 2010. In school and college/university approximately 20% of individuals, ages 
between 14 to 20, are the most affected layer of society in UK by the mephedrone 
(Dargan, Albert et al. 2010). Within the same period of time in US, National 
Forensic Laboratory Information System (NFLIS) reported an increase in synthetic 
cathinone drug enquiries from 34 in 2009 to 628 in 2010 (Forrester 2012). For 
example, MDPV was reported as the fifth and methylone as the eleventh most 
common drug that can cause hallucinations within the US as reported by NFLIS in 
2011. Moreover, calls that have been received by poison control center regarding 
exposure of bath salt increased from 304 in 2010 to 6136 in 2012 (German, 
Fleckenstein et al. 2014).  
1.3.4 Legality of synthetic cathinone 
Due to the growing risk of the synthetic cathinones, US Drug Enforcement 
Administration (DEA) took an important decision on prohibiting some of central 
nervous system stimulant drugs and schedule them in the law tables and consider 
them as illegal substances in 2010 (Banks, Worst et al. 2014). 
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Table 2: Updated list of Bath Salts (Synthetic cathinones) identified by GCMS and 
published by the General’s Bureau of Criminal Investigation 
# Name Synonyms Legality  
1 Cathinone 
 
- DEA Schedule I 
2 Ethcathinone 
 
- DEA Schedule I 
3 Mephedrone 
 
- DEA Schedule I 
4 4-methylethcathinone 
 
(4-MEC) 
 
DEA Schedule I 
5 4-fluoromethcathinone 
 
(4-FMC) DEA Schedule I 
6 Buphedrone 
 
- DEA Schedule I 
7 Pentedrone 
 
- DEA Schedule I 
8 Methylone 
 
- DEA Schedule I 
9 Butylone 
 
- DEA Schedule I 
10 Pentylone 
 
- DEA Schedule I 
11 Ethylone 
 
- DEA Schedule I 
12 3,4-Methylenedioxy-α-
pyrrolidinopropiophenone 
 
(MDPPP) 
 
DEA Schedule I 
13 3,4-Methylenedioxy-α-
pyrrolidinobutiophenone 
 
(MDPBP) 
 
DEA Schedule I 
14 3,4-Methylenedioxypyrovalerone 
 
(MDPV) 
 
DEA Schedule I 
15 α-Pyrrolidinovalerophenone 
 
(Alpha-PVP) 
 
DEA Schedule I 
16 α-Pyrrolidinobutiophenone 
 
(Alpha-PBP) 
 
DEA Schedule I 
17 α-Pyrrolidinopropiophenone 
 
(Alpha-PPP) 
 
DEA Schedule I 
18 1-(4-methylphenyl)-2-(pyrrolidinyl)-1-
propanone 
 
(MPPP) 
 
DEA Schedule I 
 
Identification of novel bath salts including their chemical structures and 
names have been done by the Ohio Attorney General’s Bureau of Criminal 
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Investigation. Not all the agents listed in table 2 have been scheduled by DEA; 
moreover pharmacological tests are not carried out yet for all of them in controlled 
human or animal studies. 
In United Arab Emirates, some of synthetic cathinones have been scheduled 
in December 2015 as shown in Table 3. 
Table 3:  List of controlled synthetic cathinones in UAE 
# IUPAC name Compound name Synonyms 
1 1-phenyl-2-(1-pyrrolidinyl)-1-
heptanone 
α-Pyrrolidinopentiophenone α-PVP 
2 1-phenyl-2-(1-pyrrolidinyl)-1-
propanone 
α-Pyrrolidinopropiophenone α-PPP 
3 2-(methylamino)-1-phenyl-1-
butanone 
Buphedrone MABP 
4 1-(1,3-benzodioxol-5-yl)-2-
(dimethylamino)-1-butanone 
Dibutylone /bk-DMBDB - 
5 2-(dimethylamino)-1-phenyl-
1-propanone 
Metamfepramone N,N-DMC 
6 1-(3,4-dimethylphenyl)-2-
(ethylamino)propan-1-one 
3,4-Dimethylethcathinone 3,4-DMEC 
7 1-(3,4-dimethylphenyl)-2-
(methylamino)-1-propanone 
3,4-Dimethylmethcathinone 3,4-DMMC 
8 1-(1,3-benzodioxol-5-yl)-2-
(dimethylamino)-1-propanone 
Dimethylone / bk-MDDMA - 
9 2-(ethylamino)-1-phenyl-1-
propanone 
Ethcathinone - 
10 2-(dimethylamino)-1-(4-
ethylphenyl)propan-1-one 
4-ethyl-N,N-
Dimethylcathinone 
4-ethyl-
N,N-DMC 
11 2-(ethylamino)-1-(4-
ethylphenyl)propan-1-one 
4-Ethylethcathinone 4-EEC 
12 1-(4-ethylphenyl)-2-
(methylamino)propan-1-one 
4-Ethylmethcathinone 4-EMC 
13 1-(benzo[d][1,3]dioxol-5-yl)-
2-(ethylamino)propan-1-one 
Ethylone /bk-MDEA MDEC 
14 1-(1,3-benzodioxol-5-yl)-2-
(ethylamino)-1-butanone 
Eutylone / bk-EBDB - 
15 2-(ethylamino)-1-(4-
fluorophenyl)propan-1-one 
4-Fluoroethcathinone 4-FEC 
16 1-amino-1-(4-
fluorophenyl)propan-2-one 
4-Fluoroisocathinone 4-FIC 
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# 
 
IUPAC name 
 
Compound name 
 
Synonyms 
17 1-(1,3-benzodioxol-5-yl)-2-
(1-pyrrolidinyl)-1-propanone 
3,4-Methylenedioxy-α-
Pyrrolidinopropiophenone 
3,4-MDPPP 
18 2-(methylamino)-1-(4-
methylphenyl)-1-butanone 
4-Methylbuphedrone 4-methyl 
BP 
19 1-(1,3-benzodioxol-5-yl)-2-
(1-pyrrolidinyl)-1-butanone 
3,4-Methylenedioxy-α-
Pyrrolidinobutiophenone 
3,4-
MDPBP 
20 1-(4-methylphenyl)-2-(1-
pyrrolidinyl)-1-butanone 
4-methyl-α-
Pyrrolidinobutiophenone 
4-methyl 
PBP 
21 2-(pyrrolidin-1-yl)-1-(p-
tolyl)hexan-1-one 
4'-methyl-α-
Pyrrolidinohexanophenone 
MPHP 
22 1-(4-methoxyphenyl)-2-
(pyrrolidin-1-yl)propan-1-one 
4'-methoxy-α-
Pyrrolidinopropiophenone 
4'-MeOPPP 
23 2-(ethylamino)-1-
phenylbutan-1-one 
N-Ethylbuphedrone NEB 
24 1-(1,3-benzodioxol-5-yl)-2-
(methylamino)-1-butanone 
Butylone / bk-MBDB - 
25 1-(1,3-benzodioxol-5-yl)-2-
(1-pyrrolidinyl)-1-pentanone 
3,4-Methylenedioxy 
Pyrovalerone 
3,4-MDPV 
26 2-(methylamino)-1-(4-
methylphenyl)-1-propanone 
Mephedrone 4-MMC 
27 1-(4-fluorophenyl)-2-
(methylamino)propan-1-one 
4-Fluoromethcathinone 4-FMC 
28 1-(4-methoxyphenyl)-2-
(methylamino)-1-propanone 
Methedrone PMMC 
29 1-(1,3-benzodioxol-5-yl)-2-
(methylamino)-1-propanone 
Methylone / bk-MDMA - 
30 2-(methylamino)-1-phenyl-1-
pentanone 
Pentedrone - 
31 1-(1,3-benzodioxol-5-yl)-2-
(methylamino)-1-pentanone 
Pentylone - 
32 1-(3-fluorophenyl)-2-
(methylamino)propan-1-one 
3-Fluoromethcathinone 3-FMC 
33 2-(ethylamino)-1-(4-
methylphenyl)-1-propanone 
4-Methylethcathinone 4-MEC 
 
 
However, the cat-and-mouse game seems to continue between lawmakers 
and clandestine laboratories, with continuous synthesis of new designer stimulants 
that will replace those outlawed psychoactive drugs (German, Fleckenstein et al. 
2014). 
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 Effect of cathinones in dopamine system 
The synthetic cathinones, induce profound behavioral changes in dopamine 
system, probably through the central monoamine systems where the actions take 
place. Dopaminergic pathways are neural pathways in the brain that carry the 
neurotransmitter dopamine from one region to another. It can be divided into four 
major dopaminergic pathways: the nigrostriatal, mesolimbic, mesocortical, and 
tuberoinfundibular pathways (Björklund and Dunnett 2007). Motor control that is 
carried out by the central nervous system is associated with the nigrostriatal pathway, 
which is responsible to organization of the musculoskeletal system that will lead to 
produce  coordinated activities and skillful movements (DeLong 1990). Reward 
system of the brain is another name of the mesolimbic pathway which is responsible 
for pleasure or the events that is usually associated with pleasure in human being like 
having sex and food in terms of rewards (Di Chiara 1998). Cognition, motivation, 
and emotional response are corresponded to the mesocortical pathway (Floresco and 
Magyar 2006). The secretion influences of hormone prolactin which counteracts the 
sexual arousal effect of dopamine is associated with tuberoinfundibular pathway 
(Porter, Kedzierski et al. 1990). 
All four dopamine pathways in the brain will be affected by any drug that can 
affect dopamine levels such as synthetic cathinones. The effect of these drugs is 
based on the following mechanisms: both stimulating the dopamine releasing, and 
also an inhibition of reuptake process where the excess dopamine in the synaptic 
cleft will be reabsorbed (den Hollander 2015). As a result of increasing levels of 
dopamine, the action on dopamine receptors of post-synaptic neurons will increase, 
leading to activation of the dopaminergic pathways. 
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As synthetic cathinones are classified as stimulation-induced drugs, they are 
strongly responsible for alerting the dopaminergic pathways but at different rate for 
each pathway. Symptoms of twitching, restlessness, and repetitive motion can be 
produced as a result of nigrostriatal pathway stimulation (DeLong 1990). Stimulation 
of mesolimbic pathway produces pleasure, euphoria, dysphoria, hallucinations and 
psychotic behavior (Di Chiara 1998). Depression, fear, and anxiety are symptoms of 
mesocortical pathway stimulation produces (Floresco and Magyar 2006). Increase in 
sexual desire can occur when dopamine in the tuberoinfundibular pathway inhibits 
the release of prolactin from the pituitary gland (Porter, Kedzierski et al. 1990). 
Table 4 shows some of the physical and neuropsychiatric effect of bath salt in 
humans. 
Table 4: Common neuropsychiatric and physical effects of synthetic cathinones 
 Desirable Adverse 
Physical Alertness 
Analgesic effects 
Increased energy 
Stimulation 
Cerebral edema 
Diaphoresis 
Hyperreflexia 
Hyperthermia 
Jaw tension 
Muscle spasms 
Mydriasis 
Myocardial infarction 
Respiratory distress 
Seizures 
Tachycardic  
 
Neuropsychiatric  Creativity 
Empathy 
Euphoria 
Sociability 
Productivity 
Mental clarity 
Sexual arousal 
Sharpened awareness 
Aggression 
Agitation 
Combative behavior 
Dysphoria 
Hallucinations 
Insomnia 
Paranoia 
Psychosis 
Suicidal thoughts 
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In fact, this is a very short and general explanation about stimulant effect in 
dopamine system. More information and details about neuropharmacology of bath 
salt, is available in the literature (Miotto, Striebel et al. 2013, Zawilska and 
Wojcieszak 2013, Banks, Worst et al. 2014, German, Fleckenstein et al. 2014, 
Vouga, Gregg et al. 2015). 
 Synthetic cathinones and chirality 
All cathinone derivatives have chiral center at their α-carbon where the 
carbon atom is attached to four different groups' schemes (6 – 10). Asymmetric 
carbon center in cathinones leads to the presence of cathinones as a racemic mixture 
of two optical isomers. 
1.5.1 What are chiral compounds?  
 Unique three-dimensional shape molecule with an asymmetric carbon center 
describes special kind of molecules called chiral molecules. The origin of chiral as a 
term is from Greek language since they use it as a meaning ‘‘hand.’’ Although chiral 
molecules are mirror image of each other, they are different in their ‘‘handedness’’ 
so they cannot be superimposable. In Greek enantios, meaning ‘‘opposite’’ and this 
was the reason for naming chiral molecules as ‘‘enantiomers,’’. In the example of 
human hand, left and right hand are enantiomers since they are mirror images, 
‘‘right’’ glove cannot be worn on a left hand. The arrangement of fingers and thumb 
in three dimensions makes a left hand and a right hand somehow different from each 
other. Enantiomers of chiral compounds exist as rectus (R) - and sinister (S) - or 
dextro(D) and levorotary (L) according to their ability to rotate plan polarized light. 
If the mixture of enantiomers contain the same concentration of each enantiomer, it 
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can be called a ‘‘racemate.’’Although the carbon frameworks of the two enantiomers 
align, the position of the functional groups is different at the chiral center. Complete 
alignment of the two molecules without breaking bonds is impossible (Li and Haynie 
2006). 
Since human biological system is chiral, dextro (D) and levorotary (L) 
enantiomers have different pharmacological effects in human being. For instance, in 
food industry, L - limonene gives a smell of lemons, while D - limonene gives a 
smell of oranges. The reason as to why enantiomers are not acting in the same 
identical way in the biological context is the difference in three-dimensional structure 
where sometimes one of the enantiomers is much suitable than the other for a precise 
interaction with a biological molecule, such as a receptor, enzyme, etc (Li and 
Haynie 2006). 
Chiral specificity of the biological system is very high. The interaction and 
metabolism pathway with each racemic drug is different which will produce different 
pharmacological activity and potencies in living organisms. The desired therapeutic 
activities can be produced by one isomer, while the other may be considered as an 
inactive compound or can create undesirable side effects (Li and Haynie 2006).   
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1.5.2 Importance of chiral separation in synthetic cathinones 
Synthetic cathinones have limited toxicological and pharmacological data 
due to their novelty (Mohr, Pilaj et al. 2012). However, few synthetic cathinones 
have been studied stereochemically in biological systems. For instance, it was found 
that R-(+) enantiomer of methcathinone and R-(-) enantiomer of amphetamine, show 
less stimulating effects than their S-(-) - and the S-(+) - antipodes (Glennon, Martin 
et al. 1995, Jirovský, Lemr et al. 1998, Rasmussen, Olsen et al. 2006). Therefore, 
enantioseparations of new class of cathinone derivatives may lead to preparative 
methods that are capable to separate racemic mixture enantiomers, which can be used 
easily in pharmacological studies. The second importance of chiral separation 
methods is to indicate the synthesis pathway, which can determine the starting 
materials used for synthesis. Drug trafficking will facilitate finding the origin lab of 
synthesis by the information that can be provided after chiral analysis of the targeted 
analytes. Chiral separation of new designer drugs could show the ratio between 
enantiomers which will help investigators to know the conditions and the chemicals 
that were used in clandestine labs (Jirovský, Lemr et al. 1998).  
1.5.3 Principles of chiral separation 
In the past 20 years, enantioseparation of molecules containing asymmetric 
chiral centers has attracted the attention of pharmaceutical industry. Chiral 
separations can be achieved by one of the following strategies: an indirect method, 
based on the reactions of chiral compounds with a chiral derivatizing agent (CDA) 
and separation of the diastereomeric derivatives on an achiral normal stationary 
phase. Second strategy of chiral separation is based on direct separation method, 
where the diastereoisomers can be formed on an immobilized chiral stationary phase 
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(CSP), or with a chiral macromolecule selector in a mobile phase with an achiral 
stationary phase (Ilisz, Berkecz et al. 2008). Table 5 shows the advantages and 
disadvantages of each technique. 
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Table 5: Comparison between indirect and direct methods of chiral separation 
Indirect method Direct method 
Advantages 
1. Good chromatographic properties 
of derivatives 
2. Good chromophoric or 
fluorophoric properties of the 
regent (enhanced sensitivity can 
be achieved) 
3. Low cost of achiral columns 
4. Method development is simple 
5. Selectivity can be increased 
(better separation is often 
achieved than with a direct 
method) 
6. Possibility of appropriate 
selection of the elution sequence 
and the elution sequence 
predictable 
Disadvantages 
1. The purity of the CDA is critical 
2. The molar absorptivity of the 
diastereomers may differ 
3. Possibility of racemization  
4. Possibility of kinetic resolution 
5. The excess of regent and side 
products may interfere with the 
separation 
6. Preparative application is 
restricted  
7. Derivatization may be time-
consuming 
Advantages 
1. The purity of the chiral selector is 
not critical 
2. Similar molar absorptivities of 
enantiomers 
3. Absence of racemization and 
kinetic resolution  
4. Racemates without functional 
groups are separable 
5. Preparative applications are 
available  
6. Change of temperature may be 
favorable  
7. Simple preparation of analytes 
and simple chromatographic runs  
Disadvantages 
1. The theoretical plate number of 
the CSP is small  
2. Slow kinetics of desorption  
3. The elution sequence is not clear  
4. No universal column exists 
5. CSPs are very sensitive to 
chromatographic conditions 
(rather difficult and lengthy 
method development) 
6. High cost of critical columns 
 
1.5.3.1 Indirect chiral separation methods 
1.5.3.1.1 Chiral derivatizating agent (CDA) 
Enantiomers can be derivatized through the use of homochiral reagents that 
lead to the formation of diastereoisomers which are separable on achiral columns. 
Achiral stationary phase cannot distinguish between enantiomers yet it interacts with 
the formed diastereoisomers in different way which leads to variation of retention 
times. Chiral derivatization was the first commonly used method in the analysis of 
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chiral drugs (Ilisz, Berkecz et al. 2008). The most critical points for this technique to 
succeed is the availability of the derivatizable group in the targeted analyte and the 
high purity of the homochiral reagent. For instance, in case of synthetic cathinones, 
tertiary amines cathinones will be excluded from this strategy since they do not 
contain a derivatizable site unlike primary and secondary amines cathinones which 
can be derivatized easily by the removal of acidic hydrogen of amine and the 
formation of new amide bond between analyte and the CDAs. 
Due to the development of new chiral chromatographic techniques, 
enantioseparations based on covalent chiral derivatization became unpreferable to 
some extent, however, CDAs are still frequently used in GC and HPLC systems. The 
reasons for this are the ability to use achiral columns, the availability of large number 
of homochiral derivatizing reagents that have well-known reactions to produce 
diastereoisomers with well separated peaks of high resolution.  
1.5.3.1.2 Gas chromatography in cathinone chiral separation 
GC in combination with MS detection was one of the most popular 
techniques for chiral analysis which can be carried out directly on chiral stationary 
phases (CSPs) or indirectly using achiral stationary phases after performing chiral 
derivatization using pure reagents that form diastereoisomers (Jirovský, Lemr et al. 
1998, Tao and Zeng 2002). Indirect analysis of enantiomers was preferable for 
GCMS users due to many reasons that were mentioned before. 
(R)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetic acid (MTPA) has been 
used for cathinone chiral separation which was considered as the most active 
derivatives of the alkaloids in Khat using Gas chromatographic-Mass spectrometric 
system (LeBelle, Lauriault et al. 1993). Another method was developed using the 
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same CDA (MTPA) for the simultaneous analysis of eight compounds that were 
structurally similar to cathinones (Wang, Lewis et al. 2005).  
 
Scheme 4: α-methoxy-α-(trifluoromethyl)phenylacetic acid (MTPA) structure 
Another CDA called (S)-(−)-N-(trifluoroacetyl)pyrrolidine-2-carbonyl 
chloride (L-TPC) was used to achieve chiral separation. L-TPC had many 
advantages, including effectiveness of derivatization reaction, commercial 
availability and good resolution of products (Wang, Wang et al. 2005).  
 
Scheme 5: (S)-(−)-N-(trifluoroacetyl)pyrrolidine-2-carbonyl chloride (L-TPC) 
structure 
Recently, Stefan Mohr et al. (Mohr, Weiß et al. 2012) used L-TPC for chiral 
analysis of new synthetic cathinones and amphetamines with GCMS. The indirect 
chiral separation using L-TPC as CDA was successful to separate 19 of cathinone 
derivatives into their diastereoisomers on a common achiral stationary phase column. 
In 2015, the same group performed an enantioseparation for a new group of synthetic 
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cathinone derivatives where they were able to separate 4 out of 10 cathinone related 
drugs in that study indirectly on GCMS after performing derivatization reaction with 
L-TPC (Weiss, Mohr et al. 2015). Taschwer et al. were able to analyze and 
characterize a novel psychoactive drug called 4-chloromethcathinone (clephedrone) 
which was available by different online suppliers (Taschwer, Weiß et al. 2014). 
Clephedrone chiral separation was carried out indirectly also by GCMS system after 
derivatization step with L-TPC. Although efficient derivatization reactions between 
targeted analytes and CDA attracted chemists, the need for direct chiral techniques is 
growing, especially in order to save analysis time. 
1.5.3.2 Direct chiral separation methods 
Direct separation of enantiomers can be carried out by introducing a suitable 
optically active moiety into the system. Chiral selectors can be added to the mobile 
phase of HPLC system, or it can be added to background electrolyte of CE; 
alternatively it can be attached on a solid stationary phase of capillary (TesaŘOvÁ 
and Armstrong 1998). Separation mechanism of enantiomers using chiral stationary 
phases (CSPs) was based on one of the following three principles: host-guest 
inclusion interactions with chiral selectors such as cyclodextrin (CD) derivatives, 
hydrogen bonding on analyte chiral center, and coordination on chiral metal 
complexes (Schurig 2002). Direct chiral separation can be achieved also in GC by 
using chiral capillary column, however, to the best of our knowledge no one has used 
this technique in synthetic cathinones chiral separation. Therefore, the focus of this 
dissertation will be on the direct enantioseparation of synthetic cathinones using 
HPLC with CSPs which has earned a lot of interest lately. 
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1.5.3.2.1 High performance liquid chromatography in cathinone chiral 
separation 
In HPLC (LC), five groups of chiral stationary phases can be used to 
facilitate the chiral separation such as: cyclodextrins, proteins, cellulose/amylose, 
small molecules and macrocyclic glycopeptides. They can be either bonded to silica 
or used as an active selector in mobile phases. Formation of diastereomeric 
adsorbates leads to high selectivity of CSPs in chiral separation of targeted analyte 
(Herraez-Hernandez, Campıns-Falcó et al. 2002).  
A simple UHPLC-PDA method using achiral column with added (2-
Hydroxypropyl)-beta-cyclodextrin (HP-β-CD) in the mobile phase has been 
developed for the successful analysis of 24 designer phenethylamines and cathinone 
derivatives (Li and Lurie 2015). Taschwer et al. were able to provide a chiral 
separation of a set of 6 amphetamine and 25 cathinone derivatives through the use of 
HPLC-UV where sulfated β-cyclodextrin was used as an additive in mobile phase 
(TASCHWER, SEIDL et al. 2014).  
CHIRALPAK AS-H™ Column is a chiral column that contains amylose as a 
CSP. It was used by Mohr et al. for enantioseparation of synthetic cathinones. It 
showed its ability to separate 19 out of 24 cathinone enantiomers in normal phase 
(Mohr, Taschwer et al. 2012). 1-(3,4-dimethoxyphenyl)-2-(ethylamino)pentan-1-one 
(DL-4662), one of the recently abused synthetic cathinone which was separated 
enantiomerically using amylose CSP (Weiss, Taschwer et al. 2015). Perera et al. 
were interested in developing chiral method for the separation of mephedrone and 
related cathinones using different kind of chiral columns on HPLC-UV system. They 
tried different CSPs while varying the composition of the mobile phase from reverse 
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to normal phase in order to build a persuasive comparison between the different 
kinds of CSP (Perera, Abraham et al. 2012). Padivitage et al. have developed a 
method that used cyclofructan based (LARIHC) and cyclobond I 2000 RSP in HPLC 
chiral analysis for a group of illicit drugs and cathinone was one of them. They were 
able to separate 14 out of 20 racemic compounds, with 7 compounds baseline 
resolved and 7 partially separated (Padivitage, Dodbiba et al. 2014). Zhang et al. 
have studied six CSPs with different structural features and their ability to perform 
separation of enantiomers for a group of drugs and one of them was cathinone. The 
immobilized chiral stationary phases were amylose based in 4 columns 
(CHIRALPAK IA, ID, IE and IF) and cellulose based in two columns 
(CHIRALPAK IB and IC). Furthermore, the study covered the effects of mobile 
phase composition, mobile phase additives and the effect of sample solvents on the 
chiral separation. They found that the best resolution and selectivity factors for 
cathinone enantiomers can be achieved by using CHIRALPAK IB column with 
hexane/ethanol/TFA/TEA 80/20/0.1/0.05 as a mobile phase (Zhang, Franco et al. 
2012). Comparisons between four different CSPs column in normal (NPLC) and 
reverse phase (RPLC) of HPLC-UV system were carried out for seven synthetic 
cathinones by Albals et al. (Albals, Vander Heyden et al. 2016). The analysis were 
done by using 4 polysaccharide-based chiral stationary phases (CSPs): cellulose 
tris(3,5-dimethylphenylcarbamate) (ODRH), amylose tris(3,5-
dimethylphenylcarbamate)(ADH), amylose tris(5-chloro-2-methylphenylcarbamate) 
(LA2), and cellulose tris(4-chloro-3-methylphenylcarbamate) (LC4). According to 
their findings, ADH and LC4 showed the highest success rate after applying them to 
each compound. However the comparison between normal and reverse phase 
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revealed that RPLC showed higher number of the separated compounds (Albals, 
Vander Heyden et al. 2015).  
Recently, an impressive paper talking about using chiral ion-exchange type 
stationary phases to separate selected synthetic cathinones has been published 
(Wolrab, Frühauf et al. 2016). They used three different kind of CSP: chiral strong 
cation exchanger c-SCX (CSP 1), chiral zwitterion ion exchanger [Chiralpak ZWIX 
(+)] (CSP 2) and the new synthesized naphthalene-based chiral SCX (CSP 3). Based 
on the separation of cathinones, the chromatographic performance was compared for 
the three CSPs. They found that the best chromatographic performance was shown 
by CSP 1 which has the smallest selector unit. It was able to separate 14 compounds 
of the synthetic cathinones (Wolrab, Frühauf et al. 2016).  
Although HPLC chiral methods show their stability and ability to perform 
chiral separation, the use of high amount of chiral selector in mobile phase and long 
analysis time in some methods obligate researchers to look for smart alternatives. 
1.5.3.2.2 Capillary electrophoresis in cathinone chiral separation 
Over the past decade, CE has been widely used as a chiral separation 
technique and can be considered as an alternative or complementary technique to 
HPLC in pharmacological science and industry. Variety of enantioseparation 
techniques that were successfully applied in HPLC have shifted to CE. In 1985 
Gassmann, Kuo, and Zare were successful to perform chiral separation by CE for the 
first time (Gallo 1983). CE as a separation technique expressed a valued advantage 
such as greater efficiency, simplifies method development by the possibility of 
combining a large number of chiral selectors, consumption of small amounts of 
solvents and chiral selector, short analysis time, low total cost, and environment 
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saving. Impurities with poor chromophores will not be an issue in CE system, since 
the use of low-UV wavelength (e.g.,200 nm) will not permit impurities to be 
observed. It is known that CE is suitable for chargable compounds which facilitate 
the separation of polar compounds for which chromatographic methods were 
inadequate for separation (Li and Haynie 2006). 
Recently, chiral analysis of synthetic cathinone derivatives became a popular 
topic and a hot area of CE method development. Several CE methods utilized 
cyclodextrin derivatives as a chiral selector in the buffer of the CE system (Mohr, 
Pilaj et al. 2012, Merola, Fu et al. 2014, Taschwer, Hofer et al. 2014, Taschwer, 
Weiß et al. 2014, Li and Lurie 2015, Moini and Rollman 2015). Most of the 
developed methods for chiral separation have used diode array detector (DAD) 
which were successfully applied for the detection of new designer cathinones. Few 
publications used tandem mass spectrometry (MS) as detector coupled with CE 
(Merola, Fu et al. 2014, Švidrnoch, Lněníčková et al. 2014, Moini and Rollman 
2015) due to the very low signal that was usually observed. In order to overcome this 
issue, a sheathless CE interface has been used in order to allow coupling of ESI-MS 
with CE in a single dynamic process within the same device to analyze various 
derivatives of cathinone (Moini and Rollman 2015).  
Enantiomeric separation into their optical diastereoisomers in CE is due to a 
set of interactions that occur between chiral selector in the buffer and analytes. As 
mentioned earlier, cyclodextrin derivatives are the most commonly used chiral 
selectors. Different kind of cyclodextrins have been used in chiral separation of 
synthetic cathinones such as: 2-hydroxypropyl-β-cyclodextrin (HP-β-CD)(Mohr, 
Pilaj et al. 2012, Li and Lurie 2015), native β-cyclodextrin (β-CD)(Mohr, Pilaj et al. 
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2012, Merola, Fu et al. 2014), highly sulfated- γ -cyclodextrin (HS- γ -CD)(Merola, 
Fu et al. 2014, Moini and Rollman 2015), highly sulfated-β-cyclodextrin (HS-β-
CD)(Mohr, Pilaj et al. 2012, Taschwer, Weiß et al. 2014), carboxymethyl-β-
CD(Mohr, Pilaj et al. 2012), native γ- cyclodextrin (γ-CD)(Mohr, Pilaj et al. 2012) 
and sulfobutylether β –cyclodextrin (SBE-CD)(Taschwer, Hofer et al. 2014). Mohr 
et al. have studied the separation ability and suitability for most of the cyclodextrin 
derivatives mentioned above (Mohr, Pilaj et al. 2012). They have chosen 3 out of 19 
cathinones as a model to validate their method by studying the effect of different 
types of CDs, pH of buffer solution and the effect of CD concentration. According to 
their findings, HS-β-CD was the best chiral selector for synthetic cathinones chiral 
analysis in terms of separation resolution and selectivity factor(Mohr, Pilaj et al. 
2012).  
On the other hand, some researchers investigated the use of another chiral 
selectors in CE for cathinones enantioseparation such as amylose tris(5-chloro-2-
methylphenylcarbamate) which can be considered as a polysaccharide-based chiral 
stationary phase and interestingly, it was the first time this kind of CSP was used in 
the analysis of cathinones by CE system (Aturki, Schmid et al. 2014).  Experimental 
parameters such as mobile phase composition, organic modifiers, pH of mobile phase 
buffer, separation voltage and capillary temperature have been studied and optimized 
to obtain an efficient and rapid chiral CE method that were capable to separate the 
studied 10 cathinone derivatives by using amylose CSP (Aturki, Schmid et al. 2014).   
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1.5.4 Quantitative analysis of synthetic cathinones 
In the forensic field, qualitative analysis of illicit drugs is important in order 
to provide the right identification of the abused drug composition. Moreover, lawyers 
need to know the dosage of illicit drugs in biological sample of the abusers which 
can be estimated by performing quantitative analysis for the targeted analytes.  
Determination of bath salt designer drugs qualitatively and quantitatively is 
one persistent need which puts great responsibility on scientists. Recently, the 
number of publications that discussed synthetic cathinones quantitative analysis has 
grown up quickly, which reflects the high interest of researchers to study and analyze 
these kinds of stimulants and narcotics. In the previous section, a lot of work 
reported in the literature showed qualitative studies on the new designer drugs. It can 
be noticed easily that the number of developed methods for cathinones chiral 
analysis using capillary electrophoresis (CE) systems is higher than chromatographic 
methods. However, HPLC and GC were preferable for quantitative analysis of 
synthetic cathinones since they are one of the most separation techniques that used in 
many laboratories around the world.  
Several quantitative methods have been developed in gas chromatography 
coupled with mass spectrometry (GC-MS) to analyze the biological samples that 
contain cathinones, some of them are shown in table 6.  
30 
 
Table 6: Analysis of synthetic cathinones in biological materials using GC–MS 
Targets Sample
s 
Purificatio
n 
Derivatization LOD 
(ppb) 
Linea
r 
range 
(ppb) 
References 
MDPV, 
metabolites 
Urine SPE Methyl, acetyl, 
trimethylsilyl 
- - (Meyer, Du 
et al. 2010) 
MDPV, 
metabolites 
Cellular 
fraction
, 
Urine 
LLE Trimethylsilyl 2 10–
2,000 
(Strano‐
Rossi, 
Cadwallader 
et al. 2010) 
Mephedrone
, MDPV 
Blood, 
urine 
LLE - - - (Spiller, 
Ryan et al. 
2011) 
MDPV Urine LLE Heptafluorobutyry
l 
10 20–
2,000 
(Ojanperä, 
Heikman et 
al. 2011) 
Methylone Blood LLE Heptafluorobutyry
l 
50 100–
2,000 
(Pearson, 
Hargraves et 
al. 2012) 
α-PVP, 
pyrovaleron
e (PV), 
MDPV 
Blood SPME - 0.5 (PV, 
PVP), 
1.0 
(MDPV
) 
1–200 (Saito, 
Namera et 
al. 2013) 
MDPV, 
α -PVP, 
α –PBP 
Blood LLE - 1 2–
2,000 
(Namera, 
Urabe et al. 
2013) 
MDPV Blood, 
tissue, 
urine 
SPE - - 10–
2,000 
(Wyman, 
Lavins et al. 
2013) 
MDPV Blood, 
urine 
LLE - - - (Wright, 
Cline‐
Parhamovic
h et al. 
2013) 
3,4-DMMC, 
metabolites 
Urine LLE Trifluoroacetyl - - (Shima, 
Katagi et al. 
2013) 
16 Synthetic 
cathinones 
Urine LLE Trifluoroacetyl - - (Uralets, 
Rana et al. 
2014) 
a-PVP, 
metabolites 
Urine LLE Trimethylsilyl - - (Shima, 
Katagi et al. 
2014) 
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Table 7 shows a set of methods used for quantitation of cathinone related 
drugs in urine, blood, hair and other biological samples by high performance liquid 
chromatography coupled with mass spectrometry (HPLC-MS).  
Table 7: Analysis of synthetic cathinones in biological materials using HPLC–MS 
Targets Samples Purification LOD 
(ppb) 
Linear 
range 
(ppb) 
References 
MDPV, 
metabolites 
Urine SPE - - (Meyer, Du et al. 
2010) 
MDPV, 
metabolites 
Cellular 
fraction, 
urine 
 
LLE - - (Strano‐ Rossi, 
Cadwallader et al. 
2010) 
MDPV Serum SPE 3 10–500 (Kriikku, Wilhelm 
et al. 2011) 
Mephedrone Plasma LLE 39 78–
10,000 
(Maskell, De Paoli 
et al. 2011) 
9 Cathinones Blood PP 0.5–3 10–400 (Sørensen 2011) 
7 Cathinones Hair LLE 10–50 
pg/mg 
- (Rust, Baumgartner 
et al. 2012) 
Butylone Blood, 
liver 
SPE 25 
(blood) 
 
50–2,000 
(blood) 
(Rojek, Kłys et al. 
2012) 
4-MEC Blood, 
urine 
LLE 0.96 
(blood), 
0.68 
(urine) 
 
10–1,000 (Gil, Adamowicz et 
al. 2013) 
MDPV, α-
PVP, α-PBP 
Hair LLE 0.02 
ng/10-
mm 
 
0.05–50 
ng/ 
10-mm 
(Namera, Urabe et 
al. 2013) 
Mephedrone Blood PP 0.08 1–100 (Adamowicz, 
Tokarczyk et al. 
2013) 
MDPV, 
mephedrone 
 
 
Blood, 
plasma, 
urine 
SPE 2 5–2,000 (Johnson and Botch-
Jones 2013) 
Mephedrone Blood, 
urine 
LLE 1 (blood), 
2 (urine) 
 
20–2,000 (Cosbey, Peters et 
al. 2013) 
 
10 Cathinones 
Blood, 
other 
specimens 
 
 
LLE 
 
- 
 
5–200 
 
(Marinetti and 
Antonides 2013) 
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Targets Samples Purification LOD 
(ppb) 
Linear 
range 
(ppb) 
References 
MDPV Hair SPE 2.0 pg/mg 
 
2–3,000 
pg/mg 
(Wyman, Lavins et 
al. 2013) 
MDPV Blood PP 0.5 5–500 (Adamowicz, Gil et 
al. 2013) 
Buphedrone Blood PP 0.3 1–1,000 (Zuba, Adamowicz 
et al. 2013) 
3,4-DMMC, 
metabolites 
 
Urine PP - 10–5,000 (Shima, Katagi et al. 
2013) 
MDPV, 
metabolites 
Plasma PP 0.1 0.25–
1,000 
(Anizan, Ellefsen et 
al. 2014) 
α-PBP 
 
Blood, 
urine, 
tissues 
 
QuEChERS 0.05 
(blood, 
urine), 
0.1 
(tissues) 
 
8.6–4,280 (Wurita, Hasegawa 
et al. 2014) 
Targets Samples Purification LOD 
(ppb) 
Linear 
range 
(ppb) 
References 
3,4-DMMC, 
metabolites 
 
Blood, 
urine 
 
QuEChERS 1.03 
(blood), 
1.37 
(urine) 
 
5–400 (Usui, Aramaki et 
al. 2014) 
MDPV 
metabolittes 
Urine PP, LLE, 
SPE 
- - (Bertol, Mari et al. 
2014) 
α-PVP, 
metabolites 
Urine PP - 10–
10,000 
(Shima, Katagi et al. 
2014) 
PV9 
 
Blood, 
urine 
 
QuEChERS 0.05 10–1,000 (Hasegawa, Wurita 
et al. 2014) 
 
Capillary electrophoresis (CE) has also been used for quantitative analysis of 
cathinones, but less than chromatographic techniques. A total of 12 cathinone 
analogs were separated optically and quantified as a racemic mixture of pure sample 
by Gustavo et al. using CE coupled with TOF-MS and UV. Only 18 minutes were 
enough to separate all analytes, where ten compounds were chiraly separated using 
β-CD in the CE-UV mode in addition to two additional cathinones which separated 
using HS-γ-CD in the MS mode. Limit of detection was found to be 1.0 ng/mL.  
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Samples of seized drugs were used as an application of the developed method 
(Merola, Fu et al. 2014). Micellar electrokinetic chromatography (MEKC) is a 
modified separation technique from CE and utilized for synthetic cathinones 
separation. Martin et al. used MEKC with tandem mass spectrometry to develop a 
method for selective separation, identification and determination of 12 synthetic 
cathinones in urine sample. Linearity in the concentration range of 10–5000 ppb was 
achieved by the developed method and detection limits were in the range of 10–78 
ppb (Švidrnoch, Lněníčková et al. 2014). They were able to validate their developed 
method and analyze a spiked urine sample using a MEKC-MS-MS system. 
Most of the synthetic cathinones are sold as a mixture of the optical 
enantiomers with one of the mixed enantiomers showing a stronger central nervous 
system (CNS) stimulatory activity than the other (Mohr, Taschwer et al. 2012). Field 
of cathinones chiral separation is growing up rapidly in parallel with the quantitative 
analysis of cathinones as a racemic mixture and strangely, to the best of our 
knowledge there is no study focusing on the quantitation of each enantiomer of 
cathinone derivatives. “Chiral quantitation” for synthetic cathinones will be carried 
out for the first time in this thesis by using chromatographic techniques. Schemes 6 - 
10 show the structures of the studied synthetic cathinones in this thesis. 
  
Scheme 6: Synthetic cathinones group 1 
    
34 
 
   
  
 
  
 
          
 
 
 
 
 
35 
 
        
 
      
 
   
 
 
 
 
 
 
36 
 
               
 
              
 
                   
 
 
 
 
  
37 
 
         
 
      
Scheme 7: Synthetic cathinones group 2 
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Scheme 8: Synthetic cathinones group 3 
 
          
                   
Scheme 9: Synthetic cathinones group 4 
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Scheme 10: Synthetic cathinones group 5 
 
 
 
 
  
42 
 
The work represented in this dissertation describes research into the 
development of methodology for the analysis of synthetic cathinones using gas 
chromatography mass spectrometry and liquid chromatography coupled to UV-Vis 
and fluorescence detections.  Chapter 2 describes the GCMS analysis using electron 
ionization of thirty one synthetic cathinones after derivatization with chiral agent, L-
TPC. Quantitative analysis of twelve synthetic cathinones in plasma and urine 
samples was conducted and the method was validated.  
Chapter 3 describes the GC-MS analysis using negative chemical ionization 
of thirty-seven synthetic cathinoines who were converted into their diastereoisomers 
after a reaction with L-TPC chiral reagent. Quantitative analysis of fourteen racemic 
mixtures of these synthetic cathinones in urine and plasma was conducted as well as 
method validation.     
Chapter 4 describes the HPLC-UV analysis of 65 synthetic cathinones using 
chiral HPLC column. Two chiral columns were examined to separate synthetic 
cathinones that have tertiary amine functional group in their structure. Around 
twenty of these compounds were successfully separated into their enantiomers on 
Astec Cellulose DMP chiral column and their separation is reported for the first time. 
Moreover, quantitative analysis of a mixture of three compounds was reported. 
Chapter 5 describes the study of the inclusion reaction between cyclodextrins 
as a host molecule and synthetic cathinones as a guest molecule; however, these 
kinds of experiments may need a large amount of the synthetic cathinones which is 
considered as an expensive and hard to get chemical. Therefore an alternative 
compound, para aminohipparic acid (PAH) has been chosen in this study as a 
simulant due to the similarity in chemical structure of this compound to cathinone 
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derivatives. A sensitive method was developed using two techniques, namely 
spectrofluorometry and liquid chromatography with fluorescence detection. 
Fluorescence signals were enhanced with the addition of β-CD in aqueous solutions. 
The experimental conditions that gave the best results were investigated in terms of 
cyclodextrin cavity size, concentration of PAH, concentration of cyclodextin, and pH 
effects. The interaction between PAH and cyclodextrin was investigated and 
considered as a host – guest inclusion which was evident by mass spectrometry and 
DFT calculations and found to be with 1:2 (host-guest) stoichiometry. A calibration 
curve was established from the spectrofluorometric data in the concentration range 
0.05 -100 µM and the detection limit was determined to be 0.015 µM. HPLC with 
fluorescence detection was investigated in the presence of β-CD in the mobile phase, 
during which the effect of concentration of β-CD in the mobile phase was also 
monitored.  
      Finally, Chapter 6 describes the conclusion of the research work in this 
dissertation and future research recommendations.    
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 Objectives of the study 
 To perform chiral separation and quantitation of primary and 
secondary amine of synthetic cathinone derivatives on GC-EI-MS 
after derivatization reaction with chiral derivatizing agent called L-
TPC.  
 To develop a sensitive and selective validated method for chiral 
quantitation of synthetic cathinones through a new GC-NCI-MS 
method and resolution enhancement by using slow heating rate in GC 
oven and the use of Ultra inert column.  
 To develope and validate a sensitive and selective method for 
detection and quantitation of the enantiomers of tertiary amine 
synthetic cathinone compounds using HPLC-UV/VIS with two 
different chiral columns in order to perform chiral separation for the 
targeted racemic mixtures. 
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Chapter 2: A validated gas chromatography mass spectrometry method 
for simultaneous determination of cathinone related drugs enantiomers in 
urine and plasma 
 Introduction 
In 1980, Khat was classified by the World Health Organization as a drug of 
abuse that can produce mild to moderate psychological dependence (Feyissa and 
Kelly 2008). It contains amphetamine-like stimulant alkaloids namely, cathinone and 
cathine (German, Fleckenstein et al. 2014), (see scheme 2 for the cathinone 
structure). In recent years, New Designer Drugs (NDDs) have been developed as 
derivatives of prohibited substances in clandestine laboratories and find their way to 
the illegal market. Different disguised names of these designer drugs have been 
marketed as “plant-growth fertilizers”, “bath-salts” and “spices” to sell them illegally 
on the black market (Boulanger-Gobeil, St-Onge et al. 2012, Wolrab, Frühauf et al. 
2016).  
All of the cathinone and amphetamine like drugs possess a chiral center 
which means that they can exist as a racemic mixture of enantiomers that have 
different potency rate in biological system as mentioned in chapter one. 
Unfortunately, drug dealers may distribute their substances as pure R or S-
enantiomers, which can increase the risk of overdose and prove lethal (Mohr, Pilaj et 
al. 2012). Recently, L-TPC has been used for chiral separation of cathinone related 
drugs on GC-MS (Mohr, Weiß et al. 2012, Weiss, Mohr et al. 2015). 
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Scheme 11: Structure of (S)-(–)-N- (trifluoroacetyl)pyrrolidine-2-carbonyl chloride 
(L-TPC) 
In this work, a GC-MS method, using electron ionization and selected ion 
monitoring (SIM) mode, has been developed to analyze 31 cathinone related 
compounds as diastereoisomers. Moreover, 18 of these compounds have been 
separated into their enantiomers for the first time. Quantitative analysis of spiked 
urine and plasma has been conducted simultaneously for a mixture of 12 cathinone 
related drugs; Scheme 12 shows the chemical structure of the 12 compounds. The 
method validation has been performed in spiked plasma and urine samples.   
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Scheme 12: Structures of synthetic cathinones that were analyzed quantitatively  
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 Experimental 
2.2.1  Chromatographic conditions 
Chromatographic separation was performed on an Agilent (Waldbronn, 
Germany) HP 6890 GC coupled to an Agilent (Waldbronn, Germany) HP 5973 mass 
selective detector. A commercially available 60 m capillary column consisting of 
(5%-Phenyl)-methylpolysiloxane, with 0.25 mm inner diameter and a 0.25 µm film 
thickness was used as stationary phase. Helium was used as carrier gas at a constant 
flow rate of 1.2 mL/min. Injection of 2 µL of sample solution was performed 
automatically with a split ratio of 21:1. The injector and GC–MS interface 
temperature were set at 250 and 280 o C, respectively. Data collection was performed 
in Selected Ion Monitoring (SIM) mode with the following selected fragments: 58, 
106, 166 and 251, and starting 10 min after injection (i.e., filament delay). The 
column temperature program was as follows: starting at 160 o C and hold for 5 min, 
followed by heating to 250 o C with a heating rate of 5oC/min. The final temperature 
was held at 250oC for 22 min. 
2.2.2 Chemicals and reagents 
All chemicals were of analytical grade. Ethylacetate, acetic acid, methanol, 2-
propanol, ammonium hydroxide, dichloromethane ,0.1 M solution of (S)-(−)-N-
(trifluoroacetyl)pyrrolidine-2-carbonyl chloride (L-TPC) with an enantiomer excess 
(ee) of 97% (according to supplier’s specification) in dichloromethane, anhydrous 
sodium sulfate, sodium phosphate and nikethamide were obtained from Sigma–
Aldrich Chemicals (St. Louis, MO, USA). Potassium carbonate was obtained from 
VWR (Darmstadt, Germany). Doubly deionized water was obtained from ultra-pure 
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Millipore system (MS, USA). All chemicals shown in Table 8 were purchased from 
Cayman chemicals (Michigan, USA). The cathinone related drugs were supplied as 
racoimic mixtures of R and S enantiomers. 
2.2.3 Sample preparation 
2.2.3.1 Samples 
This investigation conforms to the UAE community guidelines for the use of 
humans in experiments. The Human Ethics committee at the Dubai police approved 
this study.   Blood and urine samples were collected by Dubai police with the 
consent of the subjects. 
2.2.3.2 Urine and plasma spiking and solid phase extraction 
Solid phase extraction (SPE) was carried out using “Zymark rapid trace” SPE 
workstation (Artisan Technology Group, IL, USA) and the column was 200MG 
clean screen CSDAU203 from FluoroChem, (Hadfield, UK). Urine samples were 
diluted in 1:1 ratio with doubly deionized water. 3 mL of diluted urine was spiked 
with certain concentration of cathinones derivative and 50 ppm of internal standard 
(IS) (nikethamide) in addition to 1 mL of 0.1M phosphate buffer (pH 6.0). For 
plasma samples spiking, 1 mL of plasma was spiked with certain concentration of 
cathinone derivative, and 50 ppm of IS in addition to 3 mL of 0.1M phosphate buffer 
(pH 6.0). Samples were shaken well for 30 s. For SPE cartridge conditioning, 3 mL 
of methanol and the same volume of deionized water were used with 1 mL of 0.1 M 
phosphate buffer. After that the spiked urine or plasma sample was loaded to the 
cartridge and later on the cartridge was sequentially washed with 3 mL of methanol, 
3 mL of deionized water and 1 mL 0.1M acetic acid. The column was left for 5 min 
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drying. Finally, 3 mL of the eluate, which is made of a mixture of dichloromethane, 
isopropanol and ammonium hydroxide with a relative ratio of (78:20:2), was 
collected and evaporated to dryness under nitrogen gas stream.    
2.2.3.3 Derivatization step 
For pure sample and spiked sample analysis, an evaporation step was needed 
before derivatization reaction can take place. After evaporation was done, 100 µL of 
deionized water was transferred into a glass test tube together with 125 µL of a 
saturated aqueous solution of potassium carbonate, 1.5 mL of ethylacetate and 12.5 
µL of L-TPC. For the analysis of spiked urine and plasma samples, 50 µL of L-TPC 
was used.  The mixture was covered and stirred for 10 min at room temperature. 
Afterwards, the upper layer was transferred to a new test tube and dried over 
anhydrous sodium sulfate. The dried solution was evaporated under a soft nitrogen 
stream to ensure that it is free from water. The remaining L-TPC-derivative was 
reconstituted in certain amount of ethylacetate – depending on concentration, e.g.  a 
volume of 0.1 mL and 1.0 mL were used to obtain final concentration of 100 ppm 
and 10 ppm, respectively, prior to injection in GC–MS instrument.  
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 Results 
The basic idea of developing the analytical method for cathinone related 
drugs was to convert the two enantiomers of each one of these analytes into two 
diastereomers after reaction with pure chiral derivatization reagent, L-TPC (Scheme 
13). 
 
Scheme 13: Derivatization reaction between Cathinone and L-TPC 
The resulting diastereomers can be separated due to their different chemical 
and physical properties on a common stationary phase column. The derivatization 
reagent, L-TPC, reacts with analytes that have primary or secondary amine group in 
the presence of sodium carbonate that causes the amidation between the acid chloride 
and the amine group. Figure 1 shows the gas chromatogram for separation of R and S 
enantiomers of methedrone drug after derivatization with L-TPC in the presence of 
nikethamide as an internal standard. 
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Moreover, Table 8 shows the retention time of the separated enantiomers for 
the 31 cathinone related compounds.  All the tested compounds contain at least one 
primary or secondary amine in their chemical structures. Each one of these 
compounds was prepared in methanol and was analyzed individually on GC-MS 
using SIM mode, after going through the derivatization step. Among the 31 
compounds under study, twelve of these cathinone related compounds were tested in 
plasma and urine matrices. They were selected based on significant differences in the 
retention times of the two isomers as reported in Table 8. 
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Figure 1: Gas chromatogram for separation of the Rand S enantiomers of 
methedrone drug in methanol after derivatization with L-TPC in the presence of 
nikethamide internal standard 
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Table 8: List of the 31 cathinone related compounds and their synonyms, in addition 
to the retention times of the separated two diasterioisomers for each compound 
analyzed on GC-MS using SIM mode 
 
Name Abbreviation 
Time (min) 
Resolution 
Selectivity 
Factor (α) 
 
tR1 tR2 
1 4-Methylbuphedrone - 28.7 29.22 4.72 1.026 
2 Pentylone - 41.81 42.41 2.69 1.018 
3 Methedrone - 32.09 33.36 8.92 1.055 
4 
4-Methyl-α-
ethylaminobutiophenone - 29.2 29.62 3.24 1.021 
5 Nor-mephedrone - 26.15 27.5 14.89 1.079 
6 Pentedrone - 27.76 27.86 1.04 1.005 
7 Ethcathinone - 25.85 26.23 3.65 1.023 
8 Butylone - 38.6 39.59 5.22 1.033 
9 Buphedrone - 26.37 26.48 1.19 1.006 
10 2-Methoxymethcathinone 2-MeOMC 28.73 29.41 5.81 1.034 
11 4-Fluoromethcathinone 4-FMC 24.47 24.64 2.13 1.011 
12 2-Methylethcathinone 2-MEC 27.08 27.82 5.08 1.041 
13 2-Fluoromethcathinone 2-FMC 24.66 25.21 4.11 1.035 
14 2-Ethylmethcathinone 2-EMC 27.78 28.47 5.39 1.037 
15 2,3-Dimethylmethcathinone 2,3-DMMC 29.3 30.32 7.92 1.050 
16 4-Fluoroethcathinone 4-FEC 25.05 25.28 2.45 1.014 
17 4-Ethylmethcathinone 4-EMC 29.82 30.75 7.47 1.045 
18 4-Ethylethcathinone 4-EEC 30.68 31.59 6.80 1.042 
19 3-Methylmethcathinone 3-MMC 27.02 27.41 3.90 1.022 
20 3-Methylethcathinone 3-MEC 27.69 28.13 3.71 1.024 
21 3-Fluoromethcathinone 3-FMC 24.55 24.66 1.34 1.007 
22 3-Ethylmethcathinone 3-EMC 28.98 29.4 3.67 1.021 
23 3-Ethylethcathinone 3-EEC 29.7 30.17 3.91 1.023 
24 3,4-Dimethylmethcathinone 3,4-DMMC 30.6 31.54 8.04 1.044 
25 2-Methylmethcathinone 2-MMC 26.35 26.93 4.47 1.033 
26 4-Methylethcathinone 4-MEC 28.1 28.87 6.73 1.040 
27 3,4-Dimethylethcathinone 3,4-DMEC 31.42 32.34 7.39 1.041 
28 3-Fluoroethcathinone 3-FEC 25.2 25.34 1.42 1.009 
29 2,3-Methelendioxymethcathinone 2,3-MDMC 33.85 35.15 8.07 1.052 
30 3-Methoxymethcathinone 3-MeOMC 30.45 30.71 2.01 1.012 
31 Eutylone - 39.46 40.11 3.47 1.021 
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 Figure 2 shows the GC total ion chromatogram of these compounds after 
being spiked in urine. It was possible to see a good separation of the mixture 
components with good peak resolution for most of them. 
 
Figure 2: Total ion chromatogram (TIC) of the simultaneous chiral separation of 12 
cathinones related compounds. All compounds were spiked in urine and separated as 
L-TPC derivatives 
 
 
(a) 3-FMC. 
(b) 4-FEC. 
(c) Ethcathinone. 
(d) Buphedrone. 
(e) 3-MMC. 
(f) Pentedrone. 
(g) 4-Methylbuphedrone. 
(h) 3,4-DMMC. 
(i)Methedrone. 
(j) 2,3-MDMC. 
(k) Eutylone. 
(l) Pentylone. 
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Figure 3: Total ion chromatogram (TIC) of the simultaneous chiral separation of 12 
cathinones related compounds. All compounds were spiked in plasma and separated 
as L-TPC derivatives 
Figure 3 shows the total ion chromatogram of the same twelve cathinone 
related compounds spiked in plasma. It was observed that the enantiomers were 
separated nicely with good peak resolution since Rs had a value higher than 1.5 for 
most of the separated compounds. To the best of our knowledge, this is the first 
example in the literature that demonstrates the separation of 12 pairs of cathinone 
enantiomers in a single analysis and in complex matrices such as urine and plasma.  
Method validation was performed on these 12 tested compounds spiked in 
urine and plasma. The calibration curve linearity, limit of detection (LOD), limit of 
quantitation (LOQ), spike recovery in addition to inter-day and intra-day 
reproducibility were collected and are summarized in Tables 9-14.  
(a) 3-FMC. 
(b) 4-FEC. 
(c) Ethcathinone. 
(d) Buphedrone. 
(e) 3-MMC. 
(f) Pentedrone. 
(g) 4-Methylbuphedrone. 
(h) 3,4-DMMC. 
(i)Methedrone. 
(j) 2,3-MDMC. 
(k) Butylone. 
(l) Pentylone. 
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The calibration graphs for the 12 enantiomer pairs of cathinone derivatives 
were established and found to be linear within the tested range of 10 to 200 g/mL in 
urine and in plasma with mean regression coefficients (R2; n = 3) of 0.99 or higher. 
Figure 4 shows the calibration graph of the two methedrone enantiomers in plasma 
and urine. 
 
Figure 4: Calibration graphs of the two separated enantiomers of the methdrone 
compound in (a & b) urine, and (c & d) in plasma. Calibration ranges was 10-200 
ppm 
The regression coefficients and the limit of detection (LOD) and limit of 
quantitation (LOQ) values for the two enantiomers of each one of these compounds 
in urine and plasma are reported in Tables 9 and 10 respectively.  
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Table 9: Results for twelve cathinone related compounds spiked in urine including 
linearity coefficient, R2 values, Limits of detection and limits of quantitations for the 
two enantiomers of each compound 
  
R2 LOQ (ppm) LOD (ppm) 
  
E1 E2 E1 E2 E1 E2 
1 Methedrone 0.9954 0.9976 1.80 2.02 0.59 0.67 
2 Pentylone 0.9989 0.9966 2.14 1.92 0.71 0.63 
3 4M-buphedrone 0.9940 0.9986 1.33 1.25 0.44 0.41 
4 Ethcathinone 0.9954 0.9937 0.64 0.66 0.21 0.22 
5 Pentedrone 0.9907 0.9954 1.41 1.44 0.47 0.47 
6 4-FEC 0.9949 0.9957 0.67 0.67 0.22 0.22 
7 3-MMC 0.9943 0.9985 0.26 0.26 0.08 0.09 
8 3-FMC 0.9904 0.9925 0.29 0.23 0.10 0.08 
9 3,4-DMMC 0.9965 0.9979 0.31 0.32 0.10 0.11 
10 2,3-MDMC 0.9940 0.9917 0.24 0.23 0.08 0.08 
11 Eutylone 0.9988 0.9976 1.31 1.32 0.43 0.44 
12 Buphedrone 0.9952 0.9969 0.33 0.29 0.11 0.10 
 
 
Table 10: Results for twelve cathinone related compounds spiked in plasma 
including linearity coefficient, R2 values, Limits of detection and limits of 
quantitations for the two enantiomers of each compound 
 
 
R2 LOQ (ppm) LOD(ppm) 
 
 
E1 E2 E1 E2 E1 E2 
1 Methedrone 0.9927 0.9924 1.13 1.37 0.37 0.45 
2 Pentylone 0.9913 0.9973 0.81 1.00 0.27 0.33 
3 4M-buphedrone 0.9945 0.9985 1.21 2.15 0.40 0.71 
4 Ethcathinone 0.9968 0.9927 3.13 4.01 1.03 1.32 
5 pentedrone 0.9904 0.9984 4.03 2.46 1.33 0.81 
6 4-FEC 0.9972 0.9939 1.37 1.52 0.45 0.50 
7 3-MMC 0.9926 0.9983 0.50 0.52 0.16 0.17 
8 3-FMC 0.9962 0.9925 2.20 2.09 0.73 0.69 
9 3,4-DMMC 0.9986 0.9987 0.45 0.55 0.15 0.18 
10 2,3-MDMC 0.9918 0.9946 0.82 0.91 0.27 0.30 
11 Eutylone 0.9967 0.9906 0.97 1.22 0.32 0.40 
12 Buphedrone 0.9940 0.9971 0.85 1.13 0.28 0.37 
 
The accuracy and reproducibility of the method were evaluated as well in 
urine and plasma matrices. Tables 11 and 12 show the interday and intraday 
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reproducibilities of these 12 cathinone related compounds in urine and plasma 
matrices, respectively. Three different concentrations have been measured for each 
enantiomer of these compounds.  
Table 11: Inter-day and intraday reproducibility results in terms of coefficient of 
variance (CV) for twelve cathinone related compounds spiked in urine at three 
different concentration levels for the two enantiomers of each compound 
 
 
 
  
  
%CV intraday %CV interday 
  
20 ppm 100 ppm 200 ppm 20 ppm 100 ppm 200 ppm 
  
E1 E1 E2 E1 E2 E1 E1 E1 E2 E1 E2 E1 
1 Methedrone 0.31 2.04 2.86 3.05 1.50 4.13 5.39 11.27 4.68 6.29 2.78 3.91 
2 Pentylone 0.88 4.07 4.54 4.30 4.81 1.31 9.75 4.18 6.03 4.30 3.64 3.45 
3 
4Methyl- 
buphedrone 0.84 1.73 3.04 4.34 4.23 0.28 3.56 8.74 5.30 4.34 4.71 5.64 
4 Ethcathinone 1.07 3.79 2.16 3.95 5.06 3.15 3.90 9.91 1.49 3.95 4.36 2.77 
5 pentedrone 2.26 1.43 3.86 3.09 2.29 3.67 11.07 2.94 6.21 3.09 5.44 4.74 
6 4-FEC 1.23 0.91 2.04 2.27 3.66 1.59 5.61 11.87 2.31 2.27 3.72 4.98 
7 3-MMC 0.61 1.95 2.75 6.70 3.88 3.60 5.16 6.94 4.00 6.70 4.40 2.68 
8 3-FMC 1.47 10.49 0.59 2.62 2.18 2.84 3.99 14.62 6.54 2.62 1.59 2.00 
9 3,4-DMMC 2.26 1.08 4.09 3.06 1.09 1.53 6.30 9.16 6.14 3.06 2.32 2.77 
10 2,3-MDMC 5.42 2.57 3.52 2.16 5.32 2.00 6.75 7.40 5.37 2.16 3.49 1.43 
11 Eutylone 3.18 2.76 5.71 5.42 3.68 2.65 4.79 8.96 3.86 5.42 4.65 3.72 
12 Buphedrone 1.19 1.22 3.68 3.70 5.60 4.92 5.50 12.31 3.92 3.70 4.44 3.90 
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Table 12: Inter-day and intraday reproducibility results in terms of coefficient of 
variance for twelve cathinone related compounds spiked in plasma at three different 
concentration levels for the two enantiomers of each compound 
  
%CV intraday %CV interday 
  
20 ppm 100 ppm 200 ppm 20 ppm 100 ppm 200 ppm 
  
E1 E1 E2 E1 E2 E1 E1 E1 E2 E1 E2 E1 
1 Methedrone 2.44 2.95 0.39 1.67 2.91 3.06 7.92 3.90 10.90 6.30 9.56 6.27 
2 Pentylone 2.98 0.58 0.80 0.99 1.86 3.48 13.20 8.92 4.88 13.01 5.80 4.58 
3 
4Methyl- 
buphedrone 
1.45 1.30 1.38 3.65 3.01 5.29 5.91 4.94 10.85 6.57 10.25 7.89 
4 Ethcathinone 4.30 7.57 12.48 12.26 6.46 8.77 5.77 8.97 11.21 14.42 4.66 7.75 
5 pentedrone 1.35 0.48 6.20 2.20 4.70 3.21 5.77 3.06 12.27 1.97 6.64 9.59 
6 4-FEC 0.88 2.92 8.48 10.00 2.34 3.33 5.29 12.18 6.83 6.52 6.47 2.67 
7 3-MMC 1.53 1.92 6.39 8.48 5.06 9.23 3.96 6.82 9.42 13.33 12.01 12.04 
8 3-FMC 6.18 4.37 0.57 1.40 6.03 3.91 7.23 5.39 0.97 1.50 7.50 11.69 
9 3,4-DMMC 1.03 2.11 1.59 3.03 2.21 4.27 2.23 3.56 10.62 6.91 9.30 7.51 
10 2,3-MDMC 3.40 5.30 1.70 0.28 4.17 2.66 13.66 14.19 6.69 6.50 7.42 6.22 
11 Eutylone 1.62 3.21 2.59 2.01 1.73 3.20 12.12 3.33 11.24 10.72 7.35 5.37 
12 Buphedrone 2.21 5.30 7.77 9.18 2.04 3.71 2.46 9.81 5.27 12.69 8.18 5.70 
 
Moreover, the recovery measurements have been conducted by spiking 20, 
100 and 200 ppm of these compounds in urine and plasma matrices and evaluated by 
calculating the percent error. Tables 13 and 14 summarize the recovery 
measurements for the enantiomers of the 12 cathinone compounds at three different 
concentrations.  
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Table 13: Recovery measurements expressed in percent errors for three different 
concentrations of the cathinone related compounds spiked in urine matrix. 
 
 
Error % 
 
 
20 ppm 100 ppm 200 ppm 
 
 
E1 E2 E1 E2 E1 E2 
1 Methedrone 2.24 1.20 7.76 7.15 2.33 1.58 
2 Pentylone 4.69 13.26 2.97 5.09 0.23 0.36 
3 4M-buphedrone 9.98 0.45 5.51 5.35 2.24 1.21 
4 Ethcathinone 4.56 9.91 9.88 11.85 2.38 2.43 
5 pentedrone 5.87 17.72 14.01 15.14 3.10 3.30 
6 4-FEC 7.00 16.11 10.62 9.43 2.35 1.84 
7 3-MMC 2.93 0.51 10.23 4.06 2.69 0.45 
8 3-FMC 4.76 5.31 11.00 7.31 3.41 0.45 
9 3,4-DMMC 1.82 0.17 5.82 6.32 1.96 1.10 
10 2,3-MDMC 8.77 8.87 11.52 13.37 2.52 3.16 
11 Eutylone 8.11 9.13 4.02 4.32 1.14 0.30 
12 Buphedrone 4.69 12.12 9.00 7.50 2.44 1.26 
 
 
Table 14: Recovery measurements expressed in percent errors for three different 
concentrations of the cathinone related compounds spiked in plasma matrix. 
 
 
Error % 
 
 
20 ppm 100 ppm 200 ppm 
 
 
E1 E2 E1 E2 E1 E2 
1 Methedrone 18.51 10.36 11.90 9.11 2.08 2.90 
2 Pentylone 5.13 13.00 3.74 1.49 2.25 0.36 
3 4M-buphedrone 7.82 3.64 1.46 0.91 0.80 0.41 
4 Ethcathinone 4.80 12.06 2.81 9.09 0.16 0.99 
5 pentedrone 8.86 3.56 14.64 1.92 3.20 1.00 
6 4-FEC 7.81 6.40 2.67 4.26 0.17 0.25 
7 3-MMC 6.08 3.37 3.79 3.21 0.48 0.13 
8 3-FMC 4.05 0.49 4.49 9.54 1.79 2.96 
9 3,4-DMMC 16.67 2.88 3.25 4.02 0.70 1.24 
10 2,3-MDMC 23.71 13.90 9.79 9.05 2.04 2.44 
11 Eutylone 0.21 4.48 7.73 7.87 1.38 0.48 
12 Buphedrone 9.50 34.40 3.94 1.65 0.25 0.67 
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 Discussion 
L –TPC is one of the known chiral derivatizing agents (CDA) that can 
interact easily with primary and secondary amine of cathinone related drugs. It can 
react with the enantiomers and produces two corresponding diastereomers.  The 
enantioseparation was possible due to the difference of stereochemistry and stability 
of the formed diastereoisomers on achiral stationary phase which led to different 
resolution of products (Toyo'oka 2002, Płotka, Biziuk et al. 2011). The separation of 
enantiomers on achiral stationary phase is difficult since they have the same physical 
and chemical properties, by contrast, diastereoisomers have a different physical and 
chemical properties (i.e., different boiling point, solubility) which lead to variation 
on the interaction of these diastereoisomers with the achiral stationary phases.  All 
cathinone related compounds in Table 8 have been derivatized by L–TPC where each 
one of them has formed a unique product after interacting with the derivatizing 
agent. Thirty-one racemic mixtures of cathinone derivatives have been separated as 
their diastereoisomers, as shown in the example of methedrone in Figure 1. Eighteen 
of them have been separated for the first time. Moreover, the enantioseparations that  
were obtained showed that the peak areas of some enantiomers were not equal and 
the reason of that according to Mohr (Mohr, Weiß et al. 2012) is due to racemization 
of L-TPC during the derivatization reaction, kinetic resolution of the two 
enantiomers and the difference in diastereoisomers yields as a result of keto-enol 
tautomerization of the analytes. Interestingly, it was possible to separate 12 of these 
cathinone derivatives simultaneously in one chromatogram after spiking them in 
urine and plasma samples since they have a different retention times in the new 
developed method, unlike Mohr method where overlapped between many of the 
63 
 
cathinone derivatives were observed. Calibration curves of 12 selected cathinone 
derivatives in urine and plasma were constructed based on the diastereoisomers peak 
areas for the following concentrations: 5, 10, 20, 50, 100, 200 ppm. Figure 4 shows 
the calibration graphs for methedrone enantiomers in plasma and urine sample 
matrices. One can see a good linearity of the four calibration lines in addition to high 
correlation coefficient (R2) values. In all these calibration measurements, 
nikethamide (50 ppm) was added to each sample in the quantitation step as an 
internal standard, due to its similar structure to cathinones and good stability. The R2 
values of the constructed calibration curves for both enantiomers of 12 selected 
cathinone drivatives \ have been measured in spiked samples where most of them 
showed R2 value higher than 0.99 in most cases as shown in Tables 9 and 10. 
Moreover, the Limits of Detection (LOD) and Limits of Quantitation (LOQ) for 
these enantiomers were calculated according to the IUPAC Method and reported in 
the Tables 9 and 10. The LOD in urine was in the range of 0.1 -0.7 ppm and in 
plasma it was in the range of 0.17 -1.33 ppm. The LOQ in urine was in the range of 
0.29 - 2.14 ppm and in plasma it was in the range of 0.50 - 4.01 ppm. 
The inter day and intraday reproducibility measurements of the twelve 
cathinone related compounds in urine and plasma were evaluated and reported at 
three different concentration levels in Tables 11 and 12. It was observed that the 
method has good reproducibility and repeatability, since most of the coefficients of 
variance values were below 5 % in both urine and plasma matrices for measurements 
done on the same day or at two different days. Spiked urine samples were more 
reproducible than spiked plasma due to the competition between analyte and blood 
interferences unlike spiked urine samples where the dilution with deionized water 
took place. 
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Efficiency of solid phase extraction (SPE) and its effect on the method 
recovery has been studied by percent error calculations for the spiked mixture of the 
12 cathinone related compounds in plasma and urine samples at the following 
concentration levels: 20, 100 and 200 ppm. Most of the values in recovery studies 
were within the acceptable range except some of them in spiked plasma sample. The 
reason is due to the inefficiency in the extraction method for plasma sample which 
were probably because of the presence of proteins and other interferences that can 
cause difficulty in solid phase extraction process (Prabu and Suriyaprakash 2012). 
However, the spiked urine samples gave much better recovery results since they were 
diluted with deionized water twice.  
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2.5 Conclusion 
It was possible to develop a sensitive and selective method for detection and 
quantitation of cathinone related compounds using GC-MS after indirect chiral 
derivatization with (S)-(–)-N- (trifluoroacetyl) pyrrolidine-2-carbonyl chloride (L-
TPC). Thirty-one compounds of synthetic cathinones were separated as their optical 
enantiomers successfully using a 60m HP5-MS capillary column. Nikethamide was 
used as an internal standard in cathinones quantitation which has similar chemical 
structure to cathinones and showed good stability. Twelve cathinone derivatives were 
separated in one chromatogram simultaneously after spiking in urine and plasma 
sample. Calibration curves of twelve selected cathinone derivatives in urine were 
constructed including the following concentrations: 5, 10, 20, 50, 100, 200 ppm. 
Method validation in terms of recoveries, reproducibilities, linearities, LOD, and 
LOQ for all the tested compounds was also done. It was found that the LOD’s of the 
12 cathinone derivatives in urine was in the range of 0.1 -0.7 ppm and in plasma it 
was in the range of 0.17 -1.33 ppm. The LOQ’s in urine was in the range of 0.29 - 
2.14 ppm and in plasma it was in the range of 0.50 - 4.01 ppm. 
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Chapter 3: Development and validation of an analytical methodology for 
the simultaneous quantitative determination of synthetic cathinones in 
urine and plasma using GC-NCI-MS 
 Introduction 
From the beginning of the new century till now, governments and forensic 
science specialists are suffering from a nightmare called new designer drugs (NDDs) 
such as synthetic cathinones which comprise a risk in society that is growing up day 
by day. In nature, cathinone (β-keto amphetamine) exists in the leaves of the Catha 
edulis plant which can be found easily in the region of northeast Africa and the 
Arabian Peninsula (Banks, Worst et al. 2014). However, scientists have synthesized 
cathinone in laboratory when  the Germans and the French chemists reported the 
synthesis of methcathinone for the first time in late 1920’s as mentioned in chapter 
one (Sikk and Taba 2015).  
During the 1930’s and 1940’s, methcathinone was available in 
pharmacological markets as an appetite suppressant and antidepressant medicine 
(Glennon, Martin et al. 1995). Methcathinone abuse spread to USA in 1991 and as a 
result of that it was included in UN Convention on Psychotropic Substances 
(DeRuiter, Hayes et al. 1994). 
In the meantime, drug dealers were looking for new strategies to sell their 
products and they found it by the “legal high” drugs (NDD) which contain at least 
one chemical substance that has similar biological effects as of illegal drugs. For 
instance, “Explosion” is the trade name of the synthetic cathinone methylone, which 
emerged for sale in Japan and Netherlands via the Internet in 2004 (Bossong, Van 
Dijk et al. 2005). In 2007, 4-methylmethcathinone (mephedrone) became one of the 
most commonly abused drugs in Europe (Bossong, Van Dijk et al. 2005). Thus, 
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concerns about the abuse of legal highs drugs especially cathinone related derivatives 
grew up in Europe which gave rise to ban of cathinone derivatives in April 2010 by 
the UK government and by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) (Dargan, Sedefov et al. 2011). Despite all the actions taken 
by legal authorities, an intensive attention by drug dealers have been put on the 
synthesis of new generations of synthetic cathinone derivatives.  
In order to obviate the abuse risks of these psychoactive stimulants, focused 
studies should be carried out on the neuropharmacological properties for each 
enantiomer of these active compounds. As a result of that, enantioseparation of chiral 
synthetic cathinones became an attractive and promised field of research where the 
use of major separation techniques took place such as: Gas Chromatography (GC) 
(Mohr, Weiß et al. 2012, Weiss, Mohr et al. 2015), High Performance Liquid 
Chromatography (HPLC) (Mohr, Taschwer et al. 2012, Padivitage, Dodbiba et al. 
2014, TASCHWER, SEIDL et al. 2014, Li and Lurie 2015, Weiss, Taschwer et al. 
2015, Wolrab, Frühauf et al. 2016) and Capillary Electrophoresis (CE) (Fanali 2000, 
Mohr, Pilaj et al. 2012, Aturki, Schmid et al. 2014, Merola, Fu et al. 2014, Taschwer, 
Hofer et al. 2014, Taschwer, Weiß et al. 2014, Li and Lurie 2015, Moini and 
Rollman 2015).   
In the literature, only two papers have discussed the chiral separation of L-
TPC cathinone derivatives by using GC-EI-MS (Mohr, Weiß et al. 2012, Weiss, 
Mohr et al. 2015). Electron Iionization (EI) is the most preferable ionization source 
in GC/MS which provides characteristic and reproducible mass spectrum for each 
compound. EI is considered as a harsh ionization technique which provides mass 
spectra that are crowded with fragments and for some compounds (e.g., primary 
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alcohol) the molecular ion peak is absent (Li, Gan et al. 2015). Recently, a short 
communication on the analysis of twenty nine synthetic cathinones in GC – MS/MS 
with positive chemical ionization mode (PCI) has been reported (Waters, Ikematsu et 
al. 2016). However, no quantitative assessment was given for these compounds in 
biological fluids. Unlike EI source, determination of molecular weight and structure 
elucidation can be carried out through the use of chemical ionization source coupled 
with tandem mass spectrometry (Waters, Ikematsu et al. 2016). Furthermore, when 
the investigated compounds are electronegative moieties, the use of negative 
chemical ionization (NCI) mode can dramatically improve the detection sensitivity 
of the targeted compounds (Wu, Lin et al. 2008). There are no literature reports that 
discuss the use of negative chemical ionization mode in GC – MS to analyze 
synthetic cathinones.  
In this work, a sensitive and selective GC-NCI-MS method has been 
developed to analyze thirty-six synthetic cathinone compounds after their conversion 
into diastereoisomers through the derivatization reaction with L-TPC. Quantitative 
analysis of spiked urine and plasma samples were conducted for fourteen of these 
synthetic cathinones (see scheme 14) which were run in one mixture simultaneously. 
The method validation was performed in spiked biological samples.  
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Scheme 14: Structures of tertiary amine synthetic cathinones that analyzed 
quantitatively 
      
 Experimental 
3.2.1  Chromatographic conditions 
Chromatographic separation was performed on an Agilent 7890A GC 
coupled to an Agilent HP 7000 Triple Quad mass selective detector. A commercially 
available 60 m Ultra inert capillary column consisting of (5%-Phenyl)-
methylpolysiloxane, with 0.25 mm inner diameter and a 0.25 µm film thickness was 
used as stationary phase. Chemical ionization (CI) with methane gas (40%, 2.0 
ml/min) was employed in the negative ion mode at a voltage of 70 eV. Helium was 
used as carrier gas at a constant flow rate of 0.8 ml/min. Injection of 3 µl of sample 
solution was performed automatically in splitless mode. The injector and GC–MS 
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interface temperature were set at 250 and 280 ◦C, respectively. Data collection was 
performed in Selected Ion Monitoring (SIM) mode with the selected fragments as 
shown in Table 15 starting at 30 min after injection. The column temperature 
program was as follows: starting at 160 ◦C held for 5 min, followed by subsequent 
heating to 260 oC at a heating rate of 2 oC /min. The final temperature was held at 
260 oC for 10 min. 
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Table 15: Time segments table with selected ions used in SIM mode for the analysis 
of cathinones mixture 
Compound Name Abbreviation Time m/z 
(+)-Cathinone - 39.00-41.00 189, 209, 342 
4-Fluoromethcathinone 4-FMC 41.00-42.50 153, 223, 374 
4-Fluoroethcathinone 4-FEC 42.50-44.70 167, 237, 388 
Nor-Mephedrone - 44.70-45.06 189, 209, 356 
Buphedrone 
3-Methylmethcathinone 
- 
 
3-MMC 
45.06-47.13 153, 223, 370 
Nor-Mephedrone - 47.13-48.00 189, 209, 356 
3-Mehtylbuphedrone 
4-Methylbuphedrone 
3-Ethylmethcathinone 
- 
- 
 
3-EMC 
48.00-50.15 153, 223, 384 
3-Ethylethcathinone 
4-Ethylethcathinone 
3,4-Dimethylethcathinone 
3-EEC 
4-EEC 
3,4-DMEC 
50.15-54.00 167, 237, 398 
2,3-Methelendioxymethcathinone 2,3-MDMC 54.00-59.00 153, 223, 400 
Butylone - 59.00-62.00 153, 223, 414 
Pentylone - 62.00-65.00 156, 223, 428 
 
3.2.2 Chemicals and reagents 
All chemicals were of analytical grade. Ethylacetate, acetic acid, methanol, 2-
propanol, ammonium hydroxide, dichloromethane, 0.1 M solution of (S)-(−)-N-
(trifluoroacetyl) pyrrolidine-2-carbonyl chloride (L-TPC) with an enantiomer excess 
(ee) of 97% (according to supplier’s specification) in methylene chloride, anhydrous 
sodium sulfate and sodium phosphate were obtained from Sigma–Aldrich Chemicals 
(St. Louis, MO, USA). Potassium carbonate was obtained from VWR (Darmstadt, 
Germany). Doubly deionized water was obtained from ultra-pure Millipore system 
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(MS, USA). All chemicals shown in Table 16 were purchased from Cayman 
chemicals (Michigan, USA), and were provided as racemic mixtures for individual 
cathinones. 
3.2.3 Sample preparation 
3.2.3.1 Samples 
This investigation conforms to the UAE community guidelines for the use of 
humans in experiments. The Human Ethics committee at the Dubai police approved 
this study.   Blood and urine samples were collected by Dubai police with the 
consent of the subjects. 
3.2.3.2 Solid phase extraction (SPE) of spiked urine and plasma samples 
SPE was carried out for the spiked urine and plasma samples as shown in 
extraction steps of section 2.2.3.2.  
3.2.3.3 Derivatization step 
Derivatization steps were carried out for the pure and spiked samples as 
shown in section 2.2.3.3.  
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 Results 
The indirect chiral separation method that has been developed is based on the 
conversion of synthetic cathinones to L-TPC derivatives. A normal (or achiral) 
stationary phase column has been used for the separation of the resulting 
diastereomers due to their different chemical and physical properties. The primary 
and secondary amine cathinones react with the derivatization reagent L-TPC in the 
presence of sodium carbonate, the amidation reaction occurs between the acid 
chloride in L-TPC and the amine group of the target analytes. The gas chromatogram 
in Figure 5 shows the separation of the (R) and (S) enantiomers of Nor-mephedrone 
drug after derivatization with L-TPC. 
 
Figure 5: Gas chromatogram for separation of the R and S enantiomers of Nor-
mephedrone drug in ethyl acetate after derivatization with L-TPC 
Table 16 shows the retention times, resolution, and selectivity factors of the 
separated enantiomers of all the studied synthetic cathinones.  All compounds in 
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Table 16 were analyzed individually on GC-MS using SIM mode, after going 
through the derivatization step.  
Table 16: List of the 36 cathinone related compounds and their synonyms, in 
addition to the retention times of the separated two diasterioisomers for each 
compound analyzed on GC-MS using SIM mode 
 Name Abbreviations 
Time (min) 
Resolution 
Selectivity 
Factor (α) 
 
tR1 tR2 
1 2-Methoxymethcathinone 2-MeOMC 48.98 49.98 9.59 1.03 
2 3-Fluoroethcathinone 3-FEC 43 43.3 2.64 1.01 
3 4-Fluoroethcathinone 4-FEC 42.7 43.2 3.47 1.01 
4 
2,3-
Methylenedioxymethcathinone 
2,3-MDMC 55.1 56.4 10.03 1.03 
5 2-Methylmethcathinone 2-MMC 45.1 46.2 9.61 1.03 
6 Nor-Mephedrone - 44.9 47.2 17.07 1.06 
7 4-Ethylethcathinone 4-EEC 51.6 52.5 7.03 1.02 
8 3,4-Dimethylethcathinone 3,4-DMEC 52.8 53.6 6.56 1.02 
9 2-Ethylmethcathinone 2-EMC 47.5 48.6 9.69 1.03 
10 3-Methoxymethcathinone 3-MeOMC 51.4 51.7 2.97 1.01 
11 2-Fluoromethcathinone 2-FMC 41.9 43 8.71 1.03 
12 4-Ethylmethcathinone 4-EMC 50.5 51.7 11.61 1.03 
13 3-Ethylethcathinone 3-EEC 50.4 51 4.72 1.01 
14 4-Methylbuphedrone - 48.96 49.4 3.42 1.01 
15 2,3-Dimethylmethcathinone 2,3-DMMC 49.7 51.1 12.61 1.03 
16 3-Ethylmethcathinone 3-EMC 49.8 50 1.55 1.00 
17 3-Fluoromethcathinone 3-FMC 41.7 41.98 2.45 1.01 
18 4-Fluoromethcathinone 4-FMC 41.5 41.96 3.08 1.01 
19 2-Methylethcathinone 2-MEC 46.3 47.6 10.88 1.03 
20 Buphedrone - 45.2 45.4 1.48 1.01 
21 
4-Methyl-α-
ethylaminobutiophenone 
- 49.7 50.3 5.80 1.01 
22 Pentedrone - 47.6 47.7 1.07 1.00 
23 Butylone - 59.7 60.6 5.84 1.02 
24 Pentylone - 62.6 63.2 3.40 1.01 
25 4-Methylethcathinone 4-MEC 48 49.2 11.70 1.03 
26 Ethcathinone - 44.2 44.9 6.16 1.02 
27 3-Methylmethcathinone 3-MMC 46.3 47 5.33 1.02 
28 4-Bromomethcathinone 4-BMC 53.96 54.3 2.93 1.01 
29 3-Bromomethcathinone 3-BMC 42.9 43.6 4.72 1.02 
30 2,4-Dimethylmethcathinone 2,4-DMMC 48.5 49.96 13.67 1.04 
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# Name Abbreviations T1 T2 Resolution α 
31 2,4-Dimethylethcathinone 2,4-DMEC 49.8 51.2 12.15 1.03 
32 
3,4-Methylenedioxy-N-
ethylcathinone 
Ethylone 58.6 59.9 9.96 1.03 
33 3-Methylbuphedrone - 48.4 48.5 0.80 1.00 
34 N-Ethylbuphedrone NEB 45.9 46.1 1.93 1.01 
35 2,3-Pentylone isomer - 59.1 59.9 7.37 1.02 
36 3-Methylethcathinone 3-MEC 47.4 48.1 6.66 1.02 
    
Figures 6 and 7 show the total ion chromatogram of the fourteen synthetic 
cathinones spiked in urine and plasma, respectively. 
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Figure 6: Total ion chromatogram (TIC) of the simultaneous chiral separation of 14 
synthetic cathinone compounds spiked in urine and separated as L-TPC derivatives 
as the following: (a) 4-FMC, (b) 4-FEC, (c) Nor-mephedrone, (d) Buphendrone, (e) 
3-MMC, (f) 3-Methylbuphedrone, (g) 4-Methylbuphedrone, (h) 3-EMC, (i) 3-EEC, 
(j) 4-EEC, (k) 3,4-DMEC, (l) 2,3-MDMC, (m) Butylone and (n)Pentylone 
 
Figure 7: Total ion chromatogram (TIC) of the simultaneous chiral separation of 14 
synthetic cathinone compounds spiked in plasma and separated as L-TPC derivatives 
as the following: (a) 4-FMC, (b) 4-FEC, (c) Nor-mephedrone, (d) Buphendrone, (e) 
3-MMC, (f) 3-Methylbuphedrone, (g) 4-Methylbuphedrone, (h) 3-EMC, (i) 3-EEC, 
(j) 4-EEC, (k) 3,4-DMEC, (l) 2,3-MDMC, (m) Butylone and (n) Pentylone 
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
40 45 50 55 60 65
A
b
u
n
d
an
ce
Time (min)
(a)
(b (c) (c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k) (l)
(m) (n)
0
10000
20000
30000
40000
50000
60000
70000
80000
40 45 50 55 60 65
A
b
u
n
d
an
ce
Time (min)
(a (b)
(c)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k)
(l)
(m)
(n)
78 
 
The resulted enantiomer peaks were well separated with good peak 
resolution. To our knowledge, this is the first example in the literature that 
demonstrates the separation of fourteen pairs of L-TPC cathinone derivatives in one 
run analysis for these compounds in complex matrices of urine and plasma.    
Validation of the developed method was performed on spiked mixtures 
successfully. Linearity of the calibration curves, limit of detection (LOD), limit of 
quantitation (LOQ), recoveries in addition to inter-day and intra-day reproducibilities 
were collected and summarized in Tables 17-22.  
The calibration curves for the fourteen synthetic cathinones derivatives were 
found to be linear within the tested range of 1 to 100 ppb  in urine and in plasma 
except some of them which had a range that extended from 5 to 100 ppb  with mean 
regression coefficients (R2; n = 3) higher than 0.99. Figure 8 shows the calibration 
graph of the formed diastereoisomers of nor-mephedrone in plasma and urine. 
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Figure 8: Calibration graphs of the two separated enantiomers of the Nor-
mephedrone compound in (a & b) plasma, and (c & d) in urine. Calibration ranges 
was 1-100 ppb 
The regression coefficients, the limit of detection (LOD) and limit of 
quantitation (LOQ) values for the two enantiomers of the synthetic cathinone 
compounds in the mixture that were spiked in urine and plasma are reported in 
Tables 17 and 18 respectively. 
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Table 17: Results for fourteen cathinone related compounds spiked in urine including 
linearity coefficient, R2 values, limit of detection and limit of quantitations for the 
two enantiomers of each compound 
  
R2 ± SD LOQ ± SD (ppb) LOD ± SD (ppb) 
 
Name E1 E2 E1 E2 E1 E2 
1 4-FMC 
0.9912 ± 
0.0017 
0.9925 ± 
0.0006 
1.20 ± 
0.0225 
1.09 ± 
0.0259 
0.397 ± 
0.0074 
0.362 ± 
0.0085 
2 4-FEC 
0.9960 ± 
0.0005 
0.9937 ± 
0.0016 
1.17 ± 
0.0329 
1.35 ± 
0.0353 
0.38 ± 
0.0109 
0.44 ± 
0.0117 
3 Nor-mephedrone 
0.9943 ± 
0.0028 
0.992 ± 
0.0019 
0.89 ± 
0.0292 
1.366 ± 
0.0054 
0.294 ± 
0.0096 
0.451 ± 
0.0018 
4 Buphedrone 
0.9944 ± 
0.0025 
0.9938 ± 
0.0018 
0.309 ± 
0.0054 
0.254 ± 
0.0062 
0.102 ± 
0.0018 
0.084 ± 
0.0020 
5 3-MMC 
0.9943 ± 
0.0048 
0.9928 ± 
0.0023 
0.313 ± 
0.0069 
0.192 ± 
0.0047 
0.103 ± 
0.0023 
0.063 ± 
0.0016 
6 
3-
Methylbuphedrone 
0.9937 ± 
0.0039 
0.9944 ± 
0.0028 
0.147 ± 
0.0019 
0.122 ± 
0.0037 
0.0485 ± 
0.0006 
0.040 ± 
0.0012 
7 
4-
Methylbuphedrone 
0.9932 ± 
0.0034 
0.9911 ± 
0.0036 
0.238 ± 
0.0036 
0.382 ± 
0.0076 
0.078 ± 
0.0012 
0.126 ± 
0.0025 
8 3-EMC 
0.9952 ± 
0.0043 
0.9909 ± 
0.0009 
0.180 ± 
0.0046 
0.326 ± 
0.0089 
0.059 ± 
0.0015 
0.108 ± 
0.0030 
9 3-EEC 
0.994 ± 
0.0028 
0.9936 ± 
0.0029 
0.43 ± 
0.0111 
0.40 ± 
0.0127 
0.141 ± 
0.0037 
0.131 ± 
0.0042 
10 4-EEC 
0.9954 ± 
0.0014 
0.9926 ± 
0.0013 
0.207 ± 
0.0064 
0.264 ± 
0.0087 
0.068 ± 
0.0021 
0.087 ± 
0.0029 
11 3,4-DMEC 
0.9931 ± 
0.0004 
0.9925 ± 
0.0013 
0.192 ± 
0.0054 
0.218 ± 
0.0071 
0.063 ± 
0.0017 
0.072 ± 
0.0024 
12 2,3-MDMC 
0.9925 ± 
0.003 
0.9918 ± 
0.001 
0.520 ± 
0.0257 
0.520 ± 
0.0254 
0.173 ± 
0.0085 
0.172 ± 
0.0084 
13 Butylone 
0.9948 ± 
0.0024 
0.9922 ± 
0.0046 
0.326 ± 
0.0058 
0.214 ± 
0.0042 
0.107 ± 
0.0019 
0.070 ± 
0.0014 
14 Pentylone 
0.9918 ± 
0.0023 
0.9941 ± 
0.0024 
0.465 ± 
0.0067 
0.3117 ± 
0.0008 
0.153 ± 
0.0022 
0.1028 ± 
0.0002 
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Table 18: Results for fourteen cathinone related compounds spiked in plasma 
including linearity coefficient, R2 values, limit of detection and limit of quantitations 
for the two enantiomers of each compound 
 
 
   
  
R2 ± SD LOQ ± SD (ppb) LOD ± SD (ppb) 
 
Name E1 E2 E1 E2 E1 E2 
1 4-FMC 
0.9931 ± 
0.0029 
0.9939 ± 
0.0048 
1.200 ± 
0.0225 
1.09 ± 
0.0259 
0.398 ± 
0.0074 
0.362 ± 
0.0085 
2 4-FEC 
0.9943 ± 
0.0017 
0.9940 ± 
0.0009 
1.510 ± 
0.0426 
1.75 ± 
0.0456 
0.500 ± 
0.0141 
0.580 ± 
0.0151 
3 Nor-mephedrone 
0.9930 ± 
0.0004 
0.9942 ± 
0.0029 
0.910 ± 
0.0299 
1.397 ± 
0.0056 
0.301 ± 
0.0099 
0.461 ± 
0.0018 
4 Buphedrone 
0.9941 ± 
0.0036 
0.9940 ± 
0.0018 
0.326 ± 
0.0057 
0.268 ± 
0.0065 
0.108 ± 
0.0019 
0.088 ± 
0.0022 
5 3-MMC 
0.9934 ± 
0.0015 
0.9923 ± 
0.0023 
0.386 ± 
0.0085 
0.237 ± 
0.0058 
0.127 ± 
0.0028 
0.0781 ± 
0.0019 
6 
3-Methyl 
buphedrone 
0.9922 ± 
0.0018 
0.9934 ± 
0.0033 
0.160 ± 
0.0020 
0.133 ± 
0.0040 
0.0529 
± 
0.0007 
0.044 ± 
0.0013 
7 
4-Methyl 
buphedrone 
0.9916 ± 
0.0013 
0.9946 ± 
0.0016 
0.265 ± 
0.0040 
0.426 ± 
0.0084 
0.087 ± 
0.0013 
0.141 ± 
0.0028 
8 3-EMC 
0.9920 ± 
0.0010 
0.9923 ± 
0.0014 
0.209 ± 
0.0053 
0.38 ± 
0.0104 
0.069 ± 
0.0018 
0.125 ± 
0.0034 
9 3-EEC 
0.9931 ± 
0.0035 
0.9932 ± 
0.0032 
0.460 ± 
0.0119 
0.43 ± 
0.0137 
0.152 ± 
0.0039 
0.142 ± 
0.0045 
10 4-EEC 
0.9930 ± 
0.0007 
0.9931 ± 
0.0026 
0.243 ± 
0.0075 
0.31 ± 
0.0103 
0.080 ± 
0.0025 
0.103 ± 
0.0034 
11 3,4-DMEC 
0.9906 ± 
0.0009 
0.9929 ± 
0.0015 
0.229 ± 
0.0064 
0.260 ± 
0.0085 
0.076 ± 
0.0021 
0.086 ± 
0.0028 
12 2,3-MDMC 
0.9918 ± 
0.0022 
0.9929 ± 
0.0019 
0.630 ± 
0.0310 
0.63 ± 
0.0307 
0.210 ± 
0.0102 
0.210 ± 
0.0101 
13 Butylone 
0.9920 ± 
0.002 
0.9906  ± 
0.0026 
0.760 ± 
0.0134 
0.497 ± 
0.0098 
0.250 ± 
0.0044 
0.164 ± 
0.0032 
14 Pentylone 
0.9909 ± 
0.0011 
0.9934 ± 
0.0034 
0.644 ± 
0.0093 
0.431 ± 
0.0011 
0.212 ± 
0.0031 
0.1422 ± 
0.0004 
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Three different concentration levels were tested for each enantiomer of these 
compounds (20, 60 and 100 ppb) in order to ensure the reproducibility and to provide 
the recovery study of the new method. The interday and intraday reproducibilities of 
the cathinones mixture in urine and plasma matrices are shown in Tables 19 and 20 
respectively. 
Table 19: Interday and intraday reproducibility results in terms of coefficient of 
variance for fourteen cathinone related compounds spiked in urine at three different 
concentration levels for the two enantiomers of each compound 
 
 
 
 
  
  
CV% intraday CV% interday 
  
20 ppb 60 ppb 100 ppb 20 ppb 60 ppb 100 ppb 
  
E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 
1 4-FMC 3.61 3.11 1.04 1.79 0.41 1.33 10.26 11.85 10.28 12.02 8.14 7.60 
2 4-FEC 2.22 5.32 1.75 1.53 2.03 1.69 5.67 10.90 14.69 15.74 15.80 16.13 
3 
Nor-
mephedrone 
0.70 1.01 2.13 1.64 2.00 2.17 3.07 4.57 3.50 4.43 1.75 4.91 
4 Buphedrone 1.42 1.60 1.89 2.28 2.12 1.17 5.60 14.08 15.31 16.91 16.62 15.29 
5 3-MMC 3.68 2.03 0.93 1.66 0.39 1.34 12.27 9.02 1.72 2.41 0.82 1.29 
6 
3-Methyl 
buphedrone 
1.36 3.07 2.06 4.48 0.93 1.09 5.32 14.73 6.73 11.96 10.04 9.44 
7 
4-Methyl 
buphedrone 
1.25 2.16 0.35 0.75 0.68 1.14 3.73 11.28 9.25 2.04 10.22 9.93 
8 3-EMC 2.38 2.57 0.63 2.10 0.74 1.69 14.53 14.81 13.18 3.51 7.62 10.98 
9 3-EEC 3.22 6.13 1.13 3.60 1.71 2.13 13.29 15.44 8.42 10.94 3.27 4.10 
10 4-EEC 3.45 1.85 0.93 2.17 0.84 0.82 14.48 11.31 9.31 12.68 7.19 1.80 
11 3,4-DMEC 3.70 3.50 1.97 1.02 3.44 2.16 16.54 14.77 10.92 14.49 3.07 2.62 
12 2,3-MDMC 2.07 3.24 3.16 1.43 4.11 5.56 5.50 4.43 13.57 14.03 5.74 6.60 
13 Butylone 5.14 6.26 1.36 0.50 0.85 0.88 12.57 14.11 14.56 14.90 1.25 1.56 
14 Pentylone 7.10 1.34 2.59 1.84 1.83 0.19 12.98 5.99 12.77 14.03 2.29 3.86 
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Table 20: Interday and intraday reproducibility results in terms of coefficient of 
variance for fourteen cathinone related compounds spiked in plasma at three different 
concentration levels for the two enantiomers of each compound 
  
CV% intraday CV% interday 
  
20 ppb 60 ppb 100 ppb 20 ppb 60 ppb 100 ppb 
  
E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 
1 4-FMC 6.00 4.79 2.59 5.36 2.26 2.59 11.01 10.60 10.99 13.30 10.95 12.35 
2 4-FEC 10.57 11.65 5.31 3.89 1.69 2.21 7.44 8.43 7.59 11.25 6.65 7.76 
3 
Nor- 
mephedrone 
7.59 7.95 3.07 3.51 2.79 6.97 6.01 7.10 14.13 6.48 14.30 14.21 
4 Buphedrone 11.13 10.88 3.37 6.27 1.32 3.14 8.04 8.49 13.39 14.26 5.00 8.32 
5 3-MMC 9.74 12.68 4.55 6.19 2.51 3.69 8.42 9.85 4.03 4.78 16.30 16.97 
6 
3-Methyl 
buphedrone 
10.58 11.42 5.04 5.44 1.19 3.58 7.00 7.90 10.55 15.34 13.67 14.31 
7 
4-Methyl 
buphedrone 
9.77 11.67 5.41 4.49 2.42 2.82 9.25 11.85 19.55 6.83 18.03 19.59 
8 3-EMC 11.36 8.27 5.41 4.55 3.01 3.16 11.35 9.79 19.65 7.13 19.04 17.92 
9 3-EEC 8.81 12.64 4.30 5.28 3.15 3.71 6.62 9.27 10.19 12.67 14.15 14.82 
10 4-EEC 11.48 10.53 6.12 4.48 4.24 3.59 8.31 9.46 19.81 19.90 10.97 15.42 
11 3,4-DMEC 12.11 13.14 4.50 6.31 3.26 3.06 9.44 11.05 18.98 20.31 9.66 15.70 
12 2,3-MDMC 10.94 7.12 2.74 4.02 7.24 7.13 9.20 5.11 3.41 4.46 19.77 19.35 
13 Butylone 10.78 12.89 4.97 6.67 2.63 3.25 11.42 13.60 3.66 7.62 9.06 9.14 
14 Pentylone 10.20 18.64 3.74 5.93 2.00 2.06 10.29 19.91 9.77 6.67 5.01 6.59 
 
 Moreover, percent error evaluation has been done for the spiked mixture to 
obtain the recovery study which is summarized in Tables 21 and 22. 
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Table 21: Recovery measurements expressed in percent errors for three different 
concentrations of the cathinone related compounds spiked in urine matrix 
  
Error % 
  
20 ppb 60 ppb 100 ppb 
  
E1 E2 E1 E2 E1 E2 
1 4-FMC 0.80 10.57 9.49 8.47 1.24 0.68 
2 4-FEC 9.28 5.31 2.38 9.21 0.10 0.61 
3 Nor-mephedrone 8.67 7.48 1.82 4.48 1.71 0.69 
4 Buphedrone 9.12 5.58 4.84 4.88 1.90 0.72 
5 3-MMC 3.91 3.02 4.91 3.54 0.25 0.91 
6 3-Methylbuphedrone 3.71 9.13 4.09 0.15 1.54 1.77 
7 4-Methylbuphedrone 1.15 0.42 0.97 2.54 2.30 4.01 
8 3-EMC 3.61 1.27 4.86 8.04 1.55 3.32 
9 3-EEC 5.69 4.88 2.10 4.18 2.44 2.22 
10 4-EEC 2.37 12.25 0.66 6.64 0.90 1.52 
11 3,4-DMEC 9.61 7.83 7.35 8.05 2.07 1.64 
12 2,3-MDMC 7.25 10.31 9.45 6.68 0.94 0.54 
13 Butylone 2.93 3.78 8.95 8.38 0.83 0.24 
14 Pentylone 9.54 0.05 0.14 3.25 2.52 3.14 
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Table 22: Recovery measurements expressed in percent errors for three different 
concentrations of the cathinone related compounds spiked in plasma matrix. 
  Error % 
  20 ppb 60 ppb 100 ppb 
  E1 E2 E1 E2 E1 E2 
1 4-FMC 2.63 5.32 2.48 0.62 2.45 0.26 
2 4-FEC 0.17 4.89 5.80 3.10 2.19 1.60 
3 Nor-mephedrone 5.64 1.94 3.25 7.64 1.69 2.64 
4 Buphedrone 3.18 5.94 0.79 3.78 0.06 1.71 
5 3-MMC 1.03 1.47 0.87 0.55 0.74 1.40 
6 3-Methylbuphedrone 1.26 7.10 6.41 9.61 4.03 1.71 
7 4-Methylbuphedrone 0.69 5.64 1.77 0.73 2.56 1.90 
8 3-EMC 0.65 5.73 2.19 4.70 0.56 0.52 
9 3-EEC 8.70 7.62 2.22 1.06 0.42 0.34 
10 4-EEC 4.38 5.72 7.91 5.68 2.01 2.32 
11 3,4-DMEC 4.36 3.85 2.20 2.46 1.89 2.93 
12 2,3-MDMC 9.98 8.22 6.17 8.34 1.97 3.51 
13 Butylone 1.41 10.98 2.05 5.97 1.62 1.98 
14 Pentylone 5.80 10.43 1.07 1.47 1.68 0.22 
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3.4 Discussion 
L –TPC is considered as a chiral derivatizing agent (CDA) which can react 
with the primary and secondary amine enantiomers of synthetic cathinones 
producing two corresponding diastereomers. As a result of the differences in 
stereochemistry and stability of the formed diastereoisomers, the enantioseparation 
can occur on an achiral stationary phase with different resolution of product 
compounds (Toyo'oka 2002, Płotka, Biziuk et al. 2011). In this study, chiral 
separation of 36 racemic mixtures of synthetic cathinone derivatives were carried 
out, fourteen of them were selected in the spiked mixtures; each enantiomer was 
quantitated in urine and plasma as shown in the example of Nor-mephedrone in 
Figure 5. However, the enantioseparations that were obtained showed that there are 
differences in peak areas for the most resulted diastereoisomers. Mohr et al. assumed 
that the reason of inequality in the formed peaks is due to (a) racemization of L-TPC 
during the derivatization reaction, (b) kinetic resolution of the two enantiomers and 
(c) the difference in diastereoisomers yields which are explained in terms of keto-
enol tautomerization of the analytes. Moreover, the main reason for enantiomer peak 
inequality is related to the tested compounds themselves (Mohr, Weiß et al. 2012). 
Interestingly, the fourteen spiked cathinone derivatives were separated 
simultaneously in one chromatogram since they have different retention times in the 
new developed method as shown in Figures 6 and 7 respectively. Moreover, 
enhancement of the enantiomers peaks resolution has been accomplished by using a 
slow heating rate of 2 oC/min in the chromatographic method. Also the use of Ultra 
inert column helped in minimizing the overlap of the two adjacent peaks of the 
enantiomers. Ultra inert of the stationary phase means the lower column bleeding 
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you get, and as a result of lowering column bleeding, signal-to-noise ratio will 
enhance leading to better and smooth chromatogram. Construction of calibration 
curves were done for the diastereoisomers based on the peak areas of the following 
concentration: 1, 5, 10, 20, 40, 60, 80, 100 ppb. Figure 8 shows the calibration graphs 
for Nor-mephdrone enantiomers in plasma and urine sample matrices. Regression 
values (R2) confirm the good linearity of the four calibrations lines. In order to 
correct for the loss of analyte during sample inlet or sample preparation, (+)-
cathinone has been used as internal standard (IS) as it has a similar structure to 
synthetic cathinones and shows a good stability. The correlation coefficient (R2) 
values were calculated for the mixture components and they were found to be higher 
than 0.99 in all cases as shown in Tables 17 and 18. Additionally, the limits of 
detection (LOD’s) and limits of quantitation (LOQ’s) were calculated according to 
IUPAC method and are reported in Tables 17 and 18. The reported values of LOD’s 
and LOQ’s for the synthetic cathinones in this study were in the ppb range due to the 
high sensitivity of the analytical technique (GC-NCI-MS). The high sensitivity of 
NCI is due to the low mass and high mobility of the secondary or thermal electrons 
(low energy electrons) produced under the CI high pressure conditions in the 
presence of methane reagent gas, which is responsible for the enhancement factor by 
nearly 100 times in the sensitivity of NCI compared to that of positive CI for a 
suitably electrophilic compounds (Watson and Sparkman 2007). The LOD in urine 
was in the range of 0.02 -0.76 ppb and in plasma it was in the range of 0.02 - 0.34 
ppb. While the LOQ in urine was in the range of 0.07 - 2.31 ppb and in plasma it was 
in the range of 0.07 – 1.03 ppb (as shown in Tables 17 and 18).  
Three different concentration levels were chosen to test the inter-day and 
intra-day reproducibility measurements of the synthetic cathinone compounds 
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mixture in urine and plasma as shown in Tables 19 and 20. In fact, good 
reproducibility and repeatability were established using the new developed method 
since most of the coefficients of variance values were below 15 % in both urine and 
plasma matrices for measurements done on the same day or on two different days. A 
comparison between spiked urine and spiked plasma samples shows that urine 
samples were more reproducible than spiked plasma samples because of the 
competition between analyte and blood interferences unlike spiked urine samples 
where the urine was diluted with deionized water prior to the spiking step. Moreover, 
the presence of proteins and other interferences in plasma can cause difficulty in 
solid phase extraction processes and can also create competition between the targeted 
analyte and unneeded interferences which will lead to variation in spiked plasma 
results (Prabu and Suriyaprakash 2012). 
Solid phase extraction (SPE) efficiencies were studied by percent error 
calculations for the spiked mixture at the following concentration levels: 20, 60 and 
100 ppb. The calculated values in recovery studies were within the acceptable range.  
By comparing the results of the GC-EI-MS method recently reported for 
some of these synthetic cathinones (Alrumaithi, Meetani et al. 2016), and the current 
study results using GC-NCI-MS, the latter has showed lower detection limit by a 
factor of 3.    
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3.5 Conclusion 
Indirect chiral separation of synthetic cathinones after derivatization with 
trifluoroacetyl-l-prolyl chloride (L-TPC) was achieved using a new developed 
method of GC-NCI-MS that provided low detection limit and selectivity for the 
separation and quantitation of the targeted compounds. The use of 60m HP5-MS 
Ultra inert capillary column helps to separate more than thirty-six compounds of 
synthetic cathinones to their optical enantiomers. (+)-cathinone was used as internal 
standard in cathinones quantitation which has similar skeleton and chemical structure 
and showed good stability. A mixture of fourteen cathinone derivatives that were 
spiked in urine and plasma was separated in one chromatogram simultaneously. For 
each enantiomer peak in the cathinones mixture chromatogram, calibration curves 
were constructed using the following concentration: 1, 5, 10, 20, 40, 60, 80, 100 ppb. 
The developed method was validated in terms of linearities, limit of detection 
(LOD), limit of quantitation (LOQ), reproducibilities and recoveries for all the tested 
mixtures. 
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Chapter 4: Development and validation of an HPLC method for the 
determination of synthetic cathinones “bath salts” enantiomers in human 
samples 
 Introduction 
In recent years, the abuse of novel psychoactive drugs (NPD) has grown up 
very fast which has put governments on alert (Kelly 2011, Katz, Bhattacharya et al. 
2014)..  The “bath salt” term which is used mainly in United States of America, is to 
hinder a kind of new designer drugs called “synthetic cathinones” (Zawilska and 
Wojcieszak 2013, German, Fleckenstein et al. 2014). It was agreed that the 
enantiomeric determination of these kinds of compounds is important and attractive 
for a group of researchers. 
In general, chiral separation can be carried out by using one of the following 
techniques: directly on chiral stationary phase (CSP) (Mohr, Taschwer et al. 2012, 
Wolrab, Frühauf et al. 2016), or indirectly using derivatization with enantiomerically 
pure reagents that convert the enantiomers to diastereoisomers which will be 
separable on achiral stationary phases (Tao and Zeng 2002, Mohr, Weiß et al. 2012, 
Weiss, Mohr et al. 2015). CSP can be either immobilized on the stationary phase of 
the column (Mohr, Taschwer et al. 2012, Wolrab, Frühauf et al. 2016), or used as a 
chiral selector that can be added to the mobile phase composition (Mohr, Pilaj et al. 
2012, Aturki, Schmid et al. 2014, Merola, Fu et al. 2014, TASCHWER, SEIDL et al. 
2014, Li and Lurie 2015). Mostly, CSP is based on one of the following principles: 
host – guest inclusion reaction with cyclodextrins, hydrogen bonding on a chiral 
center, or coordination on chiral metal complexes (Schurig 2002).   
In this work, we focused on chiral separation of synthetic cathinones that 
contain mainly tertiary amines by HPLC-UV system. In addition to tertiary amine 
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synthetic cathinones analysis, 43 compounds of primary and secondary amine 
cathinones have been analyzed by two commercially available columns as reported 
in this study. A comparison between two columns that contain different chiral 
separation phases in terms of resolution of separation and selectivity factor has been 
conducted. The two commercially available columns were Astec Cellulose DMP 
column, and CHIRALPAK AS-H Amylose column. Finally, quantitative analysis has 
been carried out for three tertiary cathinone derivatives after spiking and extracting 
them from urine and plasma sample matrices, Scheme 15 shows the structure of the 
compounds that were analyzed quantitatively in this study. 2,3-Methylenedioxy 
Pyrovalerone (2,3-MDPV) was used as the internal standard (IS). The analytical 
method was validated in terms of linearities, limits of detection (LOD), limits of 
quantitation (LOQ), recoveries, and reproducibilities for the compounds under 
investigation. 
      
Scheme 15: Structures of tertiary amine synthetic cathinone derivatives that analyzed 
quantitatively  
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 Materials and methods 
4.2.1 Chromatographic condition 
 Separation of the enantiomers of cathinone related compounds has been 
performed on Agilant HP 1200 series HPLC system coupled with UV-VIS detector. 
λmax for ultraviolet (UV) measurement was 270 nm in the collection range from 200 
nm to 600 nm on the diode array detector. Mobile phase composition was: hexane, 
isopropanol (IPA) and triethylamine (TEA), (99 : 1.0 : 0.1), respectively. The flow 
rate was 0.5 mL/min in an isocratic condition. Two commercially available columns 
were used, namely Astec Cellulose DMP chiral column, 150 mm, 4.6 mm, in which 
dimethylphenyl carbamate-derivatized cellulose (DMPC) was coated on 5 µm silica-
gel and CHIRALPAK AS-H Amylose column, 150 mm, 4.6 mm, in which Amylose 
tris [(S)-α-methylbenzylcarbamate] was coated on 5 µm silica gel. For both columns, 
the column temperature was set at 40 oC. Prior to injection, the needle was flushed 
with 100 µl of the mobile phase. 
4.2.2 Chemicals 
All solvents used in this study were of HPLC grade. Hexane, acetic acid, 
methanol, 2-propanol, triethylamine, ammonium hydroxide, dichloromethane and 
sodium phosphate were obtained from Sigma–Aldrich Chemicals (St. Louis, MO, 
USA). Water was of nanopure quality. All analytes in Table 16, were of standard 
grade (purity > 97%), and purchased from an official supplier, Cayman chemicals 
(Michigan, USA).  
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4.2.3 Sample preparation 
4.2.3.1 Samples 
This investigation conforms to the UAE community guidelines for the use of 
humans in experiments. The Human Ethics committee at the Dubai police approved 
the study.   Blood and urine samples were collected at Dubai police with subjects’ 
consent. 
4.2.3.2 Urine and plasma spiking and SPE 
SPE was carried out for the spiked urine and plasma samples as shown in 
extraction steps of section 2.2.3.2. 
 Results 
Figure 9 shows the liquid chromatograms for separation of the R and S 
enantiomers of dimethylone drug on DMP cellulose and AS-H Amylose columns. It 
was noted that the calculated values of resolution and selectivity factor on the DMP 
column were 1.23 and 1.06 respectively, while on the A-ASH amylose column, the 
calculated values of resolution and selectivity factor were 2.54 and 1.25 respectively.  
94 
 
 
Figure 9: Liquid chromatogram for separation of the R and S enantiomers of 50 ppm 
of dimethylone drug using: a) on DMP cellulose column and (b) AS-H Amylose 
column 
Tables 23 and 24 shows the list of the 22 tertiary amine cathinone related 
compounds and their retention times in addition to calculated resolution and 
selectivity factor for the separated two enantiomers for each compound analyzed on 
HPLC-UV by DMP cellulose and AS-H Amylose columns, respectively.  
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Table 23: List of the 22 tertiary amine cathinone related compounds and their 
synonyms, in addition to the retention times, resolutions (Rs) and selectivity factor 
(α) of the separated two diasterioisomers for each compound analyzed on HPLC-UV 
by DMP cellulose column 
# 
Compound Name Abbreviation 
tR1 
(min) 
tR2 
(min) Rs 
α 
1 Dibutylone bk-DMBDB No sep. 
2 Dimethylone bk-MDDMA 12.54 13.14 1.23 1.057 
3 α-Pyrrolidinopropiophenone α-PPP 7.28 8.05 2.70 1.147 
4 N,N-Dimethylcathinone N,N-DMC 6.49 6.70 1.00 1.048 
5 2,3-Methylenedioxy Pyrovalerone 2,3-MDPV No sep. 
6 2-Methyl-α-Pyrrolidinopropiophenone 2-Methyl-α-PPP 7.06 10.65 10.55 1.708 
7 4-Ethyl-N,N-Dimethylcathinone 4-Ethyl-N,N-DMC 5.94 6.17 1.09 1.059 
8 3-Methyl-α-Pyrrolidinopropiophenone 3-Methyl-α-PPP 7.19 8.39 3.77 1.231 
9 
3,4-Methylenedioxy-α-
Pyrrolidinopropiophenone 3,4-MD-α-PPP 14.50 15.41 1.45 1.073 
10 4-Methyl-N-Methylbuphedrone 
 
No sep. 
11 4'-Methoxy-α-Pyrrolidinopropiophenone 4'-MeO-α-PPP 13.98 15.74 2.89 1.147 
12 4'-Methyl-α-Pyrrolidinohexanophenone 4'-Methyl-α-PHP 4.65 5.28 1.62 1.238 
13 Diethylcathinone 
 
4.54 5.08 3.37 1.212 
14 4-Methyl-α-Pyrrolidinobutiophenone 4-Methyl PBP 5.33 5.51 0.99 1.055 
15 α-Pyrrolidinopentiophenone α-PVP 4.84 4.99 0.95 1.055 
16 α-Pyrrolidinobutiophenone α-PBP 5.48 5.78 1.48 1.086 
17 4'-Methyl-α-Pyrrolidinopropiophenone 4'-Methyl-α-PPP 6.91 7.63 2.02 1.148 
18 3-Methyl-α-Pyrrolidinobutiophenone 3-Methyl PBP 5.18 5.57 1.86 1.121 
19 
3,4-Methylenedioxy-α- 
Pyrrolidinobutiophenone 3,4-MDPBP 11.51 12.00 1.15 1.051 
20 N-Ethyl-N-Methylcathinone 
 
5.15 5.63 2.41 1.154 
21 2-Methyl-α-Pyrrolidinobutiophenone  2-Methyl PBP 5.34 5.92 2.31 1.172 
22 4-Methoxy-N,N-Dimethylcathinone 4-MeO-N,N-DMC 9.71 10.25 1.11 1.071 
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Table 24: List of the 22 tertiary amine cathinone related compounds and their 
synonyms, in addition to the retention times, resolution and selectivity factor of the 
separated two diasterioisomers for each compound analyzed on HPLC-UV by AS-H 
Amylose column 
# Compound Name Abbreviation tR1 
(min) 
tR2 
(min) 
Rs α 
1 Dibutylone bk-DMBDB No sep. 
2 Dimethylone bk-MDDMA 5.70 6.88 2.54 1.251 
3 α-Pyrrolidinopropiophenone α-PPP No sep. 
4 N,N-Dimethylcathinone N,N-DMC 2.80 3.08 1.82 1.156 
5 2,3-Methylenedioxy Pyrovalerone 2,3-MDPV No sep. 
6 2-Methyl-α-Pyrrolidinopropiophenone 2-Methyl-α-PPP 2.00 2.64 2.46 1.642 
7 4-Ethyl-N,N-Dimethylcathinone 4-Ethyl-N,N-DMC 2.71 2.92 1.50 1.120 
8 3-Methyl-α-Pyrrolidinopropiophenone 3-Methyl-α-PPP No sep. 
9 3,4-Methylenedioxy-α- 
Pyrrolidinopropiophenone 
3,4-MD-α-PPP No sep. 
10 4-Methyl-N-Methylbuphedrone  No sep. 
11 4'-Methoxy-α-Pyrrolidinopropiophenone 4'-MeO-α-PPP 4.70 5.24 2.27 1.145 
12 4'-Methyl-α-Pyrrolidinohexanophenone 4'-Methyl-α-PHP No sep. 
13 Diethylcathinone  No sep. 
14 4-Methyl-α-Pyrrolidinobutiophenone 4-Methyl PBP No sep. 
15 α-Pyrrolidinopentiophenone α-PVP No sep. 
16 α-Pyrrolidinobutiophenone α-PBP No sep. 
17 4'-Methyl-α-Pyrrolidinopropiophenone 4'-Methyl-α-PPP No sep. 
18 3-Methyl-α-Pyrrolidinobutiophenone 3-Methyl PBP No sep. 
19 3,4-Methylenedioxy-α- 
Pyrrolidinobutiophenone 
3,4-MDPBP 4.69 5.22 2.99 1.144 
20 N-Ethyl-N-Methylcathinone  No sep. 
21 2-Methyl-α-Pyrrolidinobutiophenone  2-Methyl PBP 2.10 2.24 1.37 1.123 
22 4-Methoxy-N,N-Dimethylcathinone 4-MeO-N,N-DMC No sep. 
 
All the separated enantiomers have shown resolution values above 1 and the 
selectivity factors were above 1 as well.  The DMP cellulose column was more 
efficient in separating the cathinone related drugs with tertiary amine functionality 
more than the AS-H amylose column.  This is obvious from Table 23 where only 
three of the investigated 22 compounds were not separated while in Table 24, fifteen 
of the investigated compounds were not separated.  
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Tables 25 and 26 shows the list of the 43 primary and secondary amine 
cathinone related compounds and their retention times in addition to calculated 
resolution and selectivity factor for the separated two enantiomers for each 
compound analyzed on HPLC-UV by DMP cellulose and AS-H Amylose columns, 
respectively. 
Table 25: List of the 43 primary and secondary amine cathinone related compounds 
and their synonyms, in addition to the retention times, resolutions (Rs) and 
selectivity factor (α) of the separated two diasterioisomers for each compound 
analyzed on HPLC-UV by DMP cellulose column 
  Compound Name Abbreviation 
tR1 
(min) 
tR2 
(min) Rs α 
1 2-Methoxymethcathinone 2-MeOMC 37.61 46.12 4.77 1.239 
2 3-Fluoroethcathinone 3-FEC 7.67 9.54 3.62 1.329 
3 2-Fluoroethcathinone 2-FEC 5.36 6.67 5.12 1.390 
4 4-Fluoroethcathinone 4-FEC 11.41 11.95 1.25 1.058 
5 2,3-Methylenedioxymethcathinone 2,3-MDMC 7.38 19.45 18.15 3.244 
6 2-Methylmethcathinone 2-MMC 8.81 9.18 1.06 1.055 
7 Nor-Mephedrone - 5.57 7.69 7.56 1.593 
8 4-Ethylethcathinone  4-EEC 9.17 9.65 1.27 1.068 
9 3,4-Dimethylethcathinone 3,4-DMEC 9.77 11.18 3.19 1.182 
10 2-Ethylmethcathinone  2-EMC 7.27 12.56 11.73 2.005 
11 3-Methoxymethcathinone  3-MeOMC 25.27 26.23 1.08 1.041 
12 2-Ethylethcathinone  2-EEC 9.44 9.77 0.82 1.044 
13 2-Fluoromethcathinone 2-FMC 10.16 12.90 4.25 1.336 
14 4-Ethylmethcathinone  4-EMC 13.35 14.55 1.51 1.105 
15 3-Ethylethcathinone  3-EEC 8.29 8.63 1.16 1.055 
16 4-Methylbuphedrone  - 7.80 8.32 1.68 1.090 
17 2,3-Dimethylmethcathinone 2,3-DMMC 15.06 17.55 4.31 1.191 
18 3-Ethylmethcathinone  3-EMC No sep. 
19 3-Fluoromethcathinone 3-FMC 13.66 14.17 0.60 1.044 
20 Eutylone - 14.16 14.81 1.10 1.054 
21 4-Fluoromethcathinone 4-FMC 14.98 16.46 2.35 1.114 
22 2-Methylethcathinone 2-MEC 10.77 11.09 0.79 1.036 
23 Buphedrone - No sep. 
24 4-Methyl-α-ethylaminobutiophenone - 7.08 7.28 0.66 1.039 
25 Pentedrone - 7.26 7.66 1.27 1.075 
26 Butylone - 23.84 24.37 0.62 1.024 
27 Pentylone - 20.07 20.48 0.55 1.023 
28 4-Methylethcathinone 4-MEC 10.72 11.12 0.96 1.046 
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#  Compound Name Abbreviations 
tR1 
(min) 
tR2 
(min) Rs α 
29 3,4-Dimethylmethcathinone 3,4-DMMC 16.89 20.48 4.85 1.241 
30 Ethcathinone - 7.39 7.93 1.56 1.100 
31 Methedrone - 45.76 48.46 1.30 1.062 
32 3-Methylmethcathinone 3-MMC 6.36 8.55 7.35 1.503 
33 4-Bromomethcathinone 4-BMC 18.01 19.36 2.54 1.084 
34 3-Bromomethcathinone 3-BMC 15.87 17.37 2.26 1.108 
35 Benzedrone 4-MBC 12.52 12.99 1.02 1.045 
36 2,4-Dimethylmethcathinone 2,4-DMMC No sep. 
37 2,4-Dimethylethcathinone 2,4-DMEC 7.92 8.27 1.06 1.059 
38 3,4-Methylenedioxy-N-benzylcathinone BMDP 31.42 35.01 2.43 1.122 
39 3,4-Methylenedioxy-N-ethylcathinone Ethylone 25.22 25.99 0.87 1.033 
40 3-Methylbuphedrone 3-methyl BP 9.70 10.11 1.12 1.053 
41 N-Ethylbuphedrone NEB 6.88 7.16 0.93 1.058 
42 2,3-Pentylone isomer - 14.07 15.03 1.78 1.080 
43 3-Mehyethcathinone 3-MEC 9.77 10.16 1.08 1.049 
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Table 26: List of the 43 primary and secondary amine cathinone related compounds 
and their synonyms, in addition to the retention times, resolution (Rs) and selectivity 
factor (α) of the separated two diasterioisomers for each compound analyzed on 
HPLC-UV by AS-H Amylose column 
  Compound Name Abbreviation 
tR1 
(min) 
tR2 
(min) Rs α 
1 2-Methoxymethcathinone 2-MeOMC 8.35 9.92 3.60 1.214 
2 3-Fluoroethcathinone 3-FEC 2.94 3.07 1.07 1.067 
3 2-Fluoroethcathinone 2-FEC No sep. 
4 4-Fluoroethcathinone 4-FEC 3.28 3.55 1.62 1.119 
5 2,3-Methylenedioxymethcathinone 2,3-MDMC 9.47 12.54 5.34 1.363 
6 2-Methylmethcathinone 2-MMC 4.20 4.75 2.83 1.172 
7 Nor-Mephedrone - 15.30 16.78 1.81 1.103 
8 4-Ethylethcathinone  4-EEC 3.05 3.26 1.40 1.104 
9 3,4-Dimethylethcathinone 3,4-DMEC 3.45 4.06 3.03 1.247 
10 2-Ethylmethcathinone  2-EMC 3.22 3.37 1.10 1.066 
11 3-Methoxymethcathinone  3-MeOMC 6.91 8.24 3.72 1.225 
12 2-Ethylethcathinone  2-EEC 2.98 3.16 0.87 1.089 
13 2-Fluoromethcathinone 2-FMC 9.71 10.25 1.11 1.063 
14 4-Ethylmethcathinone  4-EMC 4.42 5.02 2.68 1.177 
15 3-Ethylethcathinone  3-EEC 2.88 3.10 1.57 1.117 
16 4-Methylbuphedrone  - 3.63 4.36 3.68 1.280 
17 2,3-Dimethylmethcathinone 2,3-DMMC 3.82 4.38 2.38 1.196 
18 3-Ethylmethcathinone  3-EMC 4.28 5.31 4.87 1.312 
19 3-Fluoromethcathinone 3-FMC 4.43 5.10 2.96 1.197 
20 Eutylone - 4.68 4.96 1.15 1.077 
21 4-Fluoromethcathinone 4-FMC 5.42 6.42 3.77 1.228 
22 2-Methylethcathinone 2-MEC 2.91 3.16 1.66 1.134 
23 Buphedrone - 3.51 4.08 3.31 1.230 
24 4-Methyl-α-ethylaminobutiophenone - 2.57 2.72 1.25 1.098 
25 Pentedrone - 2.98 3.31 2.22 1.169 
26 Butylone - 7.96 9.40 3.19 1.206 
27 Pentylone - 5.83 6.74 2.57 1.190 
28 4-Methylethcathinone 4-MEC 3.56 4.00 2.29 1.174 
29 3,4-Dimethylmethcathinone 3,4-DMMC 5.30 7.63 7.07 1.543 
30 Ethcathinone - 3.51 3.82 1.73 1.120 
31 Methedrone - 12.27 14.93 3.47 1.236 
32 3-Methylmethcathinone 3-MMC 4.03 4.80 3.39 1.253 
33 4-Bromomethcathinone 4-BMC 5.16 5.55 1.38 1.094 
34 3-Bromomethcathinone 3-BMC 3.75 4.33 3.10 1.214 
35 Benzedrone 4-MBC 4.17 5.01 3.10 1.265 
36 2,4-Dimethylmethcathinone 2,4-DMMC 3.55 3.88 1.64 1.128 
37 2,4-Dimethylethcathinone 2,4-DMEC 2.61 2.72 0.84 1.068 
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# Compound Name Abbreviation 
tR1 
(min) 
tR2 
(min) Rs α 
38 3,4-Methylenedioxy-N-benzylcathinone BMDP 13.21 14.43 1.05 1.100 
39 3,4-Methylenedioxy-N-ethylcathinone Ethylone 5.78 6.49 2.15 1.148 
40 3-Methylbuphedrone 3-methyl BP 2.98 3.69 3.17 1.361 
41 N-Ethylbuphedrone NEB 2.68 2.82 1.17 1.085 
42 2,3-Pentylone isomer - 5.44 7.37 5.34 1.434 
43 3-Mehyethcathinone 3-MEC 2.90 3.09 1.32 1.101 
 
The simultaneous HPLC separations of the enantiomers of the three 
cathinone derivatives – namely, 4'-methyl-α-Pyrrolidinopropiophenone (4'-methyl-α-
PPP), Dimethylone and 4'-methoxy-α-Pyrrolidinopropiophenone (4'-MeO-α-PPP) on 
the DMP cellulose column- after being spiked into urine and plasma are reported in 
Figures 10 and 11 respectively. 
 
Figure 10: Total ion chromatogram (TIC) of the simultaneous chiral separation of 4'-
methyl-α-PPP, Dimethylone and 4'-MeO-α-PPP in urine sample by HPLC-UV 
system 
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Figure 11: Total ion chromatogram (TIC) of the simultaneous chiral separation of 4'-
methyl-α-PPP, Dimethylone and 4'-MeO-α-PPP in plasma sample by HPLC-UV 
system 
 Furthermore, the quantitative analysis method of these three cathinone 
derivatives has been reported in urine and plasma samples. For instance, Figure 12, 
shows the calibration graphs of the two separated enantiomers of the 4-Methoxy-a-
PPP compound in urine (a & b), and in plasma (c & d). The calibration range was 5-
250 ppm.  
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Figure 12: Calibration graphs of the two separated enantiomers of the 4-Methoxy-a-
PPP compound in (a & b) urine, and (c & d) in plasma. Calibration ranges was 5-250 
ppm 
For method validation, the following parameters have been taken into 
consideration: linearity, limit of detection (LOD) and quantitation (LOQ), recovery 
studies and intra- and inter-day assay in terms of reproducibility. Linearity was tested 
by constructing of calibration curves for each enantiomer of the three cathinone 
derivatives in spiked urine and plasma ranging from 5 to 250 ppm for (4'-methyl-α-
PPP), Dimethylone, and 4'-methoxy-α- (4'-MeO-α-PPP). Moreover, the LOD and 
LOQ have been reported in plasma and urine matrices in Tables 27 and 28, 
respectively. 
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Table 27: Results for three cathinone related compounds spiked in plasma including 
linearity coefficient, R2 values, Limits of detection and limits of quantitations for the 
two enantiomers of each compound 
  
R2 ± SD LOQ ± SD (ppm) 
LOD ± SD 
(ppm) 
 
Name E1 E2 E1 E2 E1 E2 
1 4'-Methyl-α-PPP 0.9954 ± 0.0026 0.9958 ± 0.0029 
3.8 ± 
0.1061 
4.3 ± 
0.1318 
1.28 ± 
0.0350 
1.43 ± 
0.0435 
2 Dimethylone 0.9932 ± 0.0038 0.9954 ± 0.0036 
3.0 ± 
0.1441 
3.1 ± 
0.1073 
0.99 ± 
0.0476 
1.04 ± 
0.0354 
3 4'-MeO-α-PPP 0.9957 ± 0.0035 0.9965 ± 0.0025 
3.6 ± 
0.1860 
3.9 ± 
0.1648 
1.18 ± 
0.0614 
1.31 ± 
0.0544 
 
Table 28: Results for three cathinone related compounds spiked in urine including 
linearity coefficient, R2 values, Limits of detection and limits of quantitations for the 
two enantiomers of each compound 
  
R2 ± SD LOQ ± SD (ppm) 
LOD ± SD 
(ppm) 
 
Name E1 E2 E1 E2 E1 E2 
1 4'-Methyl-α-PPP 0.9943 ± 0.0030 0.9920 ± 0.0009 
1.8 ± 
0.1426 
1.9 ± 
0.1443 
0.59 ± 
0.0470 
0.63 ± 
0.0476 
2 Dimethylone 0.9924 ± 0.0010 0.9917 ± 0.0027 
0.52 ± 
0.0644 
0.55 ± 
0.0694 
0.17 ± 
0.0213 
0.17 ± 
0.0229 
3 4'-MeO-a-PPP 0.9922 ± 0.0008 0.9941 ± 0.0012 
0.43 ± 
0.0106 
0.445 ± 
0.0082 
0.142 ± 
0.0035 
0.147 ± 
0.0027 
 
 Reproducibility measured in terms of coefficients of variance at three 
different concentration levels (5, 20 and 100 ppm) within the same day and at two 
different days in plasma and urine matrices and they were reported in tables 29 and 
30, respectively.   
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Table 29: Inter-day and intraday reproducibility results in terms of coefficient of 
variance for three cathinone related compounds spiked in plasma at three different 
concentration levels for the two enantiomers of each compound 
  
CV% intraday CV% interday 
  
5 ppm 20 ppm 100 ppm 5 ppm 20 ppm 100 ppm 
  Name E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 
1 4'-Methyl-α-PPP 4.69 3.68 0.27 2.57 2.83 3.51 5.39 3.57 3.14 3.83 2.53 2.92 
2 Dimethylone 2.48 0.78 0.74 2.45 1.92 3.04 3.32 3.91 1.43 1.75 2.36 2.61 
3 4'-MeO- α -PPP 3.03 1.35 1.75 1.22 2.98 2.70 4.81 4.72 3.72 2.31 3.18 2.72 
 
Table 30: Inter-day and intraday reproducibility results in terms of coefficient of 
variance for three cathinone related compounds spiked in urine at three different 
concentration levels for the two enantiomers of each compound 
  
CV% intraday CV% interday 
  
5 ppm 20 ppm 100 ppm 5 ppm 20 ppm 100 ppm 
  Name E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 E1 E2 
1 4'-Methyl-α-PPP 1.38 2.87 1.95 0.47 0.27 0.36 1.74 2.30 1.47 1.41 1.30 1.31 
2 Dimethylone 1.41 1.53 2.08 2.69 2.46 2.12 1.68 1.41 3.12 2.87 2.50 2.46 
3 4'-MeO- α -PPP 0.79 1.68 1.58 1.63 1.54 1.79 0.86 2.26 1.43 1.48 1.58 1.60 
 
Finally, the method accuracy was reported as percent error for three 
concentration levels, 50, 100 and 250 ppm in plasma and urine matrices, through 
recovery measurements for each enantiomer of the three cathinone compounds as 
shown in Tables 31 and 32, respectively.  
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Table 31: Recovery measurements expressed in percent errors for three different 
concentrations of the cathinone related compounds spiked in plasma matrix 
  
Error % 
  
50 ppm 100 ppm 250 ppm 
  Cathinones E1 E2 E1 E2 E1 E2 
1 4'-Methyl-α-PPP 2.75 5.28 4.68 11.86 0.96 1.78 
2 Dimethylone 3.55 4.65 1.89 1.00 0.10 0.59 
3 4'-MeO- α -PPP 0.35 1.08 1.50 0.68 0.49 0.14 
 
Table 32: Recovery measurements expressed in percent errors for three different 
concentrations of the cathinone related compounds spiked in urine matrix 
  
Error % 
  
50 ppm 100 ppm 250 ppm 
  Cathinones E1 E2 E1 E2 E1 E2 
1 4'-Methyl-α-PPP 9.77 2.06 6.67 6.41 0.66 0.78 
2 Dimethylone 2.59 6.96 8.60 2.13 1.26 0.02 
3 4'-MeO- α -PPP 3.21 3.33 2.12 0.38 0.50 0.14 
 
  
106 
 
4.4 Discussion 
In this work, chiral separation was based on the interaction between the 
analytes and the chiral stationary phase in the column in which one type of the 
polysaccharide enantiomers has been immobilized on the surface of a solid support.  
Formation of diastereomeric adsorbates of different stabilities is the reason for the 
chiral selectivity of the CSP (Płotka, Biziuk et al. 2011).  During the elution process, 
if both enantiomers of analytes have the same interaction with CSP, it will not be 
able to separate them. Conversely, if they have different way of interaction with 
CSP, then they will reach the detector at different retention times which will lead to 
the chiral separation of the racemic mixture. The size of cavities of the poly-
saccharides stationary phase plays a principal role in enantioseparation of the 
cathinone derivatives where the host – guest inclusion reaction takes place between 
the analytes and the cavity of the CSP. Figure 9, shows that the two columns were 
able to separate the two enantiomers of dimethylone drug well, however, the values 
of retention times, resolution and separation factor for each column were not the 
same. This indicates that the interaction of the dimethylone enantiomers with the 
cavity of the polysaccharide immobilized on the stationary phase surface was 
different and involved different interaction mechanisms. It is expected that the 
separation mechanism of these compounds on the DMP cellulose column depends 
more on the host – guest inclusion reaction in addition to (π-π) interaction and steric 
hindrance effect while in the case of the AS-H Amylose column, the inclusion 
reaction and other factors such as dipole – dipole interaction, hydrogen bonding, and  
(π-π) interaction (Mohr, Taschwer et al. 2012) are participating in the separation 
process. 
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Mohr et al. have reported the chiral separation of synthetic cathinone 
compounds on CHIRALPAK AS-H column using HPLC-UV system. Amongst the 
24 compounds analyzed, there were 5 synthetic cathinone with tertiary amine 
functional group (Mohr, Taschwer et al. 2012). However, it was noticed that all of 
the synthetic cathinones in the previous study have been separated except 4 tertiary 
amine cathinones: MDPV, MPPP, α-PPP and naphyrone. They have explained this 
observation based on the fact that AS-H column, which consists of amylose tris [(S)-
a-methylbenzylcarbamate] as CSP, was not suitable for enantioseparation of 
cathinones that has nitrogen atom included in a ring (Mohr, Taschwer et al. 2012). 
However, in this study, the focus was on the enantioseparation of tertiary amine 
synthetic cathinones by using dimethylphenyl carbamate-derivatized cellulose 
(DMPC) as CSP which shows good separation results for 19 compounds out of 22 as 
shown in Table 23, without an interfering peak at the same retention time of the 
analytes of interest. 2,3-MDPV was one of the compounds that did not get separated 
in this work and this can be explained on the basis of steric hindrance that prevent 
the host – guest inclusion reaction between the drug of interest and the DMPC 
immobilized molecule in CSP. Due to lack of interaction between 2,3-MDPV and 
CSP, it appears as one peak in the HPLC chromatogram which let us to decide to use 
it as an internal standard (IS) for the quantitative analysis in spiked biological 
sample. Interestingly, 13 compounds of the separable cathinone derivatives in Table 
23 are compounds that have nitrogen atom included in the ring structure. Unlike AS-
H column, Astec Cellulose DMP column is not affected by ring that contains the 
nitrogen group and it can differentiate between enantiomers of tertiary amine 
cathinones easily.  
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Figures 10 and 11, show the simultaneous chiral separation of a mixture of 4'-
methyl-α-PPP, Dimethylone and 4'-MeO-α-PPP that has been spiked into samples of 
plasma and urine, respectively.  Method linearity has been tested for the three 
cathinone derivatives that have been chosen for quantitative analysis in spiked urine 
and plasma and gave comparable results in the concentrations of: 5, 10, 20, 50, 100 
and 250 ppm. Correlation coefficients for spiked cathinones are higher than 0.99 as 
shown in Figure 12 and Tables 27 & 28. Limit of detection (LOD) and limit of 
quantitation (LOQ) were also calculated for each enantiomer in spiked urine and 
plasma. It was found that the LODs of these cathinone derivatives in urine were in 
the range of 1 -1.47 ppm; while in plasma, the LODs were in the range of 0.14 -0.67 
ppm. The LOQs in urine were in the range of 3.03- 4.46 ppm and in plasma they 
were in the range of 0.42 - 2.04 ppm.  The results in Tables 29 and 30 show intra- 
and inter-assay precision reported at three different levels, 5, 100 and 200 ppm. The 
coefficient of variance were in the range of (0.27-5.39)% in plasma and (0.47-3.12)% 
in urine which lies in the acceptable range.  Tables 31 and 32 show the method 
recovery and accuracy in terms of percent error and they are less than 10% which 
match the international criteria and tell us that that SPE process displayed good 
efficiency.  
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4.5 Conclusion 
In conclusion, development of a sensitive and a selective method for 
detection and quantitation of tertiary amine cathinone related compounds using 
HPLC-UV system with Astec Cellulose DMP chiral column has been done 
successfully. To our knowledge, 18 compounds of tertiary amine synthetic 
cathinones were separated into their optical enantiomers successfully for the first 
time. 2,3-MDPV was used as an internal standard in cathinones quantitation which 
showed good stability. Three of the tertiary amine cathinones derivatives were 
separated in one chromatogram simultaneously after being spiked in urine and 
plasma samples.  It was found that the LODs of these cathinone derivatives in urine 
were in the range of 0.1 -0.7 ppm; while in plasma, the LODs were in the range of 
0.17 -1.33 ppm. The LOQs in urine were in the range of 0.29 - 2.14 ppm and in 
plasma they were in the range of 0.50 - 4.01 ppm. The method recoveries reported in 
percent error had an overall average value around 2.4% and 3.2% in plasma and 
urine respectively; while inter-day and intra-day reproducibilities reported at three 
different levels, 5, 100 and 200 ppm, in terms of coefficient of variance were in the 
range of (0.27-5.39) % in plasma and (0.47-3.12) % in urine which lies in the 
acceptable range.  
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Chapter 5: Determination of p-aminohippuric acid with β-Cyclodextrin 
sensitized fluorescence spectrometry 
 Introduction 
The correct determination of effective renal plasma flow (ERPF) is crucial to 
evaluate kidney function in clinical or research settings. One of the commonly used 
markers for estimating ERPF is para-amino hippuric acid (PAH), since it is freely 
filtered at the glomerulus and undergoes extensive secretion and negligible 
reabsorption within renal tubules when it has low plasma concentration (Baccard, 
Hoizey et al. 1999). Many analytical methods have been established to measure PAH 
in plasma and urine, such as UV/Vis spectroscopy (Karabacak, Cinar et al. 2012), 
HPLC with UV detection (Decosterd, Karagiannis et al. 1997, Marsilio, Dall'Amico 
et al. 1997, Agarwal 1998, Dowling, Frye et al. 1998, Kos, Moser et al. 2000, 
Farthing, Sica et al. 2005), electrochemical detections (Guan, Wu et al. 2005) and 
tandem mass spectrometry (Han, Shaw et al. 2009, Fan, Lin et al. 2010). Although 
PAH shows fluorescence activity, few reports have studied the determination of PAH 
using HPLC – Fluorescence detection (Song and Hsu 1996).  
In the last two decades, the macro cyclic oligosaccharides cyclodextrins, 
which consist of glucopyranose units attached together, were reported to form 
enormous host-guest inclusion complexes, enhancing the analytical signal of the 
guest molecules and therefore enhancing the sensitivity of their analytical detections 
in aqueous media. When the guest molecules are non-covalently encapsulated inside 
the cyclodextrin cavity, a modification of their chemical and physical properties 
always occurs due to the altered microenvironment, as well as confinement and 
isolation from the surrounding medium such as the enhancement in solubility and 
fluorescence emission (Manzoori and Amjadi 2003). As a result, the use of 
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cyclodextrins in improving drug solubility and stability and in particular in analytical 
sensing has increased in popularity. 
 In fact, the plan was to study the inclusion reaction between cyclodextrins as 
a host molecules and synthetic cathinones as a guest molecule, however, these kinds 
of experiments may need a large amount of the synthetic cathinones which is 
considered as an expensive and hard to get chemical. As a result of that, an 
alternative compound (PAH) has been chosen in this study due to the similarity in 
chemical structure of this compound to cathinone derivatives as shown in Scheme 
16. 
While aiming at the detection and determination of PAH utilizing the 
supramolecular approach of β-CD, a sensitive method was developed using two 
techniques, namely spectrofluorometry and liquid chromatography with fluorescence 
detection. Fluorescence signals were enhanced with the addition of β-CD in aqueous 
solutions. The experimental conditions that gave the best results were investigated in 
terms of cyclodextrin cavity size, concentration of PAH, concentration of 
cyclodextin, and pH effects. The interaction between PAH and cyclodextrin was 
investigated and considered as a host – guest inclusion which was evident by DFT 
calculations and found to be with 1:2 (host-guest) stoichiometry. A calibration curve 
was established from the spectrofluorometric data in the concentration range 0.05 -
100 µM and the detection limit was determined to be 0.015 µM. HPLC with 
fluorescence detection was investigated in the presence of β-CD in the mobile phase, 
during which the effect of concentration of β-CD in the mobile phase was also 
monitored. Finally, urine samples were spiked with 100 µM and 500 µM of PAH and 
recoveries were calculated. 
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Scheme 16: Structures of cathinone and PAH 
 Experimental 
para-aminohippuric acid, α-, β- and -cyclodextrins, acetic acid and 
acetonitrile (HPLC grade) were purchased from sigma Aldrich, USA.  Doubly 
distilled water obtained from gradient Milli-Q system (millipore) was used to prepare 
stock and working solutions. Fluorescence and UV-Visible measurements were 
carried out using Agilent Cary Eclipse fluorescence spectrofluorometer and Agilent 
Cary 50/300 UV-visible spectrophotometer, respectively. HPLC data carried out by 
Agilent 1200 LC system with a fluorescence detector (Agilent, USA). 
Liquid chromatographic separation was conducted on Waters Symmetry C18 
column (250 mm, 4.6 mm, 5µm) at ambient temperature to achieve the 
chromatographic separations with isocratic elution. The mobile phase used was 90%, 
0.1 M acetic acid in water, 10% acetonitrile and different concentrations of β-CD. 
The detection wavelengths were set at λex = 275 nm and λem = 355 nm. 
A 1 mM PAH solution was prepared in deionized water as a stock solution 
and it was kept inside a dark vial in the refrigerator. The experimental samples 
(working) solutions were prepared fresh daily from the stock solution.  
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UV-visible measurements were done in order to know the right excitation 
wavelength of PAH for fluorescence measurements. 
For the fluorescence measurements, the concentration of PAH was fixed and 
cyclodextrin concentration was varied. Different variables were tested in order to 
reach the best detection conditions. Cyclodextrin type, cyclodextrin concentration 
and pH were varied. pH was adjusted by adding aliquot amounts of HCl and KOH 
solutions and then measured using a WTW 330i pH meter with SenTix Mic glass 
electrode. The mobile phase composition was the same except the concentration of β-
CD which was varied from 0 – 15 mM. The sample PAH was pure and no internal 
standard was thus needed for the spectrofluorometric measurements. On the other 
hand, analysis of PAH in urine samples was performed after the urine samples was 
diluted 10 times without further sample processing.  
Proton NMR measurements were carried out using Varian, 400 MHz 
instrument. NMR spectra were collected for the β-CD and PAH separately in D2O 
solvent, then a mixture of 0.5 mM PAH and 10mM β-CD in D2O was measured. 
All Density Functional Theory (DFT) calculations were performed using the 
Gaussian 09 program (M. J. Frisch 2009). The structures of free β-cyclodextrin and 
para-aminohippuric acid were optimized using the B3LYP functional (D. 1993) and 
6-31G(d) basis set. Initial structures of complexes between β-cyclodextrin and para-
aminohippuric acid were optimized using the PM3 semiempirical method (Stewart 
1989, Stewart 1989). Structures were optimized for binding of one PAH molecule 
outside and inside the β-CD ring. Additionally, a structure with two PAH molecules, 
aligned 'head-to-tail' within the β-cyclodextrin cavity was optimized. Resultant 
optimized structures were further optimized using B3LYP/3-21G followed by 
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BYLYP/6-31G(d) density functional calculations. Binding energies for PAH with β-
CD were calculated with single-point energy calculations on optimized structures, 
corrected for basis-set-superposition-error using the counterpoise method (Boys and 
Bernardi 1970, Sílvia Simon 1996) in Gaussian 09. 
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5.3 Results  
UV-visible spectral measurements of β-CD in water and PAH in aqueous 
solutions with and without β-CD are shown in Figure 13 and 14. While the 
absorption maximum was not shifted, it was enhanced slightly with the addition of 
the β-CD (the absorption maximum of guest – PAH - at 275 nm is close to the 
absorption maximum of host - β-CD – at 258 nm where the host-induced change is 
difficult to track). 
 
Figure 13: UV-visible absorption spectra of 10 mM β-CD aqueous solution 
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Figure 14: UV-visible absorption spectra of 20 µM PAH in (a) water and (b) β-CD 
aqueous solution 5.5 µM at pH 4.06 
 Fluorescence measurements of the PAH in aqueous solution revealed two 
fluorescence peaks at 305 nm and 355 nm, the first one with low intensity while the 
second one is of higher intensities as shown in Figure 15. Moreover, the fluorescence 
peak position of PAH in water was red-shifted when measured in hexane (from 
305,355 nm to 395 nm), which indicates that the PAH fluorescence is affected by the 
surrounding environment such as solvent polarity in agreement with a previous 
report(Karabacak, Cinar et al. 2012). 
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Figure 15: Fluorescence spectra of 100 µM of PAH in (a) water (pH 3.1 and (b) 
hexane 
  Figure 16a shows the effect of changing the PAH concentrations on the 
fluorescence signal of PAH in the absence of β-CD. At low concentration of PAH, 
around 0.1 µM, the fluorescence at 305 nm is dominant. In order to double check the 
source of 305 nm peak, and to make sure that it is not a peak that comes from Raman 
shift of water, a fluorescence measurement was done for a blank water with the same 
excitation and emission wavelength of the PAH experiment as shown in figure 18.  
When the concentration of PAH is increased, the fluorescence at 355 nm 
increases until it becomes the major emission over that at 305 nm at concentration 
above 10 µM, (Figure 16a). Figure 16b shows the effect of altering the PAH 
concentration on the fluorescence profile of PAH at 305 nm and 355 nm in the 
presence of β-CD. Two scenarios are observed from the measured spectra at 
concentrations 1 µM and 10 µM;  at concentration 1 µM, addition of β-CD has 
enhanced the emission at 305 nm more significantly than that at 355 nm (10 times vs. 
2 times). On the contrary, the fluorescence at 355 nm at concentration 10 µM 
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overlaid the band at 305 nm with a concomitant double increase in its intensity in 
presence of the β-CD when compared to that intensity at 355 nm in water. A 
fluorescence measurement of 15 mM β-CD in water was carried out in figure 17 in 
order to assure that the enhancement of fluorescence intensity is not from the 
addition of β-CD. 
 
Figure 16: a) Fluorescence spectra of PAH in aqueous solution at concentrations of 
0.1,1 and 10 uM, b) fluorescence spectra of PAH at concentrations of 0.1,1 and 10 
uM in 5.53 mM β-CD solution 
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Figure 17: Fluorescence spectra of 15 mM β-CD solution at excitation of 275 nm 
 
Figure 18: Fluorescence spectra of deionized water at excitation of 275 nm 
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Figure 19 shows the fluorescence titration measurements of 10 µM PAH in 
aqueous solution of 0-5.53 mM of α, , and β – CD at pH 7.  A clear fluorescence 
enhancement was observed at 355 nm in the presence of β-CD.  In contrast, addition 
of α- and -CD enhances the peak at 305 nm. The fluorescence measurements of α, , 
and β – CDs has been calculated individually without the presence of PAH to make 
sure that they will not interfere guest spectra. 
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Figure 19: Titration of 10uM PAH and (0 – 5.53mM) of: (A) α-CD, (B) γ-CD 
and (C) β-CD at pH 6.8 
The pH effect on the fluorescence behavior of PAH in β-CD solution was 
also investigated.  Figure 20 shows the titration of 10 µM PAH with 4.09 mM β-CD 
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in acidic, basic and neutral solutions. After the addition of cyclodextrin, the 
fluorescence enhancement was more pronounced in acidic solution over that in 
neutral or basic solutions (three vs. two times). 
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Figure 20: Titration of 10uM PAH and (0 - 5.53) mM β-CD at: (a) acidic, (b) basic 
and (c) neutral solutions 
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Theoretical calculations of the guest-host interaction between the PAH and β-
CD were conducted using Gaussian 09. The optimized structure of binding of PAH 
to β-CD outside the β-CD cavity is shown in Scheme 18. Four hydrogen bonding 
interactions between β-CD and PAH are predicted with bond lengths varying from 
1.89 to 2.16 A.  The total binding energy after BSSE correction was calculated to be 
-18.2kcal/mole.  The optimized structure for one PAH molecule encapsulated within 
the β-CD cavity is shown in Scheme 19. The encapsulated PAH molecule is 
predicted to arrange within the β-CD cavity to maximize hydrogen-bonding between 
the carboxylic acid group and β-CD. Consequently, two hydrogen-bonding 
interactions are observed, with bond lengths of 1.71 and 1.92 A. These interactions 
occur on opposite sides of the cyclodextrin ring. Due to the maximizing of these two 
interactions, the amino group of PAH appears to have little or no interaction with the 
β- β-CD ring. The calculated binding energy after Basis set superposition error 
(BSSE) correction is -15.3 kcal/mole. Although this structure is calculated to have 
lower binding energy than that with the PAH molecule outside of the cavity, it may 
be preferred in aqueous solutions due to the displacement of water molecules from 
within the β-CD cavity. The optimized structure for two PAH molecules 
encapsulated within β-CD is show in Scheme 17.  
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Scheme 17: Optimized gas-phase structure for two PAH molecules inside β-CD 
cavity 
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Scheme 18: Optimized gas-phase structure for interaction of PAH and β-CD with 
PAH outside β-CD cavity 
 
127 
 
Scheme 19: Optimized gas-phase structure for interaction of PAH and β-CD with 
PAH inside β-CD cavity 
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Hydrogen bonding interactions are predicted between the two PAH 
molecules, and between the PAH molecules and β-CD ring. The optimized structure 
shows 6 hydrogen-bonding interactions; two between the PAH molecules and four 
between PAH and β-CD. Bond lengths vary from 1.69 to 2.10 A. The calculated 
binding energy is =-34.0kcal/mole after BSSE correction. Hence it appears that 
encapsulation of two PAH molecules is preferred over one, allowing for additional 
hydrogen-bonding interactions between the two PAH molecules, with subsequent 
enhancement in binding energy per molecule.  
NMR measurements show that there was an inclusion of the PAH inside the 
cavity of the β-CD indicated by changes in the chemical shifts of the two protons on 
the ortho-poistion relative to amine group on the benzene ring, as shown in Figure 
21. 
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Figure 21: NMR spectra of β-CD (10 mM), PAH (0.5 mM) and mixture of (0.5 mM 
PAH and 10mM β-CD), all solutions were prepared in D2O Solvent 
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The observed enhancement in the fluorescence intensity at 355 nm could be 
used as a tool to develop a spectrofluorometric analytical method for detection and 
quantitation of PAH in aqueous media by the addition of β-CD. Figure 22 shows the 
calibration curve of 0.05-100 µM solutions of PAH in the presence of 5 mM β-CD. 
The correlation coefficient shows a very good linearity over the tested concentration 
range. Moreover the limit of  detection was calculated and found to be 0.015 µM 
according to IUPAC definition for the limit of detection in analysis (Wilkinson 
1997).  
 
Figure 22: Calibration curve of (0.05 – 100 µM) PAH in aqueous solution containing 
15mM β-CD 
High performance liquid chromatography coupled with fluorescence 
detection was used to develop an analytical method for detection of PAH in urine 
samples. β-CD was added to the HPLC mobile phase at different concentrations in 
order to see its effect on the fluorescence detection of PAH compound. Figure 23 
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shows the HPLC-FLD chromatograms for 10uM PAH in the presence β-CD at 
different concentrations (0-15 mM) in the mobile phase (0.1 M acetic acid in 90:10 
(water: acetonitrile). It was observed that the PAH peak area increased as the 
concentration of the β-CD is increased in the mobile phase.  
 
Figure 23: HPLC –FLD chromatograms for 10uM PAH in the presence of different 
concentrations of β-CD; Mobile phase is 90% 0.1 M acetic acid in water, 10% 
Acetonitrile 
Figure 24 shows the calibration curves of PAH (concentrations range 0.025 - 
500 µM) at different concentrations of β-CD in the mobile phase. The correlation 
coefficients (R2) of these calibration curves show good linearity of the calibration 
results. Moreover, it was noted the slope of the calibration curves have shown an 
increase as the concentration of the β-CD increased which indicates its effect on the 
enhancement of the method sensitivity. 
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Figure 24: Calibration curves of PAH (Conc. Range 0.025-500 µM) at different 
concentrations of β-CD in the mobile phase 
Figure 25 shows the calibration curve of the PAH in urine matrix in the 
presence of 4- aminobenzoic acid as an internal standard and β-CD was added to the 
mobile phase. The curve was established over the concentration range of 10 -500 
µM. This curve was used to estimate the levels of PAH in urine after spiking it with 
two different concentrations of 100 µM and 500 µM. 
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Figure 25: Calibration curves of the HPLC –FLD data of PAH after extraction from 
urine sample matrix in the presence of 15 mM β-CD in the mobile phase 
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5.4 Discussion 
PAH has shown one absorption peak at 275 nm in aqueous solution at pH 
4.06 without β-CD as shown in Figure 14, while the same absorption maximum was 
observed when β-CD was added to the aqueous solution. However, an increase in the 
intensity of the absorption was observed, indicating an interaction between the PAH 
and β-CD. It appears that no new structure such as a dimer or charge transfer 
complex is formed in the ground state.  
Fluorescence measurements for PAH in aqueous and organic solutions are 
shown in Figure 15. Two fluorescence peaks were observed in aqueous solution at 
305 nm and 355 nm, whereas one fluorescence peak at 395 nm was observed in 
hexane. These results indicate that the fluorescence behavior of PAH is affected by 
the solvent polarity in agreement with a previous report (Karabacak, Cinar et al. 
2012). This primary result encouraged us to study the effects of microenvironment by 
adding CD to the aqueous solution of PAH and see whether the PAH’s fluorescence 
behavior would be affected or not. The effect of PAH concentration on the intensities 
of the fluorescence peaks at 305 nm and 355 nm with and without β-CD was 
obvious. Figure 15 shows that the fluorescence intensity is affected by changing the 
guest concentrations in the absence and presence of β-CD, thus supporting the 
assignment of the peak at 355 nm to the formation of excited dimer (excimer) at high 
concentration of PAH while the peak at low concentration is attributed to the 
monomer species. β-CD facilitates the excimer formation (Willner, Eichen et al. 
1989, Zhang, Deng et al. 2015) by sequestering two PAH molecules within its cavity 
(see theoretical modeling below). The results in Figure 16 can be also explained by 
two scenarios depending on PAH concentration: At low concentration of 1 µM, β-
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CD prevents aggregation and enhances the intensity of the monomer species over the 
dimer whereas at higher concentration of 10 µM, host-guest complexation does not 
compete with excimer formation and the macrocycle binds the dimer as a whole, thus 
enhancing its fluorescence intensity.  
    It was noticed that among the three types of the cyclodextrins tested, β-CD 
has shown an opposite trend to that observed upon the addition of other hosts, 
(Figure 19). This observation can be explained by the fact that only the larger β-CD 
cavity is capable of encapsulating two guest units when compared to the smaller 
cavity of α-CD.  Moreover, the cavity size for the -CD cavity is very large 
compared to the size of the PAH molecule, leading to a weaker hydrophobic 
interaction with a singly encapsulated PAH molecule with a concomitant 
enhancement in the relevant intensity at 305 nm. We have selectively pursued the use 
of β-CD in the rest of this study since it shows the optimum size and produces the 
maximum enhancement of the PAH fluorescence.  
The PAH contains –NH2 group that can be protonated or remain neutral 
depending on the pH values, thus pH effects on the fluorescence behavior of PAH in 
the absence and presence of β-CD solution in Figure 20 were expected. In the 
absence of β-CD, the peak at 305 nm is comparable to that at 355 nm at low pH, but 
decreased relatively with an increase in pH. This is true, since protonation diminishes 
the extent of dimerization (in principle the dimer is between two neutral units). Thus, 
in acidic media, the fluorescence intensity of the monomer is higher than that in basic 
and neutral solutions. The added β-CD thus enhanced the already lower intensity of 
the dimer band at 355 nm in acidic media as compared to that in neutral and basic 
media. It transpires that β-CD competes with the protonation of the –NH2 group in 
136 
 
acidic media by virtue of the host-guest complexation, particularly when the 
concentration is above 10 µM (see Figure 16 above). 
The theoretical calculations were performed in the gas phase and do not take 
into account interactions with solvent molecules. However, they do illustrate strong 
potential for binding of PAH to the rim of β-CD, and binding of PAH within β-CD. It 
is possible that binding within the β-CD ring is preferred, despite the lower 
calculated binding energy, due to the energetically favored displacement of water 
molecules from the β-CD cavity. The structure with two PAH molecules within the 
β-CD cavity appears to be even more favorable, introducing hydrogen-bonding 
between PAH molecules and between PAH and β-CD. The calculations indicate that 
such a complex is feasible with β-cyclodextrin and may promote the formation of an 
excimer upon excitation. 
NMR data confirm the gust-host interaction where the chemical shifts of the 
two protons on the ortho-position relative to amine group on the benzene ring 
occurred. 
The observed enhancement in the fluorescence intensity at 355 nm could be 
used as a tool to develop a spectrofluorometric analytical method for detection and 
quantitation of PAH in aqueous media containing β-CD. Figure 22 shows the 
calibration curve of 0.05-100 µM solutions of PAH in the presence of 5 mM β-CD. 
The correlation coefficient shows a very good linearity over the tested concentration 
range.  Moreover, high performance liquid chromatography coupled with 
fluorescence detection was used to develop an analytical method for detection of 
PAH in urine samples. β-CD was added to the HPLC mobile phase at different 
concentrations in order to see its effect fluorescence detection of PAH compound. 
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Figure 23 shows the HPLC-FLD chromatograms for 10 µM PAH in the presence β-
CD at different concentrations (0.0,  5.0, 10.0 and 15.0 mM) in the mobile phase 
which consist of 0.10 M acetic acid in 90:10 (water: acetonitrile). It was observed 
that the PAH peak area of the 10 µM concentration has been increased as the 
concentration of the β-CD is increased in the mobile phase. Higher concentration of 
β-CD will raise the probability of host – guest inclusion interaction between β-CD 
and PAH, thus the complex formation will cause the changes that have been 
observed in spectral properties of PAH. This result agrees with scientific literature 
where it was reported that unmodified cyclodextrins can be used as fluorescence 
enhancing agent in analytical measurements (Wagner and McManus 2003). 
Analysis of the PAH in urine sample was conducted by spiking a diluted 
urine sample with a known concentration of the PAH, 100 and 500 µM. The 
calibration curve shown in Figure 25 was prepared in a urine matrix and was used to 
calculate the recovery of the spiked samples. Recovery ranges for 100 µM and 500 
µM concentration were found to be in the ranges of 104%-119% and 99%-103%, 
respectively. It is possible to explain the high values of the recoveries above 100% 
by the fact that urine sample naturally contains some PAH that will show up even 
after the dilution that was used during the sample preparation.   
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5.5 Conclusion 
It was possible to develop a sensitive spectrofluorometric method and liquid 
chromatography with fluorescence detection method for detection and determination 
of PAH in the presence of β-CD. The fluorescence signal at 355 nm, which is 
produced as a result of excimer emission, was enhanced upon the use of β-CD in 
sample preparation. The interaction between PAH and cyclodextrin was considered 
as host – guest inclusion which was evident by DFT calculations and showed 1:2 
(host-guest) interaction. A calibration curve was established for the 
spectrofluorometric data of PAH with β-CD in the concentration range of 0.05 -100 
µM of PAH and the detection limit was 0.015 µM. HPLC with fluorescence 
detection in the presence of β-CD in the mobile phase has shown an increase in 
fluorescence detection and the calibration curve slope increased as the concentration 
of β-CD increased.  Finally, urine sample was spiked with 100 µM and 500 µM of 
PAH and showed recoveries in the range of 104%-118% and 99.2-103% 
respectively.   
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Chapter 6: Conclusion 
 
Chirality is an inalienable part of drug research and pharmacology. Chiral 
compounds such as synthetic cathinone derivatives can differ in toxicity, potency and 
behavior in human being where each enantiomer has different effect on the chiral 
biological system. Therefore, enantioseparations of the chiral bioactive molecules 
have gained a lot of attention from researchers and pharmacologists in order to 
understand the bioactivity of these compounds. 
Chiral separation can be achieved either by direct or indirect techniques. 
Indirect chiral analysis is about converting the inseparable racemic enantiomers to 
new products that have different physical and chemical properties which will be 
separable on achiral stationary phase column. The conversion of enantiomers to 
diastereoisomers can be done through the derivatization reaction with an optically 
pure derivatizing agent. In contrast, the use of chiral selector such as polysaccharides 
compounds can proceed to direct chiral separation. Chiral selector can be either 
immobilized on the stationary phase of the column or dissolved in the mobile phase 
of the system. Mostly, direct chiral separation is based on one of the following 
principles: host – guest inclusion reaction with polysaccharides as a host, hydrogen 
bonding on a chiral center, or coordination on chiral metal complexes.  
In chapters 2 and 3 of this work, development of a sensitive and selective 
method for detection and quantitation of cathinone related compounds using GC-MS 
after indirect chiral derivatization with (S)-(–)-N- (trifluoroacetyl)pyrrolidine-2-
carbonyl chloride (L-TPC) was possible. In the second chapter, Electron Impact (EI) 
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has been used as an ionization source while in the third chapter, Negative Chemical 
Ionization (NCI) source was used in order to enhance the detection sensitivity. 
Using GC-EI-MS system in chapter two, the enantiomers of 31 synthetic 
cathiones were separated; 18 of them were separated as L-TPC derivatives for the 
first time. Moreover, pentedrone, which has been reported earlier as one of the 
difficult racemic mixture to separate after L-TPC derivatization, has been separated 
easily. Well resolved peaks have been observed for most of cathinone derivatives as 
a result of using 60m HP5-MS capillary column. In order to correct for analyte loss 
during sample preparation step and sample loss during injection process, nikethamide 
has been used as an internal standard. It showed good stability and reproducibility. 
Among the 31 synthetic cathinone compounds, 12 have been chosen to be spiked in 
urine and plasma as a mixture prior injection to GC-MS. Calibration curves of twelve 
selected cathinone derivatives in urine were constructed including the following 
concentrations: 5, 10, 20, 50, 100, 200 ppm. To our knowledge, it is the first time to 
perform quantitative analysis for synthetic cathinones enantiomers in the spiked 
biological samples. Validation of the developed method in terms of recoveries, 
reproducibilities, linearities, LOD, and LOQ for all the tested compounds was also 
performed. It was found that the LOD’s of the 12 cathinone derivatives in urine were 
in the range of 0.1 -0.7 ppm and in plasma they were in the range of 0.17 -1.33 ppm. 
The LOQ’s in urine was in the range of 0.29 - 2.14 ppm and in plasma it was in the 
range of 0.50 - 4.01 ppm. The correlation coefficient (R2) value for each enantiomer 
for the mixture components was found to be higher than 0.99. 
In chapter three, the use of newly developed method of GC-NCI-MS 
provided high sensitivity and selectivity for the chiral separation and quantitation of 
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the targeted synthetic cathinone compounds. After derivatization step with L-TPC, 
60m HP5-MS Ultra inert capillary column was used to separate 36 compounds of 
synthetic cathinones to their optical enantiomers. (+)-cathinone was used as an 
internal standard for synthetic cathinones quantitation which has similar skeleton and 
chemical structure and showed good stability. A mixture of fourteen cathinone 
derivatives were spiked in urine and plasma and separated on one chromatogram 
simultaneously and to our knowledge, it is the highest number of cathinones L-TPC 
derivatives that have been run as a mixture in one chromatogram. Calibration curves 
were constructed for each enantiomer in the spiked mixture including the following 
concentration: 1, 5, 10, 20, 40, 60, 80 and 100 ppb. It was found that the LOD’s of 
the 14 cathinones derivatives in urine were in the range of 0.02 -0.76 ppb and in 
plasma they were in the range of 0.02 - 0.34 ppb. While the LOQ’s of the mixture in 
urine were in the range of 0.07 - 2.31 ppb and in plasma they were in the range of 
0.07 – 1.03 ppb. The correlation coefficient (R2) values for each enantiomer in the 
mixture by GC-NCI-MS also found to be higher than 0.99. The developed method 
has been validated in terms of linearities, limits of detection (LOD), limits of 
quantitation (LOQ), reproducibilities and recoveries for all tested mixture 
compounds. 
By comparing the results for GC-MS analysis presented in chapter two, 
where electron ionization was used, with that presented in chapter three, where 
negative chemical ionization was used, it was found that the later technique has 
shown higher sensitivity by three orders of magnitudes. Moreover, in both cases, an 
enhancement in enantiomer peaks resolution was achieved due to the use of Ultra 
inert 60 m column while using slow heating rate (2 oC/min) on the GC oven. 
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Some of the drawbacks of the indirect chiral separation of synthetic 
cathinones are that it will consume some time in sample derivatization step and is 
only applicable for the primary and secondary amines synthetic cathinones and it was 
useless for tertiary amine cathinones since they do not have a derivatizable site i.e., 
there are no acidic hydrogen on them. As a result of that, an alternative technique 
that utilize direct chiral separation was investigated. It was found that there are a 
limited number of papers that discussed chiral separation of synthetic tertiary 
cathinone derivatives using chiral HPLC chiral column which means that it is not 
easy to separate these kinds of compounds. 
In chapter four, we focused on chiral separation of synthetic cathinones that 
contain mainly tertiary amines by HPLC-UV system using two commercially 
available columns that has dimethylphenyl carbamate-derivatized cellulose (DMPC) 
namely Astec Cellulose DMP column and CHIRALPAK AS-H Amylose column 
(Amylose tris [(S)-α-methylbenzylcarbamate] coated on 5µm silica-gel), which were 
used as a chiral stationary phase (CSP). A comparison between the two chiral 
columns has been conducted in terms of separation resolutrion and selectivity factor. 
Sensitive and selective method has been established for detection and quantitation of 
tertiary amine cathinone related compounds using HPLC-UV system with Astec 
Cellulose DMP chiral column. To our knowledge, 18 compounds of tertiary amine 
synthetic cathinones were separated into their optical enantiomers for the first time. 
A stable internal standard (2,3-MDPV) was used in cathinones quantitation. A 
mixture of three tertiary amine cathinones derivatives were separated on one 
chromatogram simultaneously after spiking in urine and plasma sample. 
Construction of calibration curves have been obtained for the selected 3 cathinone 
derivatives including the following concentration: 5, 10, 20, 50, 100, 250 ppm. 
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Validation of the established method in terms of recoveries, reproducibilities, 
linearities, limits of detection (LOD), and limits of quantitation (LOQ) for all the 
tested compounds has been done in spiked urine and plasma samples. The linearity 
coefficient of the constructed calibration curves was higher than 0.99.  It was found 
that the LOD’s of the quantitated tertiary amines cathinone derivatives in urine was 
in the range of 0.1 -0.7 ppm; while, in plasma, the LOD’s were in the range of 0.17 -
1.33 ppm. The LOQ’s in urine was in the range of 0.29 - 2.14 ppm and in plasma it 
was in the range of 0.50 - 4.01 ppm.   
The fifth chapter discussed the host-guest inclusion reaction and its effect in 
fluorescence enhancement of the targeted analyte. In fact, the plan was to study the 
inclusion reaction between cyclodextrins as a host molecules and synthetic 
cathinones as a guest molecule, however, these kinds of experiments may need a 
large amount of synthetic cathinones which are considered as an expensive chemical. 
As a result of that, an alternative compound were chosen in this study namely “para-
amino hippuric acid”, due to its similarity to cathinone derivatives. 
It was possible to develop a sensitive spectroflourometric method and liquid 
chromatography with fluorescence detection method for detection and determination 
of PAH in the presence of β-CD. The fluorescence signal at 355 nm, which is 
produced as a result of excimer emission, enhanced upon the use of β-CD in sample 
preparation. It was found that the interaction between PAH and cyclodextrin was 
considered as host – guest inclusion as was evident by mass spectrometry and DFT 
calculations and showed 1:2 (host-guest) interaction. A calibration curve was 
established for the spectrofluorometric data of PAH with β-CD in the concentration 
range of 0.05 -100 µM of PAH and the detection limit was 0.015 µM. HPLC with 
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fluorescence detection in the presence of β-CD in the mobile phase has shown an 
increase in fluorescence detection and the slope of calibration line increased as the 
concentration of β-CD increased.  Finally, urine sample was spiked with 100 µM and 
500 µM of PAH and showed recoveries in the range of 104%-118% and 99.2-103% 
respectively. 
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 Recommendations 
The following recommendations are suggested as possible ways to extend this study: 
• Indirect chiral separation of synthetic cathinones can be investigated by 
using another kind of derivatizing agents such as menthylchloroformate which 
available at very cheap price and it has not investigated yet with synthetic 
cathinones. 
• The usage of chiral GC column instead of using chiral derivatizing agent 
(CDA) for primary and secondary synthetic cathinones analysis. 
• Negative Chemical Ionization (NCI) could lower the detection limit for the 
analysis of synthetic cathinones by using Multi Reaction Monitoring (MRM) mode. 
In order to do that an intense molecular ion peak is implied. The use of isobutene in 
CI source instead of methane is an option to observe high molecular ion peak in MS 
which will make MRM analysis possible for these kinds of compounds. 
• Comparison between different gases in the CI source is also possible by 
using methane, isobutene and argon and a mixture of methane + ammonia.  
• Sulfated β-Cyclodextrin (S-β-CD) can be used for synthetic cathinones 
enantioseparation especially for those new derivatives that have not been 
investigated in CE/UV system. 
• Fluorescent derivatizing agent can be used with primary and secondary 
cathinones in order to permit detection using fluorescence detector. 
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Appendix A: Gas chromatogram, mass spectrum and calibration plots of 
31 synthetic cathinones that analyzed in chapter 2 
 
 
Figure 26: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Ethylmethcathinone (2-EMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
(a) 
(b) 
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Figure 27: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Fluorolmethcathinone (2-FMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system  
(a) 
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Figure 28: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Methylethcathinone (2-MEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
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Figure 29: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Methoxymethcathinone (2-Me-O-MC) drug after derivatization with L-TPC in the 
presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
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Figure 30: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Methylmethcathinone (2-MMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
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Figure 31: a) Gas chromatogram for separation of the R and S enantiomers of 2,3-
Dimethylmethcathinone (2,3-DMMC) drug after derivatization with L-TPC in the 
presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
(a) 
(b) 
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Figure 32: a) Gas chromatogram for separation of the R and S enantiomers of 2,3-
Methelendioxymethcathinone (2,3-MDMC) drug after derivatization with L-TPC in 
the presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
(a) 
(b) 
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Figure 33: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Ethylethcathinone (3-EEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
(a) 
(b) 
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Figure 34: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Ethylmethcathinone (3-EMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
(a) 
(b) 
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Figure 35: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Fluoroethcathinone (3-FEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
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Figure 36: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Fluoromethcathinone (3-FMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
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(b) 
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Figure 37: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methylethcathinone (3-MEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
 
 
(a) 
(b) 
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Figure 38: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methoxymethcathinone (3-Me-O-MC) drug after derivatization with L-TPC in the 
presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
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Figure 39: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methylmethcathinone (3-MMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
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(b) 
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Figure 40: a) Gas chromatogram for separation of the R and S enantiomers of 3,4-
Dimethylethcathinone (3,4-DMEC) drug after derivatization with L-TPC in the 
presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
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Figure 41:  a) Gas chromatogram for separation of the R and S enantiomers of 3,4-
Dimethylmethcathinone (3,4-DMMC) drug after derivatization with L-TPC in the 
presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
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Figure 42: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Ethylethcathinone (4-EEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
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Figure 43: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Ethylmethcathinone (4-EMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
 
 
(a) 
(b) 
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Figure 44: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Fluoroethcathinone (4-FEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
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Figure 45: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Fluoromethcathinone (4-FMC) drug after derivatization with L-TPC in the presence 
of nikethamide internal standard and b) mass spectrum of the same compound 
analyzed by GC-EI-MS system 
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Figure 46: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Methylbuphedrone drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
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Figure 47: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Methylethcathinone (4-MEC) drug after derivatization with L-TPC in the presence of 
nikethamide internal standard and b) mass spectrum of the same compound analyzed 
by GC-EI-MS system 
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Figure 48: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Methyl-α-ethylaminobutiophenone drug after derivatization with L-TPC in the 
presence of nikethamide internal standard and b) mass spectrum of the same 
compound analyzed by GC-EI-MS system 
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Figure 49: a) Gas chromatogram for separation of the R and S enantiomers of 
Butylone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 50: a) Gas chromatogram for separation of the R and S enantiomers of 
Ethcathinone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 51: a) Gas chromatogram for separation of the R and S enantiomers of 
Eutylone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 52: a) Gas chromatogram for separation of the R and S enantiomers of 
Methedrone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 53: a) Gas chromatogram for separation of the R and S enantiomers of Nor-
mephedrone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 54: a) Gas chromatogram for separation of the R and S enantiomers of 
Pentedrone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 55: a) Gas chromatogram for separation of the R and S enantiomers of 
Pentylone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 56: a) Gas chromatogram for separation of the R and S enantiomers of 
Buphedrone drug after derivatization with L-TPC in the presence of nikethamide 
internal standard and b) mass spectrum of the same compound analyzed by GC-EI-
MS system 
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Figure 57: a) Gas chromatogram for the internal standard Nikethamide and b) mass 
spectrum of the same compound analyzed by GC-EI-MS system  
(a) 
(b) 
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Figure 58: Calibration curves of 4-Methylbuphedrone enantiomers in plasma and 
urine  
y = 0.02x - 0.1318
R² = 0.9945
0
2
4
6
0 50 100 150 200
P
ea
k
 A
re
a
Concentration (ppm)
a) Plasma E1
y = 0.0115x - 0.0635
R² = 0.9985
0
1
2
3
0 50 100 150 200
P
ea
k
 A
re
a
Concentration (ppm)
b) Plasma E2
y = 0.0195x + 0.1394
R² = 0.994
0
2
4
6
0 50 100 150 200
P
ea
k
 A
re
a
Concentration (ppm)
c) Urine E1
y = 0.0204x - 0.017
R² = 0.9986
0
2
4
6
0 50 100 150 200
P
ea
k
 A
re
a
Concentration (ppm)
d) Urine E2
192 
 
 
Figure 59: Calibration curves of Pentylone enantiomers in plasma and urine  
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Figure 60: Calibration curves of Ethcathinone enantiomers in plasma and urine 
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Figure 61: Calibration curves of Pentedrone enantiomers in plasma and urine  
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Figure 62: Calibration curves of 4-FEC enantiomers in plasma and urine  
y = 0.0124x + 0.003
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Figure 63: Calibration curves of 3-MMC enantiomers in plasma and urine  
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Figure 64: Calibration curves of 3-FMC enantiomers in plasma and urine  
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Figure 65: Calibration curves of 3,4-DMMC enantiomers in plasma and urine 
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Figure 66: Calibration curves of 2,3-MDMC enantiomers in plasma and urine  
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Figure 67: Calibration curves of Buphedrone enantiomers in plasma and urine 
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Figure 68: Calibration curves of Buphedrone enantiomers in plasma  
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Figure 69: Calibration curves of Eutylone enantiomers in urine 
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Appendix B: Gas chromatogram, mass spectrum and calibration plots of 
37 synthetic cathinones that analyzed in chapter 3 
 
 
 
Figure 70: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Methoxymethcathinone (2-Me-O-MC) drug after derivatization with L-TPC and b) 
mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 71: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Fluoroethcathinone (3-FEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 72: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Fluoroethcathinone (4-FEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 73: a) Gas chromatogram for separation of the R and S enantiomers of 2,3-
Methylenedioxymethcathinone (2,3-MDMC) drug after derivatization with L-TPC 
and b) mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 74: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Methylmethcathinone (2-MMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 75: a) Gas chromatogram for separation of the R and S enantiomers of Nor-
mephedrone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
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Figure 76: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Ethylethcathinone (4-EEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 77: a) Gas chromatogram for separation of the R and S enantiomers of 3,4-
Dimethylethcathinone (3,4-DMEC) drug after derivatization with L-TPC and b) 
mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 78: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Ethylmethcathinone (2-EMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 79: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methoxymethcathinone (3-MeOMC) drug after derivatization with L-TPC and b) 
mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 80: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Fluoromethcathinone (2-FMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 81: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Ethylmethcathinone (4-EMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 82: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Ethylethcathinone (3-EEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 83: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Methylbuphedrone drug after derivatization with L-TPC and b) mass spectrum of the 
same compound analyzed by GC-NCI-MS system 
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Figure 84: a) Gas chromatogram for separation of the R and S enantiomers of 2,3-
Dimethylmethcathinone (2,3-DMMC) drug after derivatization with L-TPC and b) 
mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 85: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Ethylmethcathinone (3-EMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 86: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Fluoromethcathinone (3-FMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 87: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Fluoromethcathinone (4-FMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 88: a) Gas chromatogram for separation of the R and S enantiomers of 2-
Methylethcathinone (2-MEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 89: a) Gas chromatogram for separation of the R and S enantiomers of 
Buphedrone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
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Figure 90: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Methyl-α-ethylaminobutiophenone drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 91: a) Gas chromatogram for separation of the R and S enantiomers of 
Pentedrone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
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Figure 92: a) Gas chromatogram for separation of the R and S enantiomers of 
Butylone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
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Figure 93: a) Gas chromatogram for separation of the R and S enantiomers of 
Pentylone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
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Figure 94: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Methylethcathinone (4-MEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 95: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methylmethcathinone (3-MMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 96: a) Gas chromatogram for separation of the R and S enantiomers of 4-
Bromomethcathinone (4-BMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 97: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Bromomethcathinone (3-BMC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 98: a) Gas chromatogram for separation of the R and S enantiomers of 
Ethcathinone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
0
10000
20000
30000
40000
50000
60000
70000
40 41 42 43 44 45 46 47 48 49 50
A
b
u
n
d
an
ce
Time (min)
(a) 
(b) nfghnfg 
232 
 
 
 
Figure 99: a) Gas chromatogram for separation of the R and S enantiomers of 2,4-
Dimethylmethcathinone (2,4-DMMC) drug after derivatization with L-TPC and b) 
mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 100: a) Gas chromatogram for separation of the R and S enantiomers of 2,4-
Dimethylethcathinone (2,4-DMEC) drug after derivatization with L-TPC and b) 
mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 101: a) Gas chromatogram for separation of the R and S enantiomers of 3,4-
Methylenedioxy-N-ethylcathinon (Ethylone) drug after derivatization with L-TPC 
and b) mass spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 102: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methylbuphedrone drug after derivatization with L-TPC and b) mass spectrum of the 
same compound analyzed by GC-NCI-MS system 
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Figure 103: a) Gas chromatogram for separation of the R and S enantiomers of N-
Ethylbuphedrone (NEB) drug after derivatization with L-TPC and b) mass spectrum 
of the same compound analyzed by GC-NCI-MS system 
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Figure 104: a) Gas chromatogram for separation of the R and S enantiomers of 2,3-
Pentylone drug after derivatization with L-TPC and b) mass spectrum of the same 
compound analyzed by GC-NCI-MS system 
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Figure 105: a) Gas chromatogram for separation of the R and S enantiomers of 3-
Methylethcathinone (3-MEC) drug after derivatization with L-TPC and b) mass 
spectrum of the same compound analyzed by GC-NCI-MS system 
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Figure 106: Calibration curves of 4-FMC enantiomers in plasma and urine 
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Figure 107: Calibration curves of 4-FEC enantiomers in plasma and urine  
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Figure 108: Calibration curves of Buphedrone enantiomers in plasma and urine 
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Figure 109: Calibration curves of 3-MMC enantiomers in plasma and urine 
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Figure 110: Calibration curves of 3-Methylbuphedrone enantiomers in plasma and 
urine  
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Figure 111: Calibration curves of 4-Methylbuphedrone enantiomers in plasma and 
urine  
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Figure 112: Calibration curves of 3-EMC enantiomers in plasma and urine  
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Figure 113: Calibration curves of 3-EEC enantiomers in plasma and urine 
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Figure 114: Calibration curves of 4-EEC enantiomers in plasma and urine 
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Figure 115: Calibration curves of 3,4-DMEC enantiomers in plasma and urine 
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Figure 116: Calibration curves of 2,3--MDMC enantiomers in plasma and urine  
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Figure 117: Calibration curves of Butylone enantiomers in plasma and urine  
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Figure 118: Calibration curves of Pentylone enantiomers in plasma and urine  
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Scheme 20: Solid phase extraction (SPE) of spiked urine and plasma samples 
 
 
 
Scheme 21: Derivatization step of synthetic cathinones by L-TPC  
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Appendix C: Liquid chromatogram of 65 synthetic cathinones analyzed 
by HPLC-DAD using cellulose/amylose column (chapter 4) 
 
 
Figure 119: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,3-Methylenedioxymethcathinone (2,3-MDMC) drug using AS-H Amylose 
column, λ max. 254 nm 
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Figure 120: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,3-Methylenedioxymethcathinone (2,3-MDMC) drug using DMP cellulose 
column, λ max. 254 nm 
 
Figure 121: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,3-Pentylone drug using AS-H Amylose column, λ max. 300 nm 
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Figure 122: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,3-Pentylone drug using DMP cellulose column, λ max. 300 nm 
 
 
Figure 123: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,4-Dimethylethcathinone (2,4-DMEC) drug using AS-H Amylose column, λ 
max. 254 nm 
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Figure 124: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,4-Dimethylethcathinone (2,4-DMEC) drug using DMP cellulose column, λ 
max. 254 nm 
 
Figure 125: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Ethylethcathinone (2-EEC) drug using AS-H Amylose column, λ max. 270 
nm 
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Figure 126: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Ethylethcathinone (2-EEC) drug using DMP cellulose column, λ max. 270 
nm 
 
Figure 127: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Ethylmethcathinone (2-EMC) drug using AS-H Amylose column, λ max. 
270 nm 
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Figure 128: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Ethylmethcathinone (2-EMC) drug using DMP cellulose column, λ max. 
270 nm 
 
Figure 129: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methoxymethcathinone drug using AS-H Amylose column, λ max. 254 nm 
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Figure 130: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methoxymethcathinone drug using DMP cellulose column, λ max. 270 nm 
 
Figure 131: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methylethcathinone (2-MEC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 132: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methylethcathinone (2-MEC) drug using DMP cellulose column, λ max. 254 
nm 
 
Figure 133: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methylmethcathinone (2-MMC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 134: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methylmethcathinone (2-MMC) drug using DMP cellulose column, λ max. 
254 nm 
 
Figure 135: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Dimethylethcathinone (3,4-DMEC) drug using AS-H Amylose column, λ 
max. 254 nm 
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Figure 136: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Dimethylethcathinone (3,4-DMEC) drug using DMP cellulose column, λ 
max. 254 nm 
 
Figure 137: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Dimethylmethcathinone (3,4-DMMC) drug using AS-H Amylose 
column, λ max. 270 nm 
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Figure 138: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Dimethylmethcathinone (3,4-DMMC) drug using DMP cellulose column, 
λ max. 270 nm 
 
Figure 139: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-N-benzylcathinone drug using AS-H Amylose column, 
λ max. 270 nm 
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Figure 140: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-N-benzylcathinone drug using DMP cellulose column, λ 
max. 270 nm 
 
Figure 141: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-N-ethylcathinone drug using AS-H Amylose column, λ 
max. 270 nm 
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Figure 142: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-N-ethylcathinone drug using DMP cellulose column, λ 
max. 270 nm 
 
Figure 143: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Bromomethcathinone (3-BMC) drug using AS-H Amylose column, λ max. 
300 nm 
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Figure 144: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Bromomethcathinone (3-BMC) drug using DMP cellulose column, λ max. 
300 nm 
 
Figure 145: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Ethylethcathinone (3-EEC) drug using AS-H Amylose column, λ max. 270 
nm 
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Figure 146: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Ethylethcathinone (3-EEC) drug using DMP cellulose column, λ max. 300 
nm 
 
Figure 147: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Fluoroethcathinone (3-FEC) drug using DMP cellulose column, λ max. 270 
nm 
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Figure 148: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Fluoroethcathinone (3-FEC) drug using AS-H Amylose column, λ max. 270 
nm 
 
Figure 149: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Fluoromethcathinone (3-FMC) drug using AS-H Amylose column, λ max. 
270 nm 
 
-0.1
0.9
1.9
2.9
3.9
4.9
5.9
6.9
7.9
8.9
0 0.5 1 1.5 2 2.5 3 3.5
A
b
so
rb
an
ce
Time (min)
0
1
2
3
4
5
6
0 1 2 3 4 5 6
A
b
so
rb
an
ce
Time (min)
269 
 
 
Figure 150: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Fluoromethcathinone (3-FMC) drug using DMP cellulose column, λ max. 
270 nm 
 
Figure 151: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Mehyethcathinone (3-MEC) drug using AS-H Amylose column, λ max. 240 
nm 
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Figure 152: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Mehyethcathinone (3-MEC) drug using DMP cellulose column, λ max. 240 
nm 
 
Figure 153: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methylbuphedrone drug using AS-H Amylose column, λ max. 270 nm 
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Figure 154: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methylbuphedrone drug using DMP cellulose column, λ max. 270 nm 
 
Figure 155: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methylmethcathinone (3-MMC) drug using AS-H Amylose column, λ max. 
270 nm 
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Figure 156: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methylmethcathinone (3-MMC) drug using DMP cellulose column, λ max. 
270 nm 
 
Figure 157: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Bromomethcathinone (4-BMC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 158: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Bromomethcathinone (4-BMC) drug using DMP cellulose column, λ max. 
254 nm 
 
Figure 159: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Ethylethcathinone (4-EEC) drug using AS-H Amylose column, λ max. 254 
nm 
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Figure 160: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Ethylethcathinone (4-EEC) drug using DMP cellulose column, λ max. 254 
nm 
 
Figure 161: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Ethylmethcathinone (4-EMC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 162: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Ethylmethcathinone (4-EMC) drug using DMP cellulose column, λ max. 
254 nm 
 
Figure 163: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Fluoroethcathinone (4-FEC) drug using AS-H Amylose column, λ max. 254 
nm 
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Figure 164: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Fluoroethcathinone (4-FEC) drug using DMP cellulose column, λ max. 254 
nm 
 
Figure 165: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Fluoromethcathinone (4-FMC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 166: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Fluoromethcathinone (4-FMC) drug using DMP cellulose column, λ max. 
254 nm 
 
Figure 167: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methylbuphedrone drug using AS-H Amylose column, λ max. 254 nm 
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Figure 168: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methylbuphedrone drug using DMP cellulose column, λ max. 254 nm 
 
Figure 169: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methylethcathinone (4-MEC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 170: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methylethcathinone (4-MEC) drug using DMP cellulose column, λ max. 254 
nm 
 
Figure 171: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methyl-α-ethylaminobutiophenone drug using AS-H Amylose column, λ 
max. 254 nm 
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Figure 172: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methyl-α-ethylaminobutiophenone drug using DMP cellulose column, λ 
max. 254 nm 
 
Figure 173: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Benzedrone drug using AS-H Amylose column, λ max. 254 nm 
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Figure 174: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Benzedrone drug using DMP cellulose column, λ max. 254 nm 
 
Figure 175: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Buphedrone drug using AS-H Amylose column, λ max. 240 nm 
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Figure 176: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Buphedrone drug using DMP cellulose column, λ max. 240 nm 
 
Figure 177: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Butylone drug using AS-H Amylose column, λ max. 300 nm 
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Figure 178: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Butylone drug using DMP cellulose column, λ max. 300 nm 
 
Figure 179: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Ethcathinone drug using AS-H Amylose column, λ max. 240 nm 
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Figure 180: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Ethcathinone drug using DMP cellulose column, λ max. 240 nm 
 
Figure 181: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Eutylone drug using AS-H Amylose column, λ max. 270 nm 
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Figure 182: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Eutylone drug using DMP cellulose column, λ max. 270 nm 
 
Figure 183: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Methedrone drug using AS-H Amylose column, λ max. 270 nm 
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Figure 184: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Methedrone drug using DMP cellulose column, λ max. 270 nm 
 
Figure 185: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of N-Ethylbuphedrone drug using AS-H Amylose column, λ max. 240 nm 
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Figure 186: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of N-Ethylbuphedrone drug using DMP cellulose column, λ max. 240 nm 
 
Figure 187: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Pentylone drug using AS-H Amylose column, λ max. 270 nm 
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Figure 188: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Pentylone drug using DMP cellulose column, λ max. 270 nm 
 
Figure 189: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,3-Dimethylmethcathinone (2,3-DMMC) drug using AS-H Amylose 
column, λ max. 300 nm 
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Figure 190: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2,4-Dimethylmethcathinone (2,4-DMMC) drug using AS-H Amylose 
column, λ max. 270 nm 
 
Figure 191: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Fluoroethcathinone (2-FEC) drug using DMP cellulose column, λ max. 254 
nm 
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Figure 192: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Fluoromethcathinone (2-FMC) drug using AS-H Amylose column, λ max. 
270 nm 
 
Figure 193: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Ethylmethcathinone (3-EMC) drug using AS-H Amylose column, λ max. 
254 nm 
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Figure 194: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methoxymethcathinone drug using AS-H Amylose column, λ max. 254 nm 
 
Figure 195: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methoxymethcathinone drug using DMP cellulose column, λ max. 254 nm 
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Figure 196: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Nor-mephedrone drug using AS-H Amylose column, λ max. 254 nm 
 
Figure 197: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Pentedrone drug using AS-H Amylose column, λ max. 254 nm 
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Figure 198: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methyl-α-Pyrrolidinobutiophenone drug using AS-H Amylose column, λ 
max. 270 nm 
 
Figure 199: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methyl-α-Pyrrolidinobutiophenone drug using DMP cellulose column, λ 
max. 254 nm 
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Figure 200: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methyl-α-Pyrrolidinopropiophenone drug using AS-H Amylose column, λ 
max. 300 nm 
 
Figure 201: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 2-Methyl-α-Pyrrolidinopropiophenone drug using DMP cellulose column, λ 
max. 300 nm 
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Figure 202: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone drug using AS-H Amylose 
column, λ max. 270 nm 
 
Figure 203: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone drug using DMP cellulose 
column, λ max. 270 nm 
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Figure 204: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Ethyl-N,N-Dimethylcathinone drug using AS-H Amylose column, λ max. 
270 nm 
 
Figure 205: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Ethyl-N,N-Dimethylcathinone drug using DMP cellulose column, λ max. 
270 nm 
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Figure 206: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4'-Methoxy-α-Pyrrolidinopropiophenone drug using AS-H Amylose column, 
λ max. 270 nm 
 
Figure 207: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4'-methoxy-α-Pyrrolidinopropiophenone drug using DMP cellulose column, 
λ max. 270 nm 
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Figure 208: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Dimethylone drug using AS-H Amylose column, λ max. 270 nm 
 
Figure 209: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Dimethylone drug using DMP cellulose column, λ max. 270 nm 
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Figure 210: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of N,N-Dimethylcathinone drug using AS-H Amylose column, λ max. 300 nm 
 
Figure 211: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of N,N-Dimethylcathinone drug using DMP cellulose column, λ max. 300 nm 
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Figure 212: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3,4-Methylenedioxy-α-Pyrrolidinopropiophenone drug using DMP cellulose 
column, λ max. 270 nm 
 
Figure 213: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methyl-α-Pyrrolidinobutiophenone drug using DMP cellulose column, λ 
max. 254 nm 
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Figure 214: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 3-Methyl-α-Pyrrolidinopropiophenone drug using DMP cellulose column, λ 
max. 240 nm 
 
Figure 215: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methoxy-N,N-Dimethylcathinone drug using DMP cellulose column, λ max. 
270 nm 
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Figure 216: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4-Methyl-α-Pyrrolidinobutiophenone drug using DMP cellulose column, λ 
max. 300 nm 
 
Figure 217: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4'-methyl-α-Pyrrolidinohexanophenone drug using DMP cellulose column, λ 
max. 254 nm. 
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Figure 218: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of 4'-methyl-α-Pyrrolidinopropiophenone drug using DMP cellulose column, λ 
max. 270 nm 
 
Figure 219: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of Diethylcathinone drug using DMP cellulose column, λ max. 240 nm 
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Figure 220: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of N-ethyl-N-methylcathinone drug using DMP cellulose column, λ max. 300 nm 
 
Figure 221: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of α-Pyrrolidinobutiophenone drug using DMP cellulose column, λ max. 300 nm 
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Figure 222: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of α-Pyrrolidinopentiophenone drug using DMP cellulose column, λ max. 300 
nm 
 
Figure 223: Liquid chromatogram for separation of the R and S enantiomers of 50 
ppm of α-Pyrrolidinopropiophenone drug using DMP cellulose column, λ max. 254 
nm 
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Figure 224: Calibration graphs of the two separated enantiomers of 4’-Methyl-α-ppp 
compound in urine and plasma 
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Figure 225: Calibration graphs of the two separated enantiomers of Dimethylone 
compound in urine and plasma 
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